EP0071819B1 - Dihydropyridines with a positive inotropic activity, their use in pharmaceutical preparations, and processes for their preparation - Google Patents

Dihydropyridines with a positive inotropic activity, their use in pharmaceutical preparations, and processes for their preparation Download PDF

Info

Publication number
EP0071819B1
EP0071819B1 EP82106537A EP82106537A EP0071819B1 EP 0071819 B1 EP0071819 B1 EP 0071819B1 EP 82106537 A EP82106537 A EP 82106537A EP 82106537 A EP82106537 A EP 82106537A EP 0071819 B1 EP0071819 B1 EP 0071819B1
Authority
EP
European Patent Office
Prior art keywords
atoms
alkyl
phenyl
halogen
substituents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
EP82106537A
Other languages
German (de)
French (fr)
Other versions
EP0071819B2 (en
EP0071819A1 (en
Inventor
Gerhard Dr. Franckowiak
Horst Dr. Böshagen
Friedrich Dr. Bossert
Siegfried Dr. Goldmann
Horst Dr. Meyer
Egbert Dr. Wehinger
Jürgen Dr. Stoltefuss
Matthias Dr. Schramm
Günter Dr. Thomas
Robertson Dr. Towart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25794943&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP0071819(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE19813130041 external-priority patent/DE3130041A1/en
Priority claimed from DE19823206671 external-priority patent/DE3206671A1/en
Application filed by Bayer AG filed Critical Bayer AG
Priority to AT82106537T priority Critical patent/ATE26706T1/en
Publication of EP0071819A1 publication Critical patent/EP0071819A1/en
Application granted granted Critical
Publication of EP0071819B1 publication Critical patent/EP0071819B1/en
Publication of EP0071819B2 publication Critical patent/EP0071819B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems

Description

Die vorliegende Erfindung betrifft die Verwendung von neuen und bekannten Dihydropyridinen in Arzneimitteln mit positiv inotroper Wirkung, neue Verbindungen aus dieser Stoffklasse, diese enthaltende Arzneimittel und ihre Herstellung.The present invention relates to the use of new and known dihydropyridines in medicaments with a positive inotropic effect, new compounds from this class of substances, medicaments containing them and their preparation.

Es ist bereits bekannt geworden, dass 1,4-Dihydropyridine gefässerweiternde Eigenschaften besitzen und als Coronarmittel und Antihypertensiva verwendet werden können (vgl. britisches Patent 1173062; britisches Patent 1358951; DE-OS 2 629 892 und DE-OS 2 752 820). Weiterhin ist bekannt, dass 1,4-Dihydropyridine als Calciumantagonisten eine Hemmung der Kontraktionskraft von glatten und kardialen Muskeln bewirken und zur Behandlung von Coronar- und Gefässerkrankungen eingesetzt werden können (vgl. A. Fleckenstein, Ann. Rev. Pharmacol. Toxicol. 17, 149-166 (1977)). Bei Kenntnis dieser Eigenschaften der Dihydropyridine war es nicht vorhersehbar, dass die erfindungsgemässen Verbindungen aus dieser Stoffklasse keine kontraktionshemmende, sondern eine kontraktionskraftverstärkende, am Herzmuskel positiv inotrope Wirkung besitzen.It has already become known that 1,4-dihydropyridines have vasodilatory properties and can be used as coronary agents and antihypertensives (cf. British Patent 1173062; British Patent 1358951; DE-OS 2 629 892 and DE-OS 2 752 820). Furthermore, it is known that 1,4-dihydropyridines act as calcium antagonists to inhibit the contractility of smooth and cardiac muscles and can be used to treat coronary and vascular diseases (cf. A. Fleckenstein, Ann. Rev. Pharmacol. Toxicol. 17, 149-166 (1977)). Knowing these properties of the dihydropyridines, it was not foreseeable that the compounds according to the invention from this class of substances would not have a contraction-inhibiting, but rather a contraction-strengthening, positive inotropic effect on the heart muscle.

Die Erfindung betrifft die Verwendung von 1,4-Dihydropyridinen der allgemeinen Formel (l)

Figure imgb0001
in welcher

  • n für 0, 1 oder 2 steht,
  • R1
    • a) für Wasserstoff, einen geradkettigen, verzweigten, cyclischen, gesättigten oder ungesättigten aliphatischen Kohlenwasserstoffrest steht, der gegebenenfalls 1 bis 3 gleiche oder verschiedene Hetero-Kettenglieder aus der Gruppe 0, CO, SOm (m = 0, 1 oder 2), =N-, NRI oder SiRIIRIII enthält und wobei dieser Kohlenwasserstoffrest gegebenenfalls substituiert ist durch Halogen, N02, CN, N3, Hydroxy, Aryl oder Heteroaryl oder
    • b) für einen Aryl- oder Heteroarylrest steht, wobei diese Reste gegebenenfalls 1 bis 5 gleiche oder verschiedene Substituenten aus der Gruppe Aryl, Alkyl, Alkenyl, Alkinyl, Alkenoxy, Alkinoxy, Aralkyl, Acyl, Alkylen, Dioxyalkylen, Halogen, CF3, OCF3, SCF3, NO2, NO, CN, N3, CORIV, COORV, ORVI, NR' oder NRVIIIRVIII tragen, wobei die Alkyl-, Alkoxy- und Arylreste der obengenannten Substituenten ihrerseits wieder durch Halogen, CORV oder NRVIIRVIII substituiert sein können oder
    • c) für den Rest NRVIIRI steht, und wobei die unter a), b) und c) genannten Reste RI, RII, RIII, RIV, RV, RVI, RVII und RVIII die unten angegebene Bedeutung haben,
  • R2
    • a) für einen der unter R1 angegebenen Substituenten steht, aber nicht mit diesem identisch sein muss oder
    • b) für die Reste NHR' oder
      Figure imgb0002
      steht,

    wobei RI, RIX und RX die unten angegebene Bedeutung besitzen,
    oder die Substituenten R1 und R2 gemeinsam einen 5- bis 8-gliedrigen, gesättigten oder ungesättigten Ring bilden, der gegebenenfalls 1, 2 oder 3 gleiche oder verschiedene Ringglieder aus der Gruppe 0, S, NR' oder CO enthält und der gegebenenfalls 1 bis 3 gleiche oder verschiedene Substituenten aus der Gruppe Halogen, Hydroxy, Alkyl, Alkoxy, Aryl oder Aralkyl enthält,
  • R3 für einen der unter R2 angegebenen Substituenten steht, und mit diesem gleich oder von diesem verschieden ist, wobei nur einer der beiden Substituenten R2 oder R3 jeweils für Alkoxy, Alkylthio oder NHR' steht,
  • R4
    • a) für Wasserstoff, NO2, NO, CN, SOm-RXI (m = 0, 1 oder 2), Halogen,
      Figure imgb0003
      oder
      Figure imgb0004
      steht, wobei RI, RVII, RVIII, RXI und RXIII die unten angegebene Bedeutung haben, oder
    • b) für einen verzweigten oder unverzweigten, cyclischen, gesättigten oder ungesättigten aliphatischen Kohlenwasserstoffrest steht, der gegebenenfalls substituiert ist durch Halogen, OH, CN, Alkoxy, Alkylthio, Aryloxy, COORV oder
      Figure imgb0005
      wobei RV, RVII und RVIII die unten angegebene Bedeutung haben, oder
    • c) für einen aromatischen Kohlenwasserstoffrest oder für einen 5- bis 7-gliedrigen gesättigten oder ungesättigten Heteroring mit 1 bis 4 gleichen oder verschiedenen Heterogliedern aus der Gruppe O, S,-N=, NRI, wobei dieser Heteroring entweder über ein Kohlenstoffatom oder ein Stickstoffatom mit dem Dihydropyridinring verknüpft ist, und wobei der aromatische Kohlenwasserstoffrest und die Heteroringe gegebenenfalls 1 bis 3 gleiche oder verschiedene Substituenten aus der Gruppe Halogen, OH, CN, CF3, OCF3, SCF3, N02, Alkyl, Alkoxy, Aryl und
      Figure imgb0006
      tragen,
    • d) für den Rest
      Figure imgb0007
      steht, wobei X Sauerstoff, Schwefel oder NRI bedeutet und Y für eine einfache Bindung, 0, S oder NR' steht, und RB die für R1 angegebene Bedeutung hat und mit dem Substituenten R1 gleich oder von diesem verschieden ist, oder
    • e) für den Rest
      Figure imgb0008
      steht,

    wobei n', R1', R2', R3', R5', R6' und R7' die für n, R1, R2, R3, R5, R6 und R7 angegebene Bedeutung haben und mit diesen gleich oder von diesen verschieden sind, und R4* und R4** gleich oder verschieden sind und jeweils für einen um ein Wasserstoff verminderten Rest der für R4 unter a) bis d) angegebenen Substituenten stehen, oder
  • R2 und R4 gemeinsam einen verzweigten, unverzweigten, gesättigten oder ungesättigten 5- bis 8-gliedrigen Ring bilden, der gegebenenfalls 1, 2 oder 3 gleiche oder verschiedene Ringglieder aus der Gruppe O, CO, CS, C=NRI, =N-, NRI, SOm (m = 0, 1 oder 2) oder SiRIIRIII enthält, und der gegebenenfalls substituiert ist durch Halogen, Hydroxy, Alkoxy, Aryl, Aralkyl,
    Figure imgb0009
    oder durch eine geradkettige oder verzweigte Alkylenkette mit 3 bis 8 Kohlenstoffatomen disubstituiert ist,
    wobei dieser gemeinsame Ring von R2 und R4 auch direkt mit dem gemeinsamen Ring von R1 und R2 anneliert sein kann,
    wobei die Reste RI, RII, RIII, RVII , RVIII die unten angegebene Bedeutung haben,
  • R5 die fürR4 angegebene Bedeutung besitzt und mit R4 gleich oder von diesem verschieden ist, oder
  • R5 und R3 gemeinsam einen Ring bilden, der mit dem durch R2 und R4 gebildeten Ring gleich oder von diesem verschieden ist,
  • R6 für Wasserstoff, Alkyl oder Halogenalkyl steht, und
  • R7
    • a) für einen gesättigten, ungesättigten, cyciischen, geradkettigen oder verzweigten aliphatischen Kohlenwasserstoffrest steht, der gegebenenfalls substituiert ist durch Halogen, Aryl oder Heteroaryl, oder
    • b) für einen Aryl- oder Heteroarylrest steht, der gegebenenfalls 1 bis 5 gleiche oder verschiedene Substituenten aus der Gruppe No2, CN, N3, NO, CF3, Halogen, CORIV, COORV, ORVI
      Figure imgb0010
      Alkyl, Aryl, Alkenyl, Alkinyl, Alkenoxy, Alkinoxy, Aralkyl, Acyl, Alkylen, oder Dioxyalkylen enthält, wobei die vorgenannten Alkyl- und Aryl-Substituenten ihrerseits wieder durch COORV oder
      Figure imgb0011
      substituiert sein können, und wobei in den vorgenannten Definitionen der Substituenten R1 bis R8 RI für Wasserstoff, Alkyl, Aryl, Aralkyl, Heteroaryl oder Acyl steht, RII und RIII gleich oder verschieden sind und jeweils für Alkyl, Aryl, Aralkyl oder Heteroaryl stehen, RIV, RV und RVI jeweils gleich oder verschieden sind und für Wasserstoff, Alkyl, Aryl, Aralkyl oder Heteroaryl stehen, wobei die Alkyl- und Acylreste gegebenenfalls durch Halogen, Alkylthio, Alkoxy, Trifluormethylnitro oder RVII und RVIII jeweils gleich oder verschieden sind und für Wasserstoff, Aryl oder Aralkyl stehen oder für Alkyl, welches gegebenenfalls durch 0, S oder NRI unterbrochen ist, stehen oder
      gemeinsam mit dem Stickstoffatom einen 5- bis 7-gliedrigen Ring bilden, der 1 oder 2 gleiche oder verschiedene Heteroringglieder aus der Gruppe O, S oder NRI enthalten kann oder
      wobei einer der Reste RVIII oder RVIII für eine aliphatische Acylgruppe mit bis zu 6 Kohlenstoffato- men steht, RIX, RX RXI, RXII und RXIII jeweils gleich oder verschieden sind und für Alkyl, Aryl oder Aralkyl stehen,
      wobei die unter R1 bis R8 und unter RI bis RXIII genannten Alkyl-, Aryl-, Aralkyl-, Heteroaryl- und Acylreste sowie der mit RVII und RVIII gebildete Heteroring ihrerseits gegebenenfalls substituiert sind durch OH, CF3, OCF3, CN, NO2, Halogen, niederes Thioalkyl, niederes Alkyl, niederes Alkoxy, Aryl oder Aralkyl,
      und wobei als Heteroaryl folgende Substituenten genannt seien:
      • Thienyl, Furyl, Pyryl, Pyridyl, Chinolyl, isochinolyl, Pyrimidyl, Pyridazinyl, Chinazolyl, Chinoxalyl, Benzothienyl, Pyrazolyl, Imidazolyl, Oxazolyl, Isoxazolyl, Thiazolyl, Triazolyl, Oxydiazolyl, Pyrazinyl, Oxazinyl, Thiazinyl, Indolizinyl, Indolyl, Benzofuranyl, Indazolyl, Benzothienyl, Benzimidazolyl, Benzoxazolyl, Benzthiazolyl, Benztriazolyl, Benzoxadiazolyl, Cinnolinyl, Phthalazinyl, Naphthyridinyl oder Benzotriazinyl, in Form von Isomeren, lsomerengemischen, Racematen und optischen Antipoden sowie ihrer pharmazeutisch unbedenklichen Salze, zur Herstellung von Arzneimitteln mit positiv inotroper Wirkung, die sich insbesondere als Cardiotonika eignen. Dieser kontraktionskraftverstärkende Effekt beruht auch darauf, dass die erfindungsgemässen Verbindungen den Ca++- Einstrom in die Zelle erhöhen und somit auch zur Behandlung von hypotonen Kreislaufzuständen, zur Senkung von Blutzucker, zur Abschwellung von Schleimhäuten und zur Beeinflussung des Salz- und Flüssigkeitshaushaltes geeignet sind.
The invention relates to the use of 1,4-dihydropyridines of the general formula (I)
Figure imgb0001
in which
  • n represents 0, 1 or 2,
  • R 1
    • a) represents hydrogen, a straight-chain, branched, cyclic, saturated or unsaturated aliphatic hydrocarbon radical which optionally contains 1 to 3 identical or different hetero chain links from the group 0, CO, SO m (m = 0, 1 or 2), = Contains N-, NR I or SiR II R III and where this hydrocarbon radical is optionally substituted by halogen, N0 2 , CN, N 3 , hydroxy, aryl or heteroaryl or
    • b) represents an aryl or heteroaryl radical, these radicals optionally 1 to 5 identical or different substituents from the group aryl, alkyl, alkenyl, alkynyl, alkenoxy, alkynoxy, aralkyl, acyl, alkylene, dioxyalkylene, halogen, CF 3 , OCF 3 , SCF 3 , NO 2 , NO, CN, N 3 , COR IV , COOR V , OR VI , NR 'or NR VIII R VIII , the alkyl, alkoxy and aryl radicals of the abovementioned substituents in turn being replaced by halogen, COR V or NR VII R VIII can be substituted or
    • c) stands for the radical NR VII R I , and wherein the radicals R I , R II , R III , R IV , R V , R VI , R VII and R VIII mentioned under a), b) and c) the below have the meaning given,
  • R 2
    • a) stands for one of the substituents specified under R 1 , but need not be identical with it or
    • b) for the residues NHR 'or
      Figure imgb0002
      stands,

    where R I , R IX and R X have the meaning given below,
    or the substituents R 1 and R 2 together form a 5- to 8-membered, saturated or unsaturated ring which optionally contains 1, 2 or 3 identical or different ring members from the group 0, S, NR 'or CO and which optionally 1 contains up to 3 identical or different substituents from the group halogen, hydroxy, alkyl, alkoxy, aryl or aralkyl,
  • R 3 represents one of the substituents indicated under R 2 , and is identical to or different from this, only one of the two substituents R 2 or R 3 each representing alkoxy, alkylthio or NHR ',
  • R 4
    • a) for hydrogen, NO 2 , NO, CN, SO m -R XI (m = 0, 1 or 2), halogen,
      Figure imgb0003
      or
      Figure imgb0004
      stands, wherein R I , R VII , R VIII , R XI and R XIII have the meaning given below, or
    • b) represents a branched or unbranched, cyclic, saturated or unsaturated aliphatic hydrocarbon radical which is optionally substituted by halogen, OH, CN, alkoxy, alkylthio, aryloxy, COOR V or
      Figure imgb0005
      wherein R V , R VII and R VIII have the meaning given below, or
    • c) for an aromatic hydrocarbon radical or for a 5- to 7-membered saturated or unsaturated hetero ring with 1 to 4 identical or different hetero members from the group O, S, -N =, NR I , this hetero ring either having a carbon atom or a Nitrogen atom is linked to the dihydropyridine ring, and wherein the aromatic hydrocarbon radical and the hetero rings optionally 1 to 3 identical or different substituents from the group halogen, OH, CN, CF 3 , OCF 3 , SCF 3 , NO 2 , alkyl, alkoxy, aryl and
      Figure imgb0006
      wear,
    • d) for the rest
      Figure imgb0007
      is where X is oxygen, sulfur or NR I and Y is a single bond, 0, S or NR ', and R B has the meaning given for R 1 and is the same as or different from the substituent R 1 , or
    • e) for the rest
      Figure imgb0008
      stands,

    where n ' , R 1' , R 2 ' , R 3' , R 5 ' , R 6' and R 7 'have the meaning given for n, R 1 , R 2 , R 3 , R 5 , R 6 and R 7 have and are the same or different from them, and R 4 * and R 4 ** are the same or different and each stand for a hydrogen-reduced radical of the substituents given for R 4 under a) to d), or
  • R 2 and R 4 together form a branched, unbranched, saturated or unsaturated 5- to 8-membered ring which optionally 1, 2 or 3 identical or different ring members from the group O, CO, CS, C = NR I , = N -, NR I , SO m (m = 0, 1 or 2) or SiR II R III , and which is optionally substituted by halogen, hydroxy, alkoxy, aryl, aralkyl,
    Figure imgb0009
    or is disubstituted by a straight-chain or branched alkylene chain having 3 to 8 carbon atoms,
    this common ring of R 2 and R 4 can also be fused directly to the common ring of R 1 and R 2 ,
    where the radicals R I , R II , R III , R VII , R VIII have the meaning given below,
  • R 5 for R 4 has the meaning given and is different with R 4 equal to or from this, or
  • R 5 and R 3 together form a ring which is the same as or different from the ring formed by R 2 and R 4 ,
  • R 6 represents hydrogen, alkyl or haloalkyl, and
  • R 7
    • a) represents a saturated, unsaturated, cyclic, straight-chain or branched aliphatic hydrocarbon radical which is optionally substituted by halogen, aryl or heteroaryl, or
    • b) represents an aryl or heteroaryl radical which may optionally have 1 to 5 identical or different substituents from the group No 2 , CN, N 3 , NO, CF3, halogen, COR IV , COOR V , OR VI
      Figure imgb0010
      Contains alkyl, aryl, alkenyl, alkynyl, alkenoxy, alkynoxy, aralkyl, acyl, alkylene, or dioxyalkylene, where the aforementioned alkyl and aryl substituents in turn by COOR V or
      Figure imgb0011
      may be substituted, and wherein in the abovementioned definitions of the substituents R 1 to R 8 R I is hydrogen, alkyl, aryl, aralkyl, heteroaryl or acyl, R II and R III are identical or different and are each alkyl, aryl, aralkyl or heteroaryl, R IV , R V and R VI are each the same or different and represent hydrogen, alkyl, aryl, aralkyl or heteroaryl, the alkyl and acyl radicals optionally being halogen, alkylthio, alkoxy, trifluoromethylnitro or R VII and R VIII are in each case identical or different and stand for hydrogen, aryl or aralkyl or for alkyl which is optionally interrupted by 0, S or NR I , or
      together with the nitrogen atom form a 5- to 7-membered ring which may contain 1 or 2 identical or different hetero ring members from the group O, S or NR I or
      wherein one of the radicals R VIII or R VIII represents an aliphatic acyl group having up to 6 Kohlenstoffato- men, R IX, R X R XI, R XII and R XIII are in each case identical or different and represent alkyl, aryl or aralkyl,
      wherein the alkyl, aryl, aralkyl, heteroaryl and acyl radicals mentioned under R 1 to R 8 and under R I to R XIII and the hetero ring formed with R VII and R VIII are in turn optionally substituted by OH, CF 3 , OCF 3 , CN, NO 2 , halogen, lower thioalkyl, lower alkyl, lower alkoxy, aryl or aralkyl,
      and the following substituents may be mentioned as heteroaryl:
      • Thienyl, furyl, pyryl, pyridyl, quinolyl, isoquinolyl, pyrimidyl, pyridazinyl, quinazolyl, quinoxalyl, benzothienyl, pyrazolyl, imidazolyl, Oxazolyl, isoxazolyl, thiazolyl, triazolyl, oxydiazolyl, pyrazinyl, oxazinyl, thiazinyl, indolizinyl, indolyl, benzofuranyl, indazolyl, benzothienyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, benztriazolyl, benzoxadiazolethyl, cinnamolethiazolethyl, cinnamolyziazolyl, benzoladiazolyl, methyltriazolyl, methyltriazolyl, methyltriazolyl, methyltriazole , Racemates and optical antipodes and their pharmaceutically acceptable salts, for the production of medicaments with a positive inotropic effect, which are particularly suitable as cardiotonics. Increase influx into the cell and are therefore suitable for the treatment of hypotonic circulatory conditions, for lowering blood sugar, for the detumescence of mucous membranes and for influencing the salt and fluid balance - This contraction force enhancing effect and the fact that the compounds of the invention the Ca ++ is based.

Die Verbindungen der allgemeinen Formel (I) sind solche, die ab einer Konzentration von 10-5 g/ml am linken Vorhof des ilosierten Meerschweinchenherzens eine Kontraktionsverstärkung um mindestens 25% bewirken.The compounds of general formula (I), the contraction gain at least 25%, such effect at the left atrium of the guinea pig heart ilosierten from a concentration of 10- 5 g / ml.

Die Versuchanordnung ist wie folgt:The experimental setup is as follows:

Die linken Vorhöfe von Meerschweinchenherzen werden isoliert und in ein thermostatisiertes Organbad gehängt, welches eine isotonische Mineralsalzlösung, die dem lonenmilieu und dem pH-Wert von Körperflüssigkeiten angepasst ist und geeignete Nährstoffe enthält. Dieses Organbad wird mit einem Gasgemisch bestehend aus Sauerstoff und Kohlendioxyd begast, wobei der Kohlendioxydgehalt so bemessen ist, dass der pH-Wert des Organbades konstant bleibt. Die linken Vorhöfe werden in das Organbad eingespannt, die Spannung wird mittels eines Kraftaufnehmers registriert, wobei ein bestimmter Grundtonus eingestellt wird. Anschliessend werden die linken Vorhöfe kontinuierlich in bestimmten Abständen elektrisch gereizt und die dabei erfolgenden Kontraktionen registriert. Nach Zugabe des Wirkstoffs werden die Kontraktionen weiterhin registriert. Eine Kontraktionsverstärkung um mindestens 25% gilt als signifikante positiv-inotrope Wirkung.The left auricles of guinea pig hearts are isolated and hung in a thermostatted organ bath containing an isotonic mineral salt solution that is adapted to the ionic environment and the pH of body fluids and contains suitable nutrients. This organ bath is gassed with a gas mixture consisting of oxygen and carbon dioxide, the carbon dioxide content being such that the pH of the organ bath remains constant. The left atria are clamped into the organ bath, the tension is registered by means of a force transducer, whereby a certain basic tone is set. The left atria are then continuously electrically stimulated at certain intervals and the contractions that occur are registered. After adding the active ingredient, the contractions are still registered. A contraction gain of at least 25% is considered a significant positive inotropic effect.

Die erfindungsgemässen Verbindungen der allgemeinen Formel (I) können nach üblichen Methoden auf verschiedene Weise hergestellt werden. Ihre Synthese erfolgt z. B.

  • A) durch direkten Aufbau der die Hydropyridinstruktur nach bekannten Dihydropyridinsynthesen oder
  • B) durch Umwandlung von funktionellen Gruppen am Dihydropyridingerüst nach bekannten Reaktionsschemen.
The compounds of general formula (I) according to the invention can be prepared in various ways by customary methods. Their synthesis takes place e.g. B.
  • A) by direct construction of the hydropyridine structure according to known dihydropyridine synthesis or
  • B) by converting functional groups on the dihydropyridine skeleton according to known reaction schemes.

A) Aufbau der 1,4-Dihydropyridin-GrundstrukturA) Structure of the 1,4-dihydropyridine basic structure

Der Aufbau der 1,4-Dihydropyridin-Grundstruktur kann erfolgen, indem man

  • a) Carbonylverbindungen der allgemeinen Formel (II)
    Figure imgb0012
    in welcher R6 und R7 die oben angegebene Bedeutung haben,
    • mit Ketonen der Formel (Ill) und (IV)
      Figure imgb0013
      in welchen R2, R3, R4 und R5 die oben angegebene Bedeutung haben,
    • und primären Aminen der Formel (V)
      Figure imgb0014
      in welcher n = 0 und R' die oben angegebene Bedeutung besitzt,
    • gegebenenfalls in Gegenwart von inerten Lösungsmitteln umsetzt, oder
  • b) Carbonylverbindungen der Formel (II)
    Figure imgb0015
    in welcher R6 und R7 die oben angegebene Bedeutung haben,
    • mit Enaminen der Formel (VI)
      Figure imgb0016
      in welcher Rl, R2, R4 und n die oben angegebene Bedeutung haben und
    • Ketonen der Formel (IV)
      Figure imgb0017
      in welcher R3 und R5 die oben angegebene Bedeutung haben,
    • gegebenenfalls in Gegenwart von inerten Lösungsmitteln umsetzt oder
  • c) Enamine der Formel (VI)
    Figure imgb0018
    in welcher R1, R2, R4 und n die oben angegebene Bedeutung haben
    • mit Ylidenverbindungen der Formel (VII)
      Figure imgb0019
      in welcher R3, R5, R6 und R7 die oben angegebene Bedeutung haben,
    • gegebenenfalls in Gegenwart von inerten Lösungsmitteln umsetzt.
The 1,4-dihydropyridine basic structure can be constructed by
  • a) carbonyl compounds of the general formula (II)
    Figure imgb0012
    in which R 6 and R 7 have the meaning given above,
    • with ketones of the formula (III) and (IV)
      Figure imgb0013
      in which R 2 , R 3 , R 4 and R 5 have the meaning given above,
    • and primary amines of the formula (V)
      Figure imgb0014
      in which n = 0 and R 'has the meaning given above,
    • if appropriate in the presence of inert solvents, or
  • b) carbonyl compounds of the formula (II)
    Figure imgb0015
    in which R 6 and R 7 have the meaning given above,
    • with enamines of the formula (VI)
      Figure imgb0016
      in which R 1 , R 2 , R 4 and n have the meaning given above and
    • Ketones of formula (IV)
      Figure imgb0017
      in which R 3 and R 5 have the meaning given above,
    • if appropriate in the presence of inert solvents or
  • c) enamines of the formula (VI)
    Figure imgb0018
    in which R 1 , R 2 , R 4 and n have the meaning given above
    • with ylidene compounds of the formula (VII)
      Figure imgb0019
      in which R 3 , R 5 , R 6 and R 7 have the meaning given above,
    • if appropriate in the presence of inert solvents.

B) Umwandlung der funktionellen GruppenB) Conversion of the functional groups

Durch Umwandlung einer oder mehrerer funktioneller Gruppen bekannter Dihydropyridine oder auch neuer Dihydropyridine die gemäss Verfahren A) a) bis c) erhalten wurden, können ebenfalls erfindungsgemäss Verbindungen der allgemeinen Formel (I) nach üblichen Methoden hergestellt werden (vgl. Houben-Weyl, Methoden der Organischen Chemie, Georg Thieme Verlag, Stuttgart 1966; Organicum, VEB Deutscher Verlag der Wissenschaften, Berlin 1969; W. Foerst, Neuere Methoden der präparativen organischen Chemie, Bd. 1-5, Verlag Chemie, Weinheim 1961; C. Ferri, Reaktionen der organischen Chemie, Georg Thieme Verlag, Stuttgart 1978; Fieser+Fieser, Reagents for Organic Synthesis, Vol. 1-8, J. Wiley & Sons, Inc., London 1967.By converting one or more functional groups of known dihydropyridines or also new dihydropyridines which according to the method ren A) a) to c), compounds of the general formula (I) can also be prepared according to the invention by customary methods (cf. Houben-Weyl, Methods of Organic Chemistry, Georg Thieme Verlag, Stuttgart 1966; Organicum, VEB Deutscher Verlag der Wissenschaften, Berlin 1969; W. Foerst, Newer Methods in Preparative Organic Chemistry, Vol. 1-5, Verlag Chemie, Weinheim 1961; C. Ferri, Reactions in Organic Chemistry, Georg Thieme Verlag, Stuttgart 1978; Fieser + Fieser, Reagents for Organic Synthesis, Vol. 1-8, J. Wiley & Sons, Inc., London 1967.

Als bevorzugte Umwandlungsreaktionen seien genannt: sauer oder basisch katalysierte Hydrolyse, Veresterung oder Umesterung, Lactamisierung, Kondensation, Acylierung, Reduktion oder Cyclisierung mit jeweils geeigneten Reaktionspartnern oder intramolekularer Art. Als besonders vorteilhaft sei die Lactonisierung erwähnt. Hierzu werden Verbindungen der allgemeinen Formel (I), in denen die Substituenten R2 und R4 oder/und R3 und R5 freie und/oder durch Schutzgruppen blokkierte Hydroxyl- und Carbonsäurefunktionen enthalten, unter geeigneten basisch oder sauer katalysierten Reaktionsbedingungen, gegebenenfalls unter vorhergehender ganz- oder teilweiser Abspaltung der Schutzgruppen, zu erfindungsgemässen Lactonen der allgemeinen Formel (I) cyclisiert.The following are preferred conversion reactions: acid or base-catalyzed hydrolysis, esterification or transesterification, lactamization, condensation, acylation, reduction or cyclization with in each case suitable reaction partners or intramolecular type. Lactonization should be mentioned as particularly advantageous. For this purpose, compounds of the general formula (I) in which the substituents R 2 and R 4 or / and R 3 and R 5 contain free and / or hydroxyl and carboxylic acid functions blocked by protective groups, under suitable base or acid-catalyzed reaction conditions, optionally under previous complete or partial removal of the protective groups, cyclized to lactones according to the invention of the general formula (I).

In der deutschen Offenlegungsschrift Nr. 2629892 werden einige der möglichen Herstellungsmethoden ausführlicher beschrieben.In German Offenlegungsschrift No. 2629892, some of the possible production methods are described in more detail.

Bevorzugt seien Verbindungen der allgemeinen Formel (I) genannt, in welcher n für 0, 1 oder 2 steht,

  • R'
    • a) für Wasserstoff, einen geradkettigen, verzweigten, cyclischen gesättigten oder ungesättigten aliphatischen Kohlenwasserstoffrest mit bis zu 10 C-Atomen steht der gegebenenfalls 1 oder 2 gleiche oder verschiedene Heterokettenglieder aus der Gruppe 0, CO, S, S02, =N- oder NR' enthält und wobei dieser Kohlenwasserstoffrest gegebenenfalls substituiert ist durch Halogen, N02, CN, N3, Hydroxy, mit 1 bis 4 C-Atomen, Phenyl, Naphthyl oder Heteroaryl oder
    • b) für einen Phenyl-, Naphthyl- oder Heteroarylrest steht, wobei diese Reste gegebenenfalls 1 bis 3 gleiche oder verschiedene Substituenten aus der Gruppe Phenyl, Alkyl, Alkenyl, Alkinyl, Alkenoxy, Alkinoxy mit jeweils bis zu 4 C-Atomen, Aralkyl mit 7 bis 14 C-Atomen, Acyl mit bis zu 6 C-Atomen, Alkylen, Dioxyalkylen mit bis zu 4 Kohlenstoffatomen in der Alkylenkette, Halogen, CF3, OCF3, SCF3, NO2, CN, N3, CORIV, COORV, ORVI, NRI oder NRVIIRVIII tragen, wobei die Alkyl-, Alkoxy-und Arylreste der oben genannten Substituenten ihrerseits wieder durch Halogen, COORV oder NRVIIRVIII substituiert sein können oder
    • c) für den Rest NRVIIRI steht,

    und wobei die unter a), b) und c) genannten Reste RI, RII, RIII, RIV, RV, RVI, RVII und RVIII die unten angegebene Bedeutung haben,
  • R2 ein
    • a) für einen der unter R1 angegebenen Substituenten steht aber nicht mit diesen identisch sein muss oder
    • b) für die Reste NHR' oder
      Figure imgb0020
      steht,

    wobei RI, RIX und RX die unten angegebene Bedeutung besitzen,
    oder die Substituenten
  • R1 und R2 gemeinsam einen 5- bis 7-gliedrigen gesättigten oder ungesättigten Ring bilden, der gegebenenfalls ein oder zwei gleiche oder verschiedene Ringglieder aus der Gruppe 0, S, NRI oder CO enthält und der gegebenenfalls ein bis drei gleiche oder verschiedene Substituenten aus der Gruppe Halogen, Hydroxy, Alkyl, Alkoxy mit jeweils 1 bis 4 C-Atomen, Phenyl, Naphthyl oder Aralkyl mit 7 bis 14 C-Atomen enthält,
  • R3 für einen der unter R2 angegebenen Substituenten steht und mit diesem gleich oder von diesem verschieden ist, wobei nur einer der beiden Substituenten R2 oder R3 jeweils für Alkoxy, Alkylthio, oder NHR' steht,
  • R4
    • a) für Wasserstoff, NO2, NO, CN, SOm-RIX (m = 0 oder 2), Halogen,
      Figure imgb0021
      oder
      Figure imgb0022
      steht. wobei RI, RVII, RVIII, RXI und RXIII die unten angegebene Bedeutung haben, oder
    • b) für einen verzweigten oder unverzweigten, cyclischen, gesättigten oder ungesättigten aliphatischen Kohlenwasserstoffrest mit bis zu 10 C-Atomen steht, der gegebenenfalls substituiert ist durch Halogen, OH, CN, Alkoxy, Alkylthio mit jeweils 1 bis 4 Kohlenstoffatomen, Phenyloxy, Naphthoxy, COORV oder
      Figure imgb0023
      wobei RV, RVII und RVIII die unten angegebene Bedeutung haben, oder
    • c) für einen aromatischen Kohlenwasserstoffrest mit 6 bis 10 C-Atomen oder für einen 5- bis 7-gliedrigen gesättigten oder ungesättigten Heteroring mit 1 bis 3 gleichen oder verschiedenen Heterogliedern aus der Gruppe 0, S, -N=, NRI, wobei dieser Heteroring entweder über ein Kohlenstoffatom oder ein Stickstoffatom mit dem Dihydropyridinring verknüpft ist, und wobei der aromatische Kohlenwasserstottrest und die Heteroringe gegebenenfalls 1 bis 3 gleiche oder verschiedene Substituenten aus der Gruppe Halogen, OH, CN, CF3, OCF3, SCF3, NO2, Alkyl, Alkoxy mit jeweils 1 bis 4 C-Atomen, Phenyl, Naphthyl und tragen,
      Figure imgb0024
      oder
    • c) für den Rest
      Figure imgb0025
      steht, wobei X Sauerstoff, Schwefel oder NRI bedeutet und Y für eine einfache Bindung, 0, S oder NR1 steht, und R8 die für R1 angegebene Bedeutung hat und mit dem Substituenten R1 gleich oder von diesem verschieden ist, oder
    • e) für den Rest
      Figure imgb0026
      steht,

    wobei n', R1', R2', R3', R5', R6' und R7' die für n, Rl, R2, R3, R5, R6 und R7 angegebene Bedeutung haben und mit diesen gleich oder von diesen verschieden sind, und
  • R4' und R4** gleich oder verschieden sind und jeweils für einen um ein Wasserstoff verminderten Rest der für R4 unter a) bis d) angegebenen Substituenten stehen, oder
  • R2 und R4 gemeinsam einen verzweigten, unverzweigten, gesättigten oder ungesättigten 5- bis 7-gliedrigen Ring bilden, der gegebenenfalls 1, 2 oder 3 gleiche oder verschiedene Ringglieder aus der Gruppe 0, CO, CS, C=NRI, =N-, NRI oder SOm (m = 0 oder 2) enthält und der gegebenenfalls substituiert ist durch Halogen, Hydroxy, Alkoxy mit 1 bis 4 C-Atomen, Phenyl, Naphthyl, Aralkyl mit 7 bis 14 C-Atomen,
    Figure imgb0027
    oder durch eine geradkettige oder verzweigte Alkylenkette mit 3 bis 8 Kohlenstoffatomen disubstituiert ist, wobei dieser gemeinsame Ring von R2 und R4 auch direkt mit dem gemeinsamen Ring von R1 und R2 anneliertsein kann, wobei die Reste RI, RII, RIII RVII, RVIII die unten angegebene Bedeutung haben,
  • R5 die für R4 angegebene Bedeutung besitzt und mit R4 gleich oder von diesem verschieden ist,
  • R6 für Wasserstoff, Alkyl oder Halogenalkyl mit jeweils 1 bis 4 C-Atomen steht und
  • R7
    • a) für einen gesättigten, ungesättigten cyclischen, geradkettigen oder verzweigten aliphatischen Kohlenwasserstoffrest mit bis zu 10 C-Atomen steht, der gegebenenfalls substituiert ist durch Halogen, Phenyl, Naphthyl oder Heteroaryl oder
    • b) einen Phenyl-, Naphthyl- oder Heteroarylrest steht, der gegebenenfalls 1 bis 3 gleiche oder verschiedene Substituenten aus der Gruppe N02, Halogen, CN, N3, NO, CF3, CORIV, COORV, ORVI,
      Figure imgb0028
      Alkyl mit 1 bis 4 C-Atomen, Phenyl, Naphthyl, Alkenyl, Alkinyl, Alkenoxy, Alkinoxy mit jeweils bis zu 4 C-Atomen, Aralkyl mit 7 bis 14 C-Atomen, Acyl mit 1 bis 4 C-Atomen, Alkylen oder Dioxyalkylen mit jeweils bis zu 4 C-Atomen enthält, wobei die vorgenannten Alkyl- und Arylsubstituenten ihrerseits wieder durch Halogen, COORV oder
      Figure imgb0029
      substituiert sein können, und wobei in den vorgenannten Definitionen der Substituenten R1 bis R7 RI für Wasserstoff, Alkyl mit 1 bis 6 C-Atomen, Phenyl, Naphthyl, Aralkyl mit 7 bis 12 C-Atomen, Heteroaryl oder Acyl mit bis zu 7 C-Atomen steht, RII und RIII gleich oder verschieden sind und jeweils für Alkyl mit 1 bis 6 C-Atomen, Phenyl, Naphthyl, Aralkyl mit 7 bis 12 C-Atomen oder Heteroaryl stehen,
  • RVII, RV und RVI jeweils gleich oder verschieden sind und für Wasserstoff, Alkyl mit 1 bis 6 C-Atomen, Phenyl, Naphthyl, Aralkyl mit 7 bis 12 C-Atomen oder Heteroaryl stehen,
  • RVII und RVIII jeweils gleich oder verschieden sind und für Wasserstoff, Phenyl, Naphthyl oder Aralkyl mit 7 bis 12 C-Atomen stehen oder für Alkyl mit 1 bis 6 C-Atomen, welches gegebenenfalls durch 0, S oder NR1 unterbrochen ist, stehen oder gemeinsam mit dem Stickstoffatom einen 5- bis 7-gliedrigen Ring bilden, der 1 oder 2 gleiche oder verschiedene Heteroringglieder aus der Gruppe 0, S oder NR' enthalten kann oder
  • wobei einer der Reste RVII und RVIII eine aliphatische Acylgruppe mit bis zu 6 Kohlenstoffatomen steht,
  • RIX, RX, RXII und RXIII jeweils gleich oder verschieden sind und für Alkyl mit 1 bis 6 C-Atomen, Phenyl, Naphthyl oder Aralkyl mit 7 bis 12 C-Atomen stehen,
  • wobei die unter R1 bis R8 und unter RI bis RVIII genannten Alkyl-, Aryl-, Aralkyl-, Heteroaryl- und Acylreste sowie der mit R6 und R7 gebildete Heteroring ihrerseits gegebenenfalls substituiert sind durch OH, CF3, OCF3, CN, NO2, Halogen, Alkyl mit 1 bis 4 C-Atomen, Alkoxy mit 1 bis 4 C-Atomen, Phenyl- oder Benzyl

    und wobei als Heteroaryl folgende Substituenten genannt seien:
    • Thienyl, Furyl, Pyryl, Pyridyl, Chinolyl, Isochinolyl, Pyrimidyl, Pyridazinyl, Chinazolyl, Chinoxalyl, Benzothienyl, Pyrazolyl, Imidazolyl, Oxazolyl, Isoxazolyl, Thiazolyl, Triazolyl, Oxydiazolyl, Pyrazinyl, Oxazinyl, Thiazinyl, Indolizinyl, Indolyl, Benzofuranyl, Indazolyl, Benzothienyl, Benzimidazolyl, Benzoxazolyl, Benzisoxazolyl, Benzthiazolyl, Benztriazolyl, Benzoxadiazolyl, Cinnolinyl, Phthalazinyl, Naphthyridinyl oder Benzotriazinyl, in Form von Isomeren, Isomerengemischen, Racematen und optischen Antipoden sowie ihrer pharmazeutisch unbedenklichen Salze.
Compounds of the general formula (I) in which n is 0, 1 or 2 are preferred,
  • R '
    • a) for hydrogen, a straight-chain, branched, cyclic saturated or unsaturated aliphatic hydrocarbon radical with up to 10 carbon atoms, the optionally 1 or 2 identical or different hetero chain links from the group 0, CO, S, S0 2 , = N or NR 'contains and wherein this hydrocarbon radical is optionally substituted by halogen, N0 2 , CN, N 3 , hydroxy, having 1 to 4 carbon atoms, phenyl, naphthyl or heteroaryl or
    • b) represents a phenyl, naphthyl or heteroaryl radical, these radicals optionally 1 to 3 identical or different substituents from the group phenyl, alkyl, alkenyl, alkynyl, alkenoxy, alkynoxy each having up to 4 carbon atoms, aralkyl having 7 up to 14 carbon atoms, acyl with up to 6 carbon atoms, alkylene, dioxyalkylene with up to 4 carbon atoms in the alkylene chain, halogen, CF3, OCF 3 , SCF 3 , NO 2 , CN, N 3 , COR IV , COOR V , OR VI , NR I or NR VII R VIII , where the alkyl, alkoxy and aryl radicals of the above-mentioned substituents can in turn be substituted by halogen, COOR V or NR VII R VIII or
    • c) represents the rest of NR VII R I ,

    and where the radicals R I , R II , R III , R IV , R V , R VI , R VII and R VIII mentioned under a), b) and c) have the meaning given below,
  • R 2 a
    • a) stands for one of the substituents specified under R 1 but need not be identical with them or
    • b) for the residues NHR 'or
      Figure imgb0020
      stands,

    where R I , R IX and R X have the meaning given below,
    or the substituents
  • R 1 and R 2 together form a 5- to 7-membered saturated or unsaturated ring which optionally contains one or two identical or different ring members from the group 0, S, NR I or CO and which optionally contains one to three identical or different substituents contains from the group halogen, hydroxy, alkyl, alkoxy, each with 1 to 4 carbon atoms, phenyl, naphthyl or aralkyl with 7 to 14 carbon atoms,
  • R 3 represents one of the substituents specified under R 2 and is identical to or different from this, only one of the two substituents R 2 or R 3 each representing alkoxy, alkylthio or NHR ',
  • R4
    • a) for hydrogen, NO 2 , NO, CN, SOm-R IX (m = 0 or 2), halogen,
      Figure imgb0021
      or
      Figure imgb0022
      stands. wherein R I , R VII , R VIII , R XI and R XIII have the meaning given below, or
    • b) represents a branched or unbranched, cyclic, saturated or unsaturated aliphatic hydrocarbon radical having up to 10 carbon atoms, which is optionally substituted by halogen, OH, CN, alkoxy, alkylthio each having 1 to 4 carbon atoms, phenyloxy, naphthoxy, COOR V or
      Figure imgb0023
      wherein R V , R VII and R VIII have the meaning given below, or
    • c) for an aromatic hydrocarbon radical with 6 to 10 carbon atoms or for a 5- to 7-membered saturated or unsaturated hetero ring with 1 to 3 identical or different hetero members from the group 0, S, -N =, NR I , where this Heteroring is linked to the dihydropyridine ring either via a carbon atom or a nitrogen atom, and wherein the aroma Tische Hydrostottrest and the hetero rings optionally 1 to 3 identical or different substituents from the group halogen, OH, CN, CF 3 , OCF 3 , SCF 3 , NO 2 , alkyl, alkoxy, each with 1 to 4 carbon atoms, phenyl, naphthyl and wear,
      Figure imgb0024
      or
    • c) for the rest
      Figure imgb0025
      is where X is oxygen, sulfur or NR I and Y is a single bond, 0, S or NR 1 , and R 8 has the meaning given for R 1 and is identical to or different from the substituent R 1 , or
    • e) for the rest
      Figure imgb0026
      stands,

    where n ', R 1' , R 2 ' , R 3' , R 5 ' , R 6' and R 7 'have the meaning given for n, R 1 , R 2 , R 3 , R 5 , R 6 and R 7 have and are the same as or different from them, and
  • R 4 ' and R 4 ** are the same or different and each represent a hydrogen-reduced radical of the substituents given for R 4 under a) to d), or
  • R 2 and R 4 together form a branched, unbranched, saturated or unsaturated 5- to 7-membered ring which may contain 1, 2 or 3 identical or different ring members from the group 0, CO, CS, C = NR I , = N -, NR I or SO m (m = 0 or 2) and which is optionally substituted by halogen, hydroxy, alkoxy with 1 to 4 carbon atoms, phenyl, naphthyl, aralkyl with 7 to 14 carbon atoms,
    Figure imgb0027
    or is disubstituted by a straight-chain or branched alkylene chain having 3 to 8 carbon atoms, this common ring of R 2 and R 4 also being able to be directly linked to the common ring of R 1 and R 2 , where the residues R I , R II , R III R VII , R VIII have the meaning given below,
  • R 5 has the meaning given for R 4 and is identical to or different from R 4 ,
  • R 6 represents hydrogen, alkyl or haloalkyl each having 1 to 4 carbon atoms and
  • R 7
    • a) represents a saturated, unsaturated cyclic, straight-chain or branched aliphatic hydrocarbon radical having up to 10 carbon atoms, which is optionally substituted by halogen, phenyl, naphthyl or heteroaryl or
    • b) a phenyl, naphthyl or heteroaryl radical which may optionally have 1 to 3 identical or different substituents from the group NO 2 , halogen, CN, N 3 , NO, CF 3 , COR IV , COOR V , OR VI ,
      Figure imgb0028
      Alkyl with 1 to 4 carbon atoms, phenyl, naphthyl, alkenyl, alkynyl, alkenoxy, alkynoxy each with up to 4 carbon atoms, aralkyl with 7 to 14 carbon atoms, acyl with 1 to 4 carbon atoms, alkylene or dioxyalkylene Contains up to 4 carbon atoms each, the aforementioned alkyl and aryl substituents in turn by halogen, COOR V or
      Figure imgb0029
      may be substituted, and wherein in the aforementioned definitions of the substituents R 1 to R 7 R I for hydrogen, alkyl having 1 to 6 carbon atoms, phenyl, naphthyl, aralkyl having 7 to 12 carbon atoms, heteroaryl or acyl with up to 7 C atoms, R II and R III are identical or different and each represent alkyl having 1 to 6 C atoms, phenyl, naphthyl, aralkyl having 7 to 12 C atoms or heteroaryl,
  • R VII , R V and R VI are each the same or different and represent hydrogen, alkyl having 1 to 6 C atoms, phenyl, naphthyl, aralkyl having 7 to 12 C atoms or heteroaryl,
  • R VII and R VIII are in each case identical or different and represent hydrogen, phenyl, naphthyl or aralkyl with 7 to 12 C atoms or for alkyl with 1 to 6 C atoms, which is optionally interrupted by 0, S or NR 1 , stand or together with the nitrogen atom form a 5- to 7-membered ring which may contain 1 or 2 identical or different hetero ring members from the group 0, S or NR 'or
  • where one of the radicals R VII and R VIII is an aliphatic acyl group having up to 6 carbon atoms,
  • R IX , R X , R XII and R XIII are each the same or different and represent alkyl with 1 to 6 C atoms, phenyl, naphthyl or aralkyl with 7 to 12 C atoms,
  • wherein the alkyl, aryl, aralkyl, heteroaryl and acyl radicals mentioned under R 1 to R 8 and under R I to R VIII and the hetero ring formed with R 6 and R 7 are in turn optionally substituted by OH, CF 3 , OCF 3 , CN, NO 2 , halogen, alkyl having 1 to 4 carbon atoms, alkoxy having 1 to 4 carbon atoms, phenyl or benzyl

    and the following substituents may be mentioned as heteroaryl:
    • Thienyl, furyl, pyryl, pyridyl, quinolyl, isoquinolyl, pyrimidyl, pyridazinyl, quinazolyl, quinoxalyl, benzothienyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, oxydiazolyl, pyrazinyl, oxazinyl, indiazyl, thiazolyl Benzothienyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzthiazolyl, benztriazolyl, benzoxadiazolyl, cinnolinyl, phthalazinyl, naphthyridinyl or benzotriazinyl, in the form of isomers, isomer mixtures, racemates and optical antipodes and their pharmaceutically acceptable salts.

Von besonderem Interesse sind Verbindungen der allgemeinen Formel (I), in welcher

  • n für 0 oder 1 steht,
    • R1
      • a) für Wasserstoff, einen geradkettigen, verzweigten cyclischen gesättigten oder ungesättigten aliphatischen Kohlenwasserstoffrest mit bis zu 10 C-Atomen steht, der gegebenenfalls durch ein oder zwei gleiche oder verschiedene Heterokettenglieder aus der Gruppe 0, CO, S, = N- oder NR' enthält und wobei dieser Kohlenwasserstoffrest gegebenenfalls substituiert ist durch F, CI, Br, N02, CN, OH, Phenyl oder Pyridyl oder
      • b) für einen Phenyl-, Naphthyl- oder Pyridylrest steht, wobei diese Reste gegebenenfalls 1 oder 2 gleiche oder verschiedene Substituenten aus der Gruppe Phenyl, Alkyl, Alkenyl, Alkoxy, Alkenoxy mit jeweils bis zu 4 C-Atomen, Benzyl, Acetyl, Alkylen, Dioxyalkylen mit 2 bis 4 C-Atomen, Fluor, Chlor, Brom, CF3, OCF3, SCF3, NO2, CN, COORV, ORVI, NRI oder NRVIIRVIII tragen, wobei die Alkyl-, Alkoxy- und Arylreste der o.g. Substituenten ihrerseits wieder Halogen substituiert sein können oder
      • c) für den Rest NRVIIRVIII steht,

      und wobei die unter a), b) und c) genannten Reste RI bis RVIII die unten angegebene Bedeutung haben,
    • R2 a) für einen der unter R1 angegebenen Substituenten steht aber nicht mit diesen identisch sein muss oder
      • b) für die Reste NHRI oder
        Figure imgb0030

        steht,
        wobei RI, RIX und RX die unten angegebene Bedeutung besitzen
        oder die Substituenten
      • R1 und R2 gemeinsam einen 5- bis 7-gliedrigen gesättigten oder ungesättigten Ring bilden, der gegebenenfalls 1 oder 2 gleiche oder verschiedene Ringglieder aus der Gruppe 0, S, NRI oder CO enthält und der gegebenenfalls 1 oder 2 gleiche oder verschiedene Substituenten aus der Gruppe Halogen, Hydroxy, Alkyl, Alkoxy mit je 1 bis 4 C-Atomen, Phenyl oder Benzyl enthält,
      • R3 für einen der unter R2 angegebenen Substituenten steht und mit diesem gleich oder von diesem verschieden ist, wobei nur einer der beiden Substituenten R2 oder R3 jeweils für Alkoxy, Alkylthio oder NHR' steht,
      • R4 a) für Wasserstoff, NO2, CN, SRXI, SO2RXI,
        Figure imgb0031
        oder
        Figure imgb0032
        steht, wobei RI, RVI, RVII, RVIII und RIX die unten angegebene Bedeutung haben,
        • b) für einen verzweigten oder unverzweigten Alkyl- oder Cycloalkylrest mit bis zu 8 C-Atomen steht, der gegebenenfalls substituiert ist durch Halogen, Hydroxy, Cyano, Alkoxy mit 1 bis 4 C-Atomen, Phenyloxy, COORV oder
          Figure imgb0033
          wobei RV, RVII und RVIII die unten angegebene Bedeutung haben oder
        • c) für einen aromatischen Kohlenwasserstoffrest mit 6 bis 10 C-Atomen oder für einen 5- bis 7-gliedrigen gesättigten oder ungesättigten Heteroring mit 1 bis 3 gleichen oder verschiedenen Heterogliedern aus der Gruppe 0, S, =N-, NRI, wobei dieser Heteroring entweder über ein Kohlenstoffatom oder ein Stickstoffatom mit dem Dihydropyridinring verknüpft ist und wobei der aromatische Kohlenwasserstoffrest und die Heteroringe gegebenenfalls 1 oder 2 gleiche oder verschiedene Substituenten aus der Gruppe Halogen, Hydroxy, Cyano, CF3, NO2, Phenyl, Alkyl und Alkoxy mit je 1 bis 4 C-Atomen tragen,
          oder
        • d) für den Rest
          Figure imgb0034
          steht, wobei X Sauerstoff oder NRI und Y für eine einfache Bindung, Sauerstoff oder NRI steht und R8 für für R1 angegebene Bedeutung hat und mit dem Substituenten gleich oder von diesem verschieden ist,
          oder
          Figure imgb0035
          5 wobei n', R1', R2', R3', R5', R6' und R7' die für n, R1, R 2, R 3, R 5, R6 und R7 angegebene Bedeutung haben und mit diesen gleich oder von diesen verschieden sind, und
      • R4* und R4** gleich oder verschieden sind und jeweils für einen um ein Wasserstoff verminderten Rest der für R4 unter a) bis d) angegebenen Substituenten stehen, oder
        • R2 und R4 gemeinsam einen verzweigten unverzweigten, gesättigten oder ungesättigten 5- bis 7-gliedrigen Ring bilden, der gegebenenfalls 1 oder 2 gleiche oder verschiedene Ringglieder aus der Gruppe 0, CO, CS, C=NRI, =N- oder NR' enthält und der gegebenenfalls substituiert ist durch Halogen oder Hydroxy,
        • wobei R1 die unten angegebene Bedeutung hat,
        • R5 die für R4 angegebene Bedeutung besitzt und mit R4 gleich oder von diesen verschieden ist oder
        • R5 und R3 gemeinsam einen Ring bilden, wie er für R2 und R4 definiert ist und mit diesem gleich oder von diesem verschieden ist,
        • R6 für Wasserstoff oder Alkyl mit 1 bis 4 C-Atomen steht, welches gegebenenfalls durch Fluor, Chlor oder Brom substituiert ist und
        • R 7
          • a) für einen gesättigten, ungesättigten cyclischen, geradkettigen oder verzweigten aliphatischen Kohlenwasserstoffrest mit bis zu 8 C-Atomen steht, der gegebenenfalls substituiert ist durch Halogen, oder
          • b) für einen Phenyl- oder Heteroarylrest steht, der gegebenenfalls 1 bis 3 gleiche oder verschiedene Substituenten aus der Gruppe N02, CN, N3, CF3, Halogen, CORIV, CORV, ORVI, SRXI,
            Figure imgb0036
            Phenyl, Alkyl mit 1 bis 4 C-Atomen, Benzyl oder Acyl mit 1 bis 4 C-Atomen enthält,

          wobei in den vorgenannten Definitionen der Substituenten R1 bis R8
        • R' für Wasserstoff, Alkyl mit 1 bis 6 C-Atomen, Phenyl, Naphthyl, Benzyl, Phenethyl, Heteroaryl oder Acyl mit bis zu 4 C-Atomen steht,
        • RII und RIII gleich oder verschieden sind und jeweils für Alkyl mit 1 bis 6 C-Atomen, Phenyl, Naphthyl, Benzyl oder Heteroaryl stehen,
        • RIV, RV und RVI jeweils gleich oder verschieden sind und für Wasserstoff, Alkyl mit 1 bis 6 C-Atomen, Phenyl, Naphthyl, Benzyl oder Heteroaryl stehen,
        • RVII und RVIII die jeweils gleich oder verschieden sind und für Wasserstoff, Phenyl oder Benzyl stehen oder für Alkyl mit 1 bis 6 Kohlenstoffatomen stehen, welches gegebenenfalls durch 0 oder NR1 unterbrochen ist, oder
          gemeinsam mit dem Stickstoffatom einen 5- bis 7-gliedrigen Ring bilden, der 1 oder 2 gleiche verschiedene Heteroringglieder aus der Gruppe 0, S oder NR' enthalten kann,
          oder
          wobei einer der Reste RVII oder RVIII für eine aliphatische Acylgruppe mit bis zu 6 Kohlenstoffatomen steht und
        • RIX, RX, RXI, RXII und RXIII jeweils gleich oder verschieden sind und für Alkyl mit 1 bis 6 C-Atomen, Phenyl oder Benzyl stehen,
          wobei als Heteroaryl folgende Substituenten genannt seien:
          • Thienyl, Furyl, Pyryl, Pyridyl, Chinolyl, Isochinolyl, Pyrimidyl, Pyridazinyl, Chinazolyl, Chinoxalyl, Benzothienyl, Pyrazolyl, Imidazolyl, Oxazolyl, Isoxazolyl, Thiazolyl, Triazolyl, Oxydiazolyl, Pyrazinyl, Oxazinyl, Thiazinyl, Indolyl, Benzofuranyl, Indazolyl, Benzothienyl, Benzimidazolyl, Benzoxazolyl, Benzisoxazolyl, Benzthiazolyl, Benztriazolyl, oder Benzoxadiazolyl.
Of particular interest are compounds of the general formula (I) in which
  • n represents 0 or 1,
    • R 1
      • a) represents hydrogen, a straight-chain, branched cyclic saturated or unsaturated aliphatic hydrocarbon radical having up to 10 carbon atoms, which optionally contains one or two identical or different hetero chain links from the group 0, CO, S, = N or NR ' and wherein this hydrocarbon radical is optionally substituted by F, CI, Br, N0 2 , CN, OH, phenyl or pyridyl or
      • b) represents a phenyl, naphthyl or pyridyl radical, these radicals optionally 1 or 2 identical or different substituents from the group phenyl, alkyl, alkenyl, alkoxy, alkenoxy each having up to 4 carbon atoms, benzyl, acetyl, alkylene , Dioxyalkylene with 2 to 4 carbon atoms, fluorine, chlorine, bromine, CF 3 , OCF 3 , SCF 3 , NO 2 , CN, COOR V , OR VI , NR I or NR VII R VIII , the alkyl, Alkoxy and aryl radicals of the abovementioned substituents can in turn be halogen substituted or
      • c) represents the radical NR VII R VIII ,

      and wherein the radicals R I to R VIII mentioned under a), b) and c) have the meaning given below,
    • R 2 a) stands for one of the substituents specified under R 1 but need not be identical to them or
      • b) for the residues NHR I or
        Figure imgb0030

        stands,
        where R I , R IX and R X have the meaning given below
        or the substituents
      • R 1 and R 2 together form a 5- to 7-membered saturated or unsaturated ring which optionally contains 1 or 2 identical or different ring members from the group 0, S, NR I or CO and which optionally 1 or 2 identical or different substituents contains from the group halogen, hydroxy, alkyl, alkoxy, each with 1 to 4 carbon atoms, phenyl or benzyl,
      • R 3 represents one of the substituents indicated under R 2 and is identical to or different from this, only one of the two substituents R 2 or R 3 each representing alkoxy, alkylthio or NHR ',
      • R 4 a) for hydrogen, NO 2 , CN, SR XI , SO 2 R XI ,
        Figure imgb0031
        or
        Figure imgb0032
        where R I , R VI , R VII , R VIII and R IX have the meaning given below,
        • b) represents a branched or unbranched alkyl or cycloalkyl radical having up to 8 carbon atoms, which is optionally substituted by halogen, hydroxy, cyano, alkoxy having 1 to 4 carbon atoms, phenyloxy, COOR V or
          Figure imgb0033
          wherein R V , R VII and R VIII have the meaning given below or
        • c) for an aromatic hydrocarbon radical with 6 to 10 carbon atoms or for a 5- to 7-membered saturated or unsaturated hetero ring with 1 to 3 identical or different hetero members from the group 0, S, = N-, NR I , where this Heteroring is linked to the dihydropyridine ring either via a carbon atom or a nitrogen atom and the aromatic hydrocarbon radical and the hetero rings optionally have 1 or 2 identical or different substituents from the group consisting of halogen, hydroxy, cyano, CF 3 , NO 2 , phenyl, alkyl and alkoxy each carry 1 to 4 carbon atoms,
          or
        • d) for the rest
          Figure imgb0034
          where X is oxygen or NR I and Y is a single bond, oxygen or NR I and R 8 has the meaning given for R 1 and is the same as or different from the substituent,
          or
          Figure imgb0035
          5 where n ', R 1' , R 2 ' , R 3' , R 5 ' , R 6' and R 7 'are those for n, R 1 , R 2 , R 3 , R 5 , R 6 and R 7 have the meaning given and are the same as or different from these, and
      • R 4 * and R 4 ** are the same or different and each represent a hydrogen-reduced radical of the substituents given for R 4 under a) to d), or
        • R 2 and R 4 together form a branched unbranched, saturated or unsaturated 5- to 7-membered ring, which optionally 1 or 2 identical or different ring members from the group 0, CO, CS, C = NR I , = N or NR contains and which is optionally substituted by halogen or hydroxy,
        • where R 1 has the meaning given below,
        • R 5 has the meaning given for R 4 and is identical to or different from R 4 or
        • R 5 and R 3 together form a ring as it is defined for R 2 and R 4 and is identical to or different from it,
        • R 6 represents hydrogen or alkyl having 1 to 4 carbon atoms, which is optionally substituted by fluorine, chlorine or bromine and
        • R 7
          • a) represents a saturated, unsaturated cyclic, straight-chain or branched aliphatic hydrocarbon radical having up to 8 C atoms, which is optionally substituted by halogen, or
          • b) represents a phenyl or heteroaryl radical which may optionally have 1 to 3 identical or different substituents from the group NO 2 , CN, N 3 , CF 3 , halogen, COR IV , COR V , OR VI , SR XI ,
            Figure imgb0036
            Contains phenyl, alkyl with 1 to 4 carbon atoms, benzyl or acyl with 1 to 4 carbon atoms,

          where in the aforementioned definitions of the substituents R 1 to R 8
        • R 'represents hydrogen, alkyl having 1 to 6 carbon atoms, phenyl, naphthyl, benzyl, phenethyl, heteroaryl or acyl having up to 4 carbon atoms,
        • R II and R III are the same or different and each represents alkyl having 1 to 6 carbon atoms, phenyl, naphthyl, benzyl or heteroaryl,
        • R IV , R V and R VI are each the same or different and represent hydrogen, alkyl having 1 to 6 carbon atoms, phenyl, naphthyl, benzyl or heteroaryl,
        • R VII and R VIII are each the same or different and represent hydrogen, phenyl or benzyl or represent alkyl having 1 to 6 carbon atoms, which is optionally interrupted by 0 or NR 1 , or
          together with the nitrogen atom form a 5- to 7-membered ring which can contain 1 or 2 identical hetero ring members from the group 0, S or NR ',
          or
          wherein one of the radicals R VII or R VIII stands for an aliphatic acyl group with up to 6 carbon atoms and
        • R IX , R X , R XI , R XII and R XIII are each the same or different and represent alkyl having 1 to 6 carbon atoms, phenyl or benzyl,
          the following substituents may be mentioned as heteroaryl:
          • Thienyl, furyl, pyryl, pyridyl, quinolyl, isoquinolyl, pyrimidyl, pyridazinyl, quinazolyl, quinoxalyl, benzothienyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, oxydiazolyl, pyrazinyl, oxazanyyl, indazolylyl, indazolylyl, indazolylyl, indazolylyl, indazolylyl, indazolylyl, indazolylylazolyl, indazolylylazolyl, indazazolyl, benzazylyl, indazylyl, benzazylyl, indazylyl, indazylyl Benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzthiazolyl, benztriazolyl, or benzoxadiazolyl.

Insbesondere seien Verbindungen der allgemeinen Formel (I) genannt, in welcher n für 0 steht,

  • R1
    • a) für Wasserstoff, einen aliphatischen Kohlenwasserstoffrest mit bis zu 6 C-Atomen, der gegebenenfalls ein Heterokettenglied aus der Gruppe 0, CO, = N- oder NR' enthält und der gegebenenfalls substituiert ist durch Halogen, Nitro, Hydroxy oder Phenyl oder
    • b) für einen Phenyl- oder Pyridylrest steht, die gegebenenfalls substituiert sind durch Halogen, NO2, CFa, OCF3, CN, COORV oder NRVIIRVIII,
  • R2 für einen der unter R1 angegebenen Substituenten steht, aber nicht mit diesem identisch sein muss oder für einen der Reste NHR' oder N = CRXRXI steht,
  • R3 für einen der unter R2 angegebenen Substituenten steht und mit diesem gleich oder von diesem verschieden ist,
  • R 4
    • a) für Wasserstoff, NO2, NRVIIRVIII, NH-CO-NRVIIRVIII oder Halogen steht, oder
    • b) für einen Alkylrest mit 1 bis 4 C-Atomen steht, der gegebenenfalls substituiert ist durch Halogen, OH, CN, Alkoxy mit 1 bis 4 C-Atomen, COORV oder NRVIIRVIII oder
    • c) für Phenyl, Pyridyl oder Thienyl steht, die gegebenenfalls substituiert sind durch Halogen, OH, CN, Alkyl oder Alkoxy mit jeweils 1 bis 4 C-Atomen oder durch NRVIIRVIII oder
    • d) für den Rest
      Figure imgb0037
      steht,
  • wobei X Sauerstoff bedeutet und Y für eine einfache Bindung, Sauerstoff oder NRI steht und R8 die für R1 angegebene Bedeutung hat und mit dem Substituenten R1 gleich oder von diesem verschieden ist oder
    Figure imgb0038
    steht, wobei n', R1', R2', R3', R5', R6' und R7' die für n, R1, R2, R3, R5, R6 und R7 angegebene Bedeutung haben und mit diesen gleich oder von diesen verschieden sind, und
  • R4* und R4** gleich oder verschieden sind und jeweils für einen um ein Wasserstoff verminderten Rest der für R4 unter a) bis d) angegebenen Substituenten stehen, oder
  • R2 und R4 gemeinsam einen 5- bis 7-gliedrigen Ring bilden, der gegebenenfalls 1 oder 2 verschiedene Ringglieder aus der Gruppe O, CO, CS oder C=NR' enthält und der gegebenenfalls substituiert ist durch Halogen,
  • R5 die für R4 angegebene Bedeutung besitzt und mit R4 gleich oder von diesem verschieden ist,
  • R6 für Wasserstoff oder Alkyl mit 1 bis 4 C-Atomen steht und R7 die oben angegebene Bedeutung besitzt,

wobei in den vorgenannten Definitionen die mit römischen Ziffern gekennzeichneten Substituenten RI bis RVIII die oben angegebene Bedeutung besitzen.Compounds of the general formula (I) in which n is 0
  • R 1
    • a) for hydrogen, an aliphatic hydrocarbon radical with up to 6 carbon atoms, which optionally contains a hetero chain link from the group 0, CO, = N- or NR 'and which is optionally substituted by halogen, nitro, hydroxy or phenyl or
    • b) represents a phenyl or pyridyl radical which are optionally substituted by halogen, NO 2 , CF a , OCF 3 , CN, COOR V or NR VII R VIII ,
  • R 2 stands for one of the substituents given under R 1 , but need not be identical to it, or stands for one of the radicals NHR 'or N = CR X R XI ,
  • R 3 represents one of the substituents indicated under R 2 and is identical to or different from this,
  • R 4
    • a) represents hydrogen, NO 2 , NR VII R VIII , NH-CO-NR VII R VIII or halogen, or
    • b) represents an alkyl radical with 1 to 4 carbon atoms, which is optionally substituted by halogen, OH, CN, alkoxy with 1 to 4 carbon atoms, COOR V or NR VII R VIII or
    • c) represents phenyl, pyridyl or thienyl, which are optionally substituted by halogen, OH, CN, alkyl or alkoxy each having 1 to 4 carbon atoms or by NR VII R VIII or
    • d) for the rest
      Figure imgb0037
      stands,
  • where X is oxygen and Y is a simple bond, oxygen or NR I and R 8 has the meaning given for R 1 and is the same as or different from the substituent R 1 or
    Figure imgb0038
    stands, where n ', R 1' , R 2 ' , R 3' , R 5 ' , R 6' and R 7 'have the meaning given for n, R 1 , R 2 , R 3 , R 5 , R 6 and R 7 have and are the same as or different from them, and
  • R 4 * and R 4 ** are the same or different and each represent a hydrogen-reduced radical of the substituents given for R 4 under a) to d), or
  • R 2 and R 4 together form a 5- to 7-membered ring which optionally contains 1 or 2 different ring members from the group O, CO, CS or C = NR 'and which is optionally substituted by halogen,
  • R 5 has the meaning given for R 4 and is identical to or different from R 4 ,
  • R 6 represents hydrogen or alkyl having 1 to 4 carbon atoms and R 7 has the meaning given above,

wherein in the above definitions, the substituents R I to R VIII marked with Roman numerals have the meaning given above.

Besonders hervorgehoben seien Verbindungen, in denen wenigstens einer der Substituenten R4 und R5 für NO2 stehen,
und/oder
in denen R2 und R4 gemeinsam oder R3 und R5 gemeinsam einen Lactonring bilden.
Particular emphasis is given to compounds in which at least one of the substituents R 4 and R 5 is NO 2 ,
and or
in which R 2 and R 4 together or R 3 and R 5 together form a lactone ring.

Die Herstellung der erfindungsgemässen 1,4-Dihydropyridinderivate mit positiv inotroper Wirkung erfolgt nach üblichen Methoden, die für die Herstellung von 1,4-Dihydropyridinen bekannt sind (vgl. z. B. britisches Patent 1 305 793; britisches Patent 1 358 951; DE-OS 2 752 820; DE-OS 2 847 237; DE-OS 2 629 892; DE-OS 2 658 804).The 1,4-dihydropyridine derivatives according to the invention with a positive inotropic effect are prepared by customary methods which are known for the preparation of 1,4-dihydropyridines (cf., for example, British patent 1 305 793; British patent 1 358 951; DE -OS 2 752 820; DE-OS 2 847 237; DE-OS 2 629 892; DE-OS 2 658 804).

Einige der erfindungsgemäss verwendbaren Verbindungen sind bereits aus dem Stand der Technik bekannt. Die Verbindungen der Herstellungsbeispiele 1 bis 10, 19 bis 23, 26, 28, 29, 30, 31, 32, 35 bis 38, 41, 42, 43, 45 und 46 bis 254 sind neu. Diese neuen Verbindungen werden z.T. durch allgemeine Substituentendefinitionen des Standes der Technik umfasst ohne jedoch bisher namentlich genannt worden zu sein.Some of the compounds which can be used according to the invention are already known from the prior art. The compounds of Preparation Examples 1 to 10, 19 to 23, 26, 28, 29, 30, 31, 32, 35 to 38, 41, 42, 43, 45 and 46 to 254 are new. These new connections are partly encompassed by general substituent definitions of the prior art without having been mentioned so far.

Neu sind auch solche Verbindungen aus der allgemeinen Formel 1, in denen mindestens einer der Substituenten R4 und R5 für die Gruppe

Figure imgb0039
steht, wobei RVIII und RVII und die Substituenten R1, R2, R 3, R6 und R7 und n die oben angegebene Bedeutung haben, und solche Verbindungen aus der allgemeinen Formel I, in denen mindestens einer der Substituenten R4 und R5 für Methyl steht, wobei R1, R2, R3, R6 und R7 und n die oben angegebene Bedeutung haben, und solche Verbindungen aus der allgemeinen Formel I, in denen einer der Reste R4 oder R5 Wasserstoff bedeutet, R1 für Wasserstoff und n für 0 steht, und R2, R3, R6 und R7, sowie der andere Rest von R4 oder R5 die oben angegebene Bedeutung haben, und solche Verbindungen aus der allgemeinen Formel in denen einer der Reste R4 oder R5 Halogen bedeutet, und R1, R2, R3, R6, R7 und n, sowie der andere Rest von R4 oder R5 die oben angegebene Bedeutung haben.Also new are those compounds of the general formula 1 in which at least one of the substituents R 4 and R 5 for the group
Figure imgb0039
where R VIII and R VII and the substituents R 1 , R 2 , R 3 , R 6 and R 7 and n have the meaning given above, and those compounds of the general formula I in which at least one of the substituents R 4 and R 5 is methyl, where R 1 , R 2 , R 3 , R 6 and R 7 and n have the meaning given above, and those compounds of the general formula I in which one of the radicals R 4 or R 5 is hydrogen means R 1 is hydrogen and n is 0, and R 2 , R 3 , R 6 and R 7 , and the other radicals of R 4 or R 5 have the meaning given above, and compounds of the general formula in which one of the radicals R 4 or R 5 is halogen, and R 1 , R 2 , R 3 , R 6 , R 7 and n, and the other radical of R 4 or R 5 have the meaning given above.

Die vorliegende Erfindung betrifft auch die neuen Verbindungen unter der allgemeinen Formel (I), ihre Herstellung und ihre Verwendung in Arzneimitteln mit positiv inotroper Wirkung.The present invention also relates to the new compounds of the general formula (I), their preparation and their use in medicaments with a positive inotropic effect.

Verbindungen der allgemeinen Formel (I), in denen R2 von R3 oder R4 von R5 verschieden ist, können aufgrund der Anwesenheit eines asymmetrischen Kohlenstoffatoms in 4-Position des Dihydropyridinringes als racemische Mischungen oder in Form von optischen Isomeren erhalten werden. Einige der erfindungsgemässen Verbindungen die mindestens 2 asymmetrische Kohlenstoffatome enthalten, können in Form einzelner Diastereomeren oder in Form der Mischungen davon erhalten werden. Die diastereomere Mischung kann unter Anwendung konventioneller Verfahren aufgetrennt werden. Beispielsweise durch fraktionierte Umkristallisation oder durch chromatographische Verfahren. Racemische Mischungen lassen sich nach üblichen Methoden, beispielsweise durch Aufspaltung, durch fraktionierte Umkristallisation eines Salzes mit optisch aktiven Säuren in die jeweiligen optischen lsomeren auftrennen.Compounds of the general formula (I) in which R 2 is different from R 3 or R 4 is different from R 5 can be obtained as racemic mixtures or in the form of optical isomers due to the presence of an asymmetric carbon atom in the 4-position of the dihydropyridine ring. Some of the compounds according to the invention which contain at least 2 asymmetric carbon atoms can be obtained in the form of individual diastereomers or in the form of mixtures thereof. The diastereomeric mixture can be separated using conventional methods. For example, by fractional recrystallization or by chromatographic methods. Racemic mixtures can be separated into the respective optical isomers by customary methods, for example by splitting, by fractional recrystallization of a salt with optically active acids.

Durch die Definition der Substituenten der allgemeinen Formel (I) werden auch einige Verbindungen umfasst, die keine positiv inotrope Wirkung besitzen. Durch die oben angegebene Testmethode am isolierten Meerschweinchenvorhof ist es für den Fachmann jedoch unproblematisch, die erfindungsgemässen Verbindungen mit positiv inotroper Wirkung zu erkennen und von den evtl. umfassten Verbindungen mit negativ inotroper Wirkung zu unterscheiden. Die vorliegende Anmeldung ist auf solche Verbindungen gerichtet, die ab einer Konzentration von 10-5 g/ml im oben angegebenen Test am linken isolierten Vorhof des Meerschweinchenherzens eine Kontraktionsverstärkung um mindestens 25% bewirken.The definition of the substituents of the general formula (I) also includes some compounds which have no positive inotropic action. By means of the above-mentioned test method on the isolated guinea pig atrium, it is unproblematic for the person skilled in the art to recognize the compounds according to the invention with a positive inotropic effect and to distinguish them from the possibly included compounds with a negative inotropic effect. The present application is directed to such compounds / ml effect at a concentration of 10- 5 g in the above test on the left atrium of the guinea pig isolated heart contraction gain at least 25%.

Die folgende Tabelle zeigt beispielhaft die positiv inotrope bzw. kontraktionskraftverstärkende Wirkung um mindestens 25% einiger der erfindungsgemässen Verbindungen.

Figure imgb0040
Figure imgb0041
Figure imgb0042
The following table shows an example of the positive inotropic or contraction-strengthening effect of at least 25% of some of the compounds according to the invention.
Figure imgb0040
Figure imgb0041
Figure imgb0042

Die erfindungsgemässen Verbindungen zeigen ein nicht vorhersehbares und wertvolles pharmakologisches Wirkungsspektrum. Sie können als Cardiotonika zur Verbesserung der Herzkontraktilität dienen. Darüber hinaus können sie dadurch, dass sie den Ca++-Einstrom in die Zellen erhöhten, als Antihypotonica, zur Senkung von Blutzukker, zur Abschwellung von Schleimhäuten und zur Beeinflussung des Salz- und Flüssigkeitshaushaltes eingesetzt werden.The compounds according to the invention show an unforeseeable and valuable pharmacological spectrum of activity. They can serve as cardiotonics to improve heart contractility. Moreover, they can by the fact that the Ca ++ - increased influx into the cells, are used as Antihypotonica, for lowering blutzukker, for the detumescence of mucous membranes and for influencing the salt and fluid balance.

Die erfindungsgemässen Verbindungen können in bekannter Weise in die üblichen Formulierungen überführt werden.The compounds according to the invention can be converted into the customary formulations in a known manner.

Die neuen Wirkstoffe können in bekannter Weise in die üblichen Formulierungen übergeführt werden, wie Tabletten, Kapseln, Dragees, Pillen, Granulate, Aerosole, Sirupe, Emulsionen, Suspensionen und Lösungen, unter Verwendung inerter, nicht-toxischer, pharmazeutisch geeigneter Trägerstoffe oder Lösungsmittel. Hierbei soll die therapeutisch wirksame Verbindung jeweils in einer Konzentration von etwa 0,5 bis 90 Gew.-% der Gesamtmischung vorhanden sein, d.h. in Mengen, die ausreichend sind, um den angegebenen Dosierungsspielraum zu erreichen.The new active compounds can be converted into the customary formulations in a known manner, such as tablets, capsules, dragees, pills, granules, aerosols, syrups, emulsions, suspensions and solutions, using inert, non-toxic, pharmaceutically suitable excipients or solvents. Here, the therapeutically active compound should in each case be present in a concentration of about 0.5 to 90% by weight of the total mixture, i.e. in amounts sufficient to achieve the dosage range indicated.

Die Formulierungen werden beispielsweise hergestellt durch Verstrecken der Wirkstoffe mit Lösungsmitteln und/oder Trägerstoffen, gegebenenfalls unter Verwendung von Emulgiermitteln und/oder Dispergiermitteln, wobei z. B. im Fall der Benutzung von Wasser als Verdünnungsmittel gegebenenfalls organische Lösungsmittel als Hilfslösungsmittel verwendet werden können.The formulations are prepared, for example, by stretching the active ingredients with solvents and / or carriers, optionally using emulsifiers and / or dispersants, z. B. in the case of the use of water as a diluent, organic solvents can optionally be used as auxiliary solvents.

Als Hilfsstoffe seien beispielsweise aufgeführt:Examples of auxiliary substances are:

Wasser, nicht-toxische organische Lösungsmittel, wie Paraffine (z.B. Erdölfraktionen), pflanzliche Öle (z.B. Erdnuss-/Sesamöl), Alkohole (z.B. Ethylalkohol, Glycerin), Glykole (z. B. Propylenglykol, Polyethylenglykol), feste Trägerstoffe, wie z.B. natürliche Gesteinsmehle (z.B. Kaoline, Tonerden, Talkum, Kreide), synthetische Gesteinsmehle (z.B. hochdisperse Kieselsäure, Silikate), Zucker (z.B. Rohr-, Milch- und Traubenzucker), Emulgiermittel (z. B. Polyoxyethylen-FettsäureEster, Polyoxyethylen-Fettalkohol-Ether, Alkylsulfonate und Arylsulfonate), Dispergiermittel (z.B. Lignin, Sulfitablaugen, Methylcellulose, Stärke und Polyvinylpyrrolidon) und Gleitmittel (z.B. Magnesiumstearat, Talkum, Stearinsäure und Natriumlaurylsulfat).Water, non-toxic organic solvents such as paraffins (e.g. petroleum fractions), vegetable oils (e.g. peanut / sesame oil), alcohols (e.g. ethyl alcohol, glycerin), glycols (e.g. propylene glycol, polyethylene glycol), solid carriers such as e.g. natural stone flours (e.g. kaolins, clays, talc, chalk), synthetic stone flours (e.g. highly disperse silica, silicates), sugar (e.g. cane, milk and glucose), emulsifiers (e.g. polyoxyethylene fatty acid esters, polyoxyethylene fatty alcohol ethers , Alkyl sulfonates and aryl sulfonates), dispersants (e.g. lignin, sulfite lye, methyl cellulose, starch and polyvinylpyrrolidone) and lubricants (e.g. magnesium stearate, talc, stearic acid and sodium lauryl sulfate).

Die Applikation erfolgt in üblicher Weise, vorzugsweise oral oder parenteral, insbesondere perlingual oder intravenös. Im Falle der oralen Anwendung können Tabletten selbstverständlich ausser den genannten Trägerstoffen auch Zusätze, wie Natriumcitrat, Calciumcarbonat und Dicalciumphosphat zusammen mit verschiedenen Zuschlagstoffen, wie Stärke, vorzugsweise Kartoffelstärke, Gelatine und dergleichen enthalten. Weiterhin können Gleitmittel, wie Magnesiumstearat, Natriumlaurylsulfat und Talkum zum Tablettieren mitverwendet werden. Im Falle wässriger Suspensionen und/oder Elixieren, die für orale Anwendungen gedacht sind, können die Wirkstoffe ausser den obengenannten Hilfsstoffen mit verschiedenen Geschmacksaufbesserern oder Farbstoffen versetzt werden.The application is carried out in the usual way, preferably orally or parenterally, in particular perlingually or intravenously. In the case of oral use, tablets can of course also contain additives, such as sodium citrate, calcium carbonate and dicalcium phosphate, together with various additives, such as starch, preferably potato starch, gelatin and the like, in addition to the carrier substances mentioned. Lubricants such as magnesium stearate, sodium lauryl sulfate and talc can also be used for tableting. In the case of aqueous suspensions and / or elixirs which are intended for oral applications, the active ingredients can be mixed with various flavor enhancers or colorants in addition to the abovementioned auxiliaries.

Für den Fall der parenteralen Anwendung können Lösungen der Wirkstoffe unter Verwendung geeigneter flüssiger Trägermaterialien eingesetzt werden.In the case of parenteral use, solutions of the active ingredients can be used using suitable liquid carrier materials.

Im allgemeinen hat es sich als vorteilhaft erwiesen, bei intravenöser Applikation Mengen von etwa 0,001 bis 1 mg/kg, vorzugsweise etwa 0,01 bis 0,5 mg/kg Körpergewicht zur Erzielung wirksamer Ergebnisse zu verabreichen, und bei oraler Applikation beträgt die Dosierung etwa 0,01 bis 20 mg/kg, vorzugsweise 0,1 bis 10 mg/kg Körpergewicht.In general, it has proven to be advantageous to administer amounts of approximately 0.001 to 1 mg / kg, preferably approximately 0.01 to 0.5 mg / kg of body weight in the case of intravenous administration in order to achieve effective results, and the dosage is approximately in the case of oral administration 0.01 to 20 mg / kg, preferably 0.1 to 10 mg / kg body weight.

Trotzdem kann es gegebenenfalls erforderlich sein, von den genannten Mengen abzuweichen, und zwar in Abhängigkeit vom Körpergewicht des Versuchstieres bzw. der Art des Applikationsweges, aber auch aufgrund der Tierart und deren individuellem Verhalten gegenüber dem Medikament bzw. deren Art von dessen Formulierung und dem Zeitpunkt bzw. Intervall, zu welchem die Verabreichung erfolgt. So kann es in einigen Fällen ausreichend sein, mit weniger als der vorgenannten Mindestmenge auszukommen, während in anderen Fällen die genannte obere Grenze überschritten werden muss. Im Falle der Applikation grösserer Mengen kann es empfehlenswert sein, diese in mehrere Einzelgaben über den Tag zu verteilen. Für die Applikation in der Humanmedizin ist der gleiche Dosierungsspielraum vorgesehen. Sinngemäss gelten hierbei auch die obigen Ausführungen.Nevertheless, it may be necessary to deviate from the quantities mentioned, depending on the body weight of the test animal or the type of application route, but also on the basis of the animal type and its individual behavior towards the medication or its type of formulation and the time or interval at which the administration takes place. In some cases it may be sufficient to make do with less than the aforementioned minimum quantity, while in other cases the above upper limit must be exceeded. In the case of application of larger quantities, it may be advisable to distribute them in several single doses throughout the day. The same dosage range is provided for application in human medicine. The above statements also apply mutatis mutandis.

HerstellungsbeispieleManufacturing examples Beispiel 1example 1

2-Methyl-4-(2-trifluormethylphenyl)-5-oxo-1,4-dihydro-5,7-dihydrofuro[3,4-b]pyridin-3-carbonsäureethylester

Figure imgb0043
Je 50 mmol 4-Acetoxy-3-oxo-buttersäureethyl- ester, 3-Aminocrotonsäureethylester und 2-Trifluormethylbenzaldehyd wurden in 100 ml Ethanol 24 h am Rückfluss gekocht, anschliessend mit 2 g Kaliumhydroxid versetzt und eine weitere Stunde gekocht. Nach Abkühlung wurde mit Wasser/ Kochsalz-Gemisch ausgefällt und aus Methanol umkristallisiert.

  • Ausbeute: 45% der Theorie; Fp.: 195 °C.
2-Methyl-4- (2-trifluoromethylphenyl) -5-oxo-1,4-dihydro-5,7-dihydrofuro [3,4-b] pyridine-3-carboxylic acid ethyl ester
Figure imgb0043
50 mmol each of 4-acetoxy-3-oxo-butyric acid ethyl ester, 3-aminocrotonic acid ethyl ester and 2-trifluoromethylbenzaldehyde were boiled under reflux in 100 ml of ethanol, then mixed with 2 g of potassium hydroxide and boiled for a further hour. After cooling, it was precipitated with a water / sodium chloride mixture and recrystallized from methanol.
  • Yield: 45% of theory; Mp: 195 ° C.

Beispiel 2Example 2

2-Methyl-4-(3-methoxyphenyl)-5-oxo-1,4-dihydro-5,7-dihydrofuro[3,4-b]pyridin-3-carbon- sänreethvlester

Figure imgb0044
Darstellung analog Beispiel 1 mit 3-Methoxybenzaldehyd statt 2-Trifluormethylbenzaldehyd.

  • Ausbeute: 30% der Theorie; Fp.: 180 °C.
2-Methyl-4- (3-methoxyphenyl) -5-oxo-1,4-dihydro-5,7-dihydrofuro [3,4-b] pyridine-3-carbon-sänreethvlester
Figure imgb0044
Representation analogous to Example 1 with 3-methoxybenzaldehyde instead of 2-trifluoromethylbenzaldehyde.
  • Yield: 30% of theory; Mp .: 180 ° C.

Beispiel 3Example 3

2-Methyl-4-(3-chlorphenyl)-5-oxo-1,4-dihydro-5,7-dihydrofuro[3,4-b]pyridin-3-carbonsäure- ethlester

Figure imgb0045
Darstellung analog Beispiel 1 mit 3-Chlorbenzaldehyd statt 2-Trifluormethylbenzaldehyd.

  • Ausbeute: 50% der Theorie; Fp.: 196 °C.
2-Methyl-4- (3-chlorophenyl) -5-oxo-1,4-dihydro-5,7-dihydrofuro [3,4-b] pyridine-3-carboxylic acid, ethyl ester
Figure imgb0045
Representation analogous to Example 1 with 3-chlorobenzaldehyde instead of 2-trifluoromethylbenzaldehyde.
  • Yield: 50% of theory; Mp .: 196 ° C.

Beispiel 4Example 4

2-Methyl-4-(3-chlorphenyl)-5-oxo-1,4-dihydro-5,7-dihydrofuro[3,4-b]pyridin-3-carbonsäure- DroDvlester ri

Figure imgb0046
Darstellung analog Beispiel 1 mit 3-Chlorbenzaldehyd statt 2-Trifluormethylbenzaldehyd und 3-Aminocrotonsäurepropylester statt 3-Aminocrotonsäureethylester.

  • Ausbeute: 42% der Theorie; Fp.: 166 °C.
2-methyl-4- (3-chlorophenyl) -5-oxo-1,4-dihydro-5,7-dihydrofuro [3,4-b] pyridine-3-carboxylic acid D ro D vlester ri
Figure imgb0046
Representation analogous to Example 1 with 3-chlorobenzaldehyde instead of 2-trifluoromethylbenzaldehyde and 3-aminocrotonic acid propyl ester instead of 3-aminocrotonic acid ethyl ester.
  • Yield: 42% of theory; Mp: 166 ° C.

Beispiel 5Example 5

2-Methyl-4-(3-nitrophenyl)-5-oxo-1,4-dihydropyridin-5,7-dihydrofuro[3,4-b]pyridin-3-carbon- säureDroDvlester

Figure imgb0047
Darstellung analog Beispiel 1 mit 3-Nitrobenzaldehyd statt 2-Trifluormethylbenzaldehyd und 3-Aminocrotonsäurepropylester statt -ethylester. Ausbeute: 50% der Theorie; Fp.: 196 °C.2-methyl-4- (3-nitrophenyl) -5-oxo-1,4-dihydropyridine-5,7-dihydrofuro [3,4-b] pyridine-3-carboxylic acid dro D vlester
Figure imgb0047
Representation analogous to Example 1 with 3-nitrobenzaldehyde instead of 2-trifluoromethylbenzaldehyde and 3-aminocrotonic acid propyl ester instead of ethyl ester. Yield: 50% of theory; Mp .: 196 ° C.

Beispiel 6Example 6

2-Methyl-4-(3-trifluormethylphenyl)-5-oxo-1,4-dihydro-5,7-dihydrofuro[3,4-b]pyridin-3-carbonsäure-isopropylester

Figure imgb0048
Darstellung analog Beispiel 1 mit 3-Aminocrotonsäureisopropylester statt -ethylester.

  • Ausbeute: 18% der Theorie; Fp.: 219-223 °C.
2-Methyl-4- (3-trifluoromethylphenyl) -5-oxo-1,4-dihydro-5,7-dihydrofuro [3,4-b] pyridine-3-carboxylic acid isopropyl ester
Figure imgb0048
Representation analogous to Example 1 with 3-aminocrotonic acid isopropyl ester instead of ethyl ester.
  • Yield: 18% of theory; Mp: 219-223 ° C.

Beispiel 7Example 7

2-Methyl-4-(2-trifluormethylphenyl)-5-oxo-1,4-dihydro-5,7-dihydrofuro[3,4-b]pyridin-3-carbonsäurebutylester

Figure imgb0049
Darstellung analog Beispiel 1 mit 3-Aminocrotonsäurebutylester statt -ethylester.

  • Ausbeute: 10% der Theorie; Fp.: 194-195 °C.
2-Methyl-4- (2-trifluoromethylphenyl) -5-oxo-1,4-dihydro-5,7-dihydrofuro [3,4-b] pyridine-3-carboxylic acid butyl ester
Figure imgb0049
Representation analogous to Example 1 with 3-aminocrotonic acid butyl ester instead of ethyl ester.
  • Yield: 10% of theory; Mp: 194-195 ° C.

Beispiel 8Example 8

2-Methyl-4-(2-trifluormethylphenyl)-5-oxo-1,4-dihydro-5,7-dihydrofuro[3,4-b]-pyridin-3-carbonsäure-(2-methoxy)-ethylester

Figure imgb0050
Darstellung analog Beispiel 1 mit 3-Aminocroton- säure-(2-methoxy)-ethylester statt 3-Aminocrotonsäureethylester.

  • Ausbeute: 16% der Theorie; Fp.: 196-197 °C.
2-Methyl-4- (2-trifluoromethylphenyl) -5-oxo-1,4-dihydro-5,7-dihydrofuro [3,4-b] pyridine-3-carboxylic acid (2-methoxy) ethyl ester
Figure imgb0050
Representation analogous to Example 1 with 3-aminocrotonic acid (2-methoxy) ethyl ester instead of 3-aminocrotonic acid ethyl ester.
  • Yield: 16% of theory; Mp .: 196-197 ° C.

Beispiel 9Example 9

2-Methyl-4-(2-benzylthiophenyl)-5-oxo-1,4-dihydro-5,7-dihydrofuro[3,4-b]pyridin-3-carbonsäureethylester

Figure imgb0051
Darstellung analog Beispiel 1 mit 2-Benzyithiobenzaldehyd anstatt 2-Trifluormethylbenzaldehyd.

  • Ausbeute: 31% der Theorie; Fp.: 189-190 °C (aus EtOH).
2-Methyl-4- (2-benzylthiophenyl) -5-oxo-1,4-dihydro-5,7-dihydrofuro [3,4-b] pyridine-3-carboxylic acid ethyl ester
Figure imgb0051
Representation analogous to Example 1 with 2-benzyithiobenzaldehyde instead of 2-trifluoromethylbenzaldehyde.
  • Yield: 31% of theory; Mp: 189-190 ° C (from EtOH).

Beispiel 10Example 10

2-Methyt-4-(2-methy)phenyl)-5-oxo-1,4-dihydro-5,7-dihydrofuro[3,4-b]pyridin-3-carbonsäureethylester

Figure imgb0052
Darstellung analog Beispiel 1 mit 2-Methylbenzaldehyd anstatt 2-Trifluormethylbenzaldehyd.

  • Ausbeute: 45%, Fp. 196-198 °C.
2-Methyl-4- (2-methy) phenyl) -5-oxo-1,4-dihydro-5,7-dihydrofuro [3,4-b] pyridine-3-carboxylic acid ethyl ester
Figure imgb0052
Representation analogous to Example 1 with 2-methylbenzaldehyde instead of 2-trifluoromethylbenzaldehyde.
  • Yield: 45%, mp 196-198 ° C.

Beispiel 11Example 11

Figure imgb0053
Figure imgb0053

33,8 g (90 mmol) 2-Amino-1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-pyridin-3,5-dicarbonsäurediethylester wurden zusammen mit 14,6 g (90 mmol) Dichlormethylen-dimethyl-ammoniumchlorid in 200 ml Chlorbenzol 2 Stunden bei 80 °C gerührt. Anschliessend wurde mit Eis gekühlt, das ausgefallene Produkt abgesaugt und in einer kalten 10%igen Natriumbicarbonatlösung aufgenommen. Die wässrige Phase wurde mit Methylenchlorid mehrmals extrahiert. Nach Trocknen der Extrakte über Na2S04 und Abdestillation des Lösungsmittels resultierten 16,6 g'(46% der Theorie) des Reaktionsproduktes vom Schmelzpunkt Fp.: 216-218 °C.33.8 g (90 mmol) of 2-amino-1,4-dihydro-2,6-dimethyl-4- (2-nitrophenyl) pyridine-3,5-dicarboxylic acid diethyl ester together with 14.6 g (90 mmol) Dichloromethylene-dimethyl-ammonium chloride in 200 ml of chlorobenzene for 2 hours at 80 ° C. It was then cooled with ice, the precipitated product was filtered off with suction and taken up in a cold 10% sodium bicarbonate solution. The aqueous phase was extracted several times with methylene chloride. After drying the extracts over Na 2 S0 4 and distilling off the solvent, 16.6 g '(46% of theory) of the reaction product of melting point m.p .: 216-218 ° C resulted.

Beispiel 12Example 12

1,4-Dihydro-2-methyl-5-oxo-7,7-pentamethylen-4-(2'-nitrophenyl)-7H-pyrano[4,3-b]pyridin-3-carbonsäuremethylester

Figure imgb0054
4,6 g 6,6-Pentamethylentetrahydropyrandion-2,4, 3,8 g 2-Nitrobenzaldehyd und 2,9 g 3-Aminocrotonsäuremethylester werden in 100 ml Ethanol/ Eisessig (5:1) 10 Stunden unter Rückfluss gekocht. Man kühlt auf Raumtemperatur und saugt den Niederschlag ab. Aus Ethanol umkristallisiert werden 6 g (58% der Theorie) vom Fp.: 228 °C erhalten.1,4-Dihydro-2-methyl-5-oxo-7,7-pentamethylene-4- (2'-nitrophenyl) -7H-pyrano [4,3-b] pyridine-3-carboxylic acid methyl ester
Figure imgb0054
4.6 g of 6,6-pentamethylene tetrahydropyranedione-2,4, 3,8 g of 2-nitrobenzaldehyde and 2.9 g of 3-aminocrotonic acid methyl ester are boiled under reflux in 100 ml of ethanol / glacial acetic acid (5: 1) for 10 hours. The mixture is cooled to room temperature and the precipitate is filtered off with suction. Recrystallized from ethanol 6 g (58% of theory) of mp: 228 ° C are obtained.

Beispiel 13Example 13

1,4-Dihydro-2,7-dimethyl-4-(2'-methylphenyl)-5-oxo-7H-pyrano[4,3-b]pyridin-3-carbonsäureethylester

Figure imgb0055
Eine Lösung von 4,3 g 6-Methyltetrahydropyrandion-2,4, 4,0 g 2-Methylbenzaldehyd und 4,3 g 3-Aminocrotonsäureethylester in 80 ml Ethanol/ Eisessig (5: 1) wird 10 Stunden unter Rückfluss gekocht. Man engt im Vakuum ein und kristallisiert den Rückstand aus Ethanol um: 5,3 g (50% der Theorie) vom Fp.: 213 °C.

  • Analog wurden erhalten:
1,4-Dihydro-2,7-dimethyl-4- (2'-methylphenyl) -5-oxo-7H-pyrano [4,3-b] pyridine-3-carboxylic acid ethyl ester
Figure imgb0055
A solution of 4.3 g of 6-methyltetrahydropyranedione-2,4, 4.0 g of 2-methylbenzaldehyde and 4.3 g of 3-aminocrotonic acid ethyl ester in 80 ml of ethanol / glacial acetic acid (5: 1) is boiled under reflux for 10 hours. The mixture is concentrated in vacuo and the residue is recrystallized from ethanol: 5.3 g (50% of theory), mp: 213 ° C.
  • The following were obtained analogously:

Beispiel 14Example 14

1,4-Dihydro-2,7-dimethyl-4-(3'-trifluormethylphenyl)-5-oxo-7H-pyrano[4,3-b]pyridin-3-carbonsäureethylester vom Fp.: 210 °C

Figure imgb0056
1,4-Dihydro-2,7-dimethyl-4- (3'-trifluoromethylphenyl) -5-oxo-7H-pyrano [4,3-b] pyridine-3-carboxylic acid ethyl ester of mp: 210 ° C.
Figure imgb0056

Beispiel 15Example 15

1,4-Dihydro-2,7-dimethyl-4-(2'-chlorphenyl)-5-oxo-7H-pyrano[4,3-b]pyridin-4-carbonsäuremethylester vom Fp.: 252-254 °C

Figure imgb0057
1,4-Dihydro-2,7-dimethyl-4- (2'-chlorophenyl) -5-oxo-7H-pyrano [4,3-b] pyridine-4-carboxylic acid methyl ester, mp: 252-254 ° C
Figure imgb0057

Beispiel 16Example 16

1,4-Dihydro-2,6-dimethyl-3-nitro-4-(3-nitrophenyl)-pyridin-5-carbonsäurecyclopentylester

Figure imgb0058
15,1 g (0,1 Mol) 3-Nitrobenzaldehyd werden zusammen mit 16,9 g (0,1 Mol) ß-Aminocrotonsäurecyclopentylester und 10,3 g (0,1 Mol) Nitroaceton in 150 ml Ethanol 6 Stunden zum Rückfluss erhitzt. Nach dem Erkalten der Reaktionsmischung wird das Lösungsmittel im Vakuum abdestilliert, der ölige Rückstand in wenig Chloroform aufgenommen und auf einer Kieselgelsäule mit Chloroform unter Zusatz von Methanol chromatographiert. Die das Reaktionsprodukt enthaltenden Fraktionen- werden eingeengt, der Rückstand in wenig Isopropanol, das Nitrodihydropyridin kristallisierte in gelben Kristallen vom Schmp. 174 °C. Ausbeute: 37% der Theorie.1,4-Dihydro-2,6-dimethyl-3-nitro-4- (3-nitrophenyl) pyridine-5-carboxylic acid cyclopentyl ester
Figure imgb0058
15.1 g (0.1 mol) of 3-nitrobenzaldehyde together with 16.9 g (0.1 mol) of β-aminocrotonic acid cyclopentyl ester and 10.3 g (0.1 mol) of nitroacetone in 150 ml of ethanol are refluxed for 6 hours . After the reaction mixture has cooled, the solvent is distilled off in vacuo, the oily residue is taken up in a little chloroform and chromatographed on a silica gel column using chloroform with the addition of methanol. The fractions containing the reaction product are concentrated, the residue in a little isopropanol, the nitrodihydropyridine crystallized in yellow crystals of mp. 174 ° C. Yield: 37% of theory.

Beispiel 17Example 17

1,4-Dihydro-2,6-dimethyl-3-nitro-4-(3-nitro- phenyi)-pyridin-5-carbonsäure-(ß-n-propoxy- ethyl)-ester

Figure imgb0059
15,1 g (0,1 Mol) 3-Nitrobenzaldehyd werden zusammen mit 18,8 g (0,1 Mol) Acetessigsäure-(ß-n-propoxyethyl)-ester und 10,2 g (0,1 Mol) 2-Amino-1-nitro-1-propen in 150 ml Ethanol 6 Stunden zum Rückfluss erhitzt. Nach dem Erkalten wird das Lösungsmittel im Vakuum abdestilliert, der ölige Rückstand in wenig Chloroform aufgenommen und auf einer Kieselgelsäule mit Chloroform unter Zusatz von Methanol chromatographiert. Die das Produkt enthaltenden Fraktionen werden eingeengt, der Rückstand in wenig Isopropanol aufgenommen, das Nitrodihydropyridin kristallisierte in gelben Kristallen vom Schmp. 161 °C.

  • Ausbeute: 41% der Theorie.
1,4-Dihydro-2,6-dimethyl-3-nitro-4- (3-nitro-phenyi) pyridine-5-carboxylic acid (ß-n-propoxy-ethyl) ester
Figure imgb0059
15.1 g (0.1 mol) of 3-nitrobenzaldehyde together with 18.8 g (0.1 mol) of acetoacetic acid (β-n-propoxyethyl) ester and 10.2 g (0.1 mol) of 2- Amino-1-nitro-1-propene in 150 ml of ethanol heated to reflux for 6 hours. After cooling, the solvent is distilled off in vacuo, the oily residue is taken up in a little chloroform and chromatographed on a silica gel column with chloroform with the addition of methanol. The fractions containing the product are concentrated, the residue is taken up in a little isopropanol, and the nitrodihydropyridine crystallizes in yellow crystals with a melting point of 161 ° C.
  • Yield: 41% of theory.

Beispiel 18Example 18

1,4-Dihydro-2,6-dimethyl-3,5-dinitro-4-(3-nitrophenyl)-pyridin

Figure imgb0060
23,6 g (0,1 Mol) 2-Nitro-1-(3-nitrophenyl)-buten-1- on-3 und 10,2 g (0,1 Mol) 2-Amino-1-nitro-1-propen werden in 150 ml Ethanol 12 Stunden zum Rückfluss erhitzt. Nach dem Erkalten wird das Lösungsmittel im Vakuum abdestilliert, der ölige Rückstand wird in Chloroform aufgenommen und auf einer Kieselgelsäule mit Chloroform unter Zusatz von Methanol chromatographiert. Das Produkt bildet in Isopropanol gelbe Kristalle vom Schmp. 237-240 °C (Zers.).

  • Ausbeute: 38% der Theorie.
1,4-dihydro-2,6-dimethyl-3,5-dinitro-4- (3-nitrophenyl) pyridine
Figure imgb0060
23.6 g (0.1 mol) of 2-nitro-1- (3-nitrophenyl) -buten-1- on-3 and 10.2 g (0.1 mol) of 2-amino-1-nitro-1- propene is heated to reflux in 150 ml of ethanol for 12 hours. After cooling, the solvent is distilled off in vacuo, the oily residue is taken up in chloroform and chromatographed on a silica gel column with chloroform with the addition of methanol. In isopropanol, the product forms yellow crystals with a melting point of 237-240 ° C. (dec.).
  • Yield: 38% of theory.

Beispiel 19Example 19

Figure imgb0061
Analog Beispiel 16 wurde durch Umsetzung von 50 mmol Pyridin-4-aldehyd mit 50 mmol Acetessigsäuremethylester und 50 mmol 2-Amino-1-nitro-1-propen in Ethanol 1,4-Dihydro-2,6-dimethyl-4-(4-pyridyl)-3-nitro- pyridin-5-carbonsäuremethylester vom Schmp. 210 °C (Zers.) (Isopropanol) erhalten.

  • Ausbeute: 19% der Theorie.
Figure imgb0061
Analogously to Example 16, 1,4-dihydro-2,6-dimethyl-4- (4 -pyridyl) -3-nitro-pyridine-5-carboxylic acid methyl ester of mp. 210 ° C (dec.) (Isopropanol) obtained.
  • Yield: 19% of theory.

Beispiel 20Example 20

Figure imgb0062
Figure imgb0062

Analog Beispiel 16 wurde durch Umsetzung von 50 mmol 3-Trifluormethylbenzaldehyd mit 50 mmol Nitroaceton und 50 mmol ß-Aminocrotonsäuremethylester 1,4-Dihydro-2,6-dimethyl-3-nitro-4-(3-trifluormethylphenyl)-pyridin-5-carbonsäuremethylester vom Schmp. 175 °C (Isopropanol) erhalten.

  • Ausbeute: 42% der Theorie.
Analogously to Example 16, 1,4-dihydro-2,6-dimethyl-3-nitro-4- (3-trifluoromethylphenyl) pyridine-5- was reacted with 50 mmol of 3-trifluoromethylbenzaldehyde with 50 mmol of nitroacetone and 50 mmol of methyl β-aminocrotonic acid. carboxylic acid methyl ester of mp. 175 ° C (isopropanol) obtained.
  • Yield: 42% of theory.

Beispiel 21Example 21

Figure imgb0063
Figure imgb0063

Analog Beispiel 16 wurde durch Umsetzung von 50 mmol 2-Nitrobenzaldehyd mit 50 mmol Nitroaceton und 50 mmol ß-Aminocrotonsäuremethylester 1,4-Dihydro-2,6-dimethyl-3-nitro-4-(2-nitrophenyl)-pyridin-5-carbonsäuremethylester vom Schmp. 190 °C (Isopropanol) als sehr lichtempfindliche Verbindung erhalten.

  • Ausbeute: 12% der Theorie.
Analogously to Example 16, 1,4-dihydro-2,6-dimethyl-3-nitro-4- (2-nitrophenyl) pyridine-5- was converted by reacting 50 mmol of 2-nitrobenzaldehyde with 50 mmol of nitroacetone and 50 mmol of methyl β-aminocrotonic acid. carboxylic acid methyl ester of mp. 190 ° C (isopropanol) obtained as a very light-sensitive compound.
  • Yield: 12% of theory.

Beispiel 22Example 22

1,4-Dihydro-2,6-dimethyl-3-nitro-4-(4-nitrophenyl)-pyridin-5-carbonsäure-(ß-cyanoethyl)-ester

Figure imgb0064
Analog Beispiel 18 wurde durch Umsetzung von. 50 mmol 2-Nitro-1-(3-nitrophenyl)-buten-1-on-3 mit 50 mmol β-Aminocrotonsäure-β-cyanoethylester in 100 ml Ethanol 1,4-Dihydro-2,6-dimethyl-3-nitro-4-(3-nitrophenyl)-pyridin-5-carbonsäure-(β-cyanoethyl)-ester vom Schmp. 210 °C (Isopropanol) erhalten. Ausbeute: 33% der Theorie.1,4-Dihydro-2,6-dimethyl-3-nitro-4- (4-nitrophenyl) pyridine-5-carboxylic acid (β-cyanoethyl) ester
Figure imgb0064
Analogously to Example 18 was implemented by. 50 mmol of 2-nitro-1- (3-nitrophenyl) -buten-1-one-3 with 50 mmol of β-aminocrotonic acid-β-cyanoethyl ester in 100 ml of ethanol 1,4-dihydro-2,6-dimethyl-3-nitro -4- (3-nitrophenyl) pyridine-5-carboxylic acid (β-cyanoethyl) ester of mp. 210 ° C (isopropanol) obtained. Yield: 33% of theory.

Beispiel 23Example 23

Figure imgb0065
Figure imgb0065

Analog Beispiel 18 wurde durch Umsetzung von 50 mmol 2-Methoxybenzylidenacetessigsäuremethylester und 50 mmol 2-Amino-1-nitrol-propen in Ethanol 1,4-Dihydro-2,6-dimethyl-4-(2-methoxyphenyl)-3-nitro-pyridin-5-carbonsäuremethylester vom Schmp. 206 °C (Ethanol) erhalten.

  • Ausbeute: 44% der Theorie.
Analogously to Example 18, 1,4-dihydro-2,6-dimethyl-4- (2-methoxyphenyl) -3-nitro- was reacted by reacting 50 mmol of 2-methoxybenzylideneacetoacetic acid methyl ester and 50 mmol of 2-amino-1-nitrol-propene in ethanol. pyridine-5-carboxylic acid methyl ester of mp. 206 ° C (ethanol) obtained.
  • Yield: 44% of theory.

Beispiel 24Example 24

Figure imgb0066
Figure imgb0066

Analog Beispiel 18 wurde durch Umsetzung von 3-Nitro-benzylidenacetessigsäure-(ß-trifluorethyl)-ester mit 2-Amino-1-nitro-1-propen in Ethanol 1,4-Dihydro-2,6-dimethyl-3-nitro-4-(3-nitrophenyl)-pyridin-5-carbonsäure-(ß-trifluorethyl)-ester vom Schmp. 196 °C (Ethanol) erhalten.

  • Ausbeute: 28% der Theorie.
Analogously to Example 18, 1,4-dihydro-2,6-dimethyl-3-nitro- was reacted with 3-nitro-benzylideneacetoacetic acid (β-trifluoroethyl) ester with 2-amino-1-nitro-1-propene in ethanol. 4- (3-nitrophenyl) pyridine-5-carboxylic acid (ß-trifluoroethyl) ester of mp. 196 ° C (ethanol) obtained.
  • Yield: 28% of theory.

Beispiel 25Example 25

Figure imgb0067
Figure imgb0067

Analog Beispiel 16 wurde durch Umsetzung von Pyridin-3-aldehyd mit ß-Aminocrotonsäureethylester und Nitroaceton in Ethanol 1,4-Dihydro-2,6-dimethyl-3-nitro-4-(pyridyl-3)-pyridin-5-carbonsäureethylester vom Schmp. 264 °C (Isopropanol) erhalten.

  • Ausbeute: 34% der Theorie.
Analogously to Example 16, 1,4-dihydro-2,6-dimethyl-3-nitro-4- (pyridyl-3) pyridine-5-carboxylic acid ethyl ester was reacted with ethyl β-aminocrotonic acid and nitroacetone in ethanol by reacting pyridine-3-aldehyde Mp. 264 ° C (isopropanol) obtained.
  • Yield: 34% of theory.

Beispiel 26Example 26

Figure imgb0068
Figure imgb0068

Analog Beispiel 17 wurde durch Umsetzung von 2-Benzylthiobenzaldehyd mit 2-Amino-1-nitro-1-propen und Acetessigsäuremethylester in Ethanol 4-(2-Benzylthiophenyl)-1,4-dihydro-2,6-dimethyl-3-nitropyridin-5-carbonsäuremethylester vom Schmp. 173 °C (Isopropanol) erhalten.

  • Ausbeute: 21 % der Theorie.
Analogously to Example 17, by reaction of 2-benzylthiobenzaldehyde with 2-amino-1-nitro-1-propene and methyl acetoacetate in ethanol, 4- (2-benzylthiophenyl) -1,4-dihydro-2,6-dimethyl-3-nitropyridine 5-carboxylic acid methyl ester of mp. 173 ° C (isopropanol) obtained.
  • Yield: 21% of theory.

Beispiel 27Example 27

Figure imgb0069
Figure imgb0069

Analog Beispiel 16 wurde durch Umsetzung von 2-Trifluormethylbenzaldehyd mit ß-Aminocrotonsäuremethylester und Nitroaceton in Ethanol 1,4-Dihydro-2,6-dimethyl-3-nitro-4-(2-trifluormethylphenyl)-pyridin-5-carbonsäuremethylester vom Schmp. 176 °C (Ethanol) erhalten.

  • Ausbeute: 36% der Theorie.
Analogously to Example 16, 1,4-dihydro-2,6-dimethyl-3-nitro-4- (2-trifluoromethylphenyl) pyridine-5-carboxylic acid methyl ester of mp. 1 was obtained by reacting 2-trifluoromethylbenzaldehyde with methyl β-aminocrotonic acid and nitroacetone in ethanol. Obtained 176 ° C (ethanol).
  • Yield: 36% of theory.

Beispiel 28Example 28

Figure imgb0070
Figure imgb0070

Analog Beispiel 16 wurde durch Umsetzung von 2-Chlorbenzaldehyd mit ß-Aminocrotonsäuremethylester und Nitroaceton in Ethanol 4-(2-Chlorphenyl)-1,4-dihydro-2,6-dimethyl-3-nitro-pyridin-5-carbonsäuremethylester vom Schmp. 167 °C (Isopropanol) erhalten.

  • Ausbeute: 42% der Theorie.
Analogous to Example 16, 4- (2-chlorophenyl) -1,4-dihydro-2,6-dimethyl-3-nitro-pyridine-5-carboxylic acid methyl ester of mp. Get 167 ° C (isopropanol).
  • Yield: 42% of theory.

Beispiel 29Example 29

Figure imgb0071
Figure imgb0071

Analog Beispiel 18 wurde durch Umsetzung von 50 mmol 2-Trifluormethoxybenzylidenacetessigsäuremethylester mit 50 mmol 2-Amino-1-nitro-1-propen in Ethanol 1,4-Dihydro-2,6-dimethyl-3-nitro-4-(2-trifluormethoxyphenyl)-pyridin-5-carbonsäuremethylester vom Schmp. 175 °C(lsopropanol) erhalten.

  • Ausbeute: 39% der Theorie.
Analogously to Example 18, 1,4-dihydro-2,6-dimethyl-3-nitro-4- (2-trifluoromethoxyphenyl) was obtained by reacting 50 mmol of 2-trifluoromethoxybenzylideneacetoacetic acid methyl ester with 50 mmol of 2-amino-1-nitro-1-propene in ethanol ) -Pyridine-5-carboxylic acid methyl ester of mp. 175 ° C (isopropanol) obtained.
  • Yield: 39% of theory.

Beispiel 30Example 30

Figure imgb0072
Figure imgb0072

Die Behandlung von 1,4-Dihydro-2,6-dimethyl-3-nitro-4-(2-trifluormethylphenyl)-pyridin-5-carbonsäure-(ß-cyanoethyl)-ester in 1,2 Äquivalenten Kaliumhydroxid in wässrigem Ethylenglykoldimethylether bei Raumtemperatur ergibt nach Ansäuern mit verd. HCI 1,4-Dihydro-2,6-dimethyl-3-nitro-4-(2-trifluormethylphenyl)-pyridin-5-carbonsäure vom Schmp. 183 °C (Zersetzung) (Methanol).

  • Ausbeute: 89% der Theorie.
The treatment of 1,4-dihydro-2,6-dimethyl-3-nitro-4- (2-trifluoromethylphenyl) pyridine-5-carboxylic acid (ß-cyanoethyl) ester in 1.2 equivalents of potassium hydroxide in aqueous ethylene glycol dimethyl ether After acidification with dil. HCI, room temperature gives 1,4-dihydro-2,6-dimethyl-3-nitro-4- (2-trifluoromethylphenyl) pyridine-5-carboxylic acid with a melting point of 183 ° C. (decomposition) (methanol).
  • Yield: 89% of theory.

Beispiel 31Example 31

Figure imgb0073
Figure imgb0073

Beim Erhitzen in Ethanol unter Zusatz einer Spur Schwefelsäure decarboxyliert 1,4-Dihydro-2,6-dimethyl-3-nitro-4-(trifluormethylphenyl)-pyridin-5-carbonsäure (Beispiel 30) zu 1,4-Dihydro-2,6-dimethyl-3-nitro-4-(trifluormethylphenyl)-pyridin mit quantitativer Ausbeute.

  • Schmp. 201 °C.
When heated in ethanol with the addition of a trace of sulfuric acid, decarboxylated 1,4-dihydro-2,6-dimethyl-3-nitro-4- (trifluoromethylphenyl) pyridine-5-carboxylic acid (Example 30) to 1,4-dihydro-2, 6-dimethyl-3-nitro-4- (trifluoromethylphenyl) pyridine in quantitative yield.
  • Mp 201 ° C.

Beispiel 32Example 32

Figure imgb0074
Figure imgb0074

Analog Beispiel 18 wurde durch Umsetzung von 2-Methylbenzyliden-acetessigsäureethylester mit 2-Amino-1-nitro-1-propen in Ethanol 1,4-Dihydro-2,6-dimethyl-4-(2-tolyl)-3-nitro- pyridin-5-carbonsäureethylester vom Schmp.155 °C (Isopropanol) erhalten.

  • Ausbeute: 42% der Theorie.
Analogously to Example 18, 1,4-dihydro-2,6-dimethyl-4- (2-tolyl) -3-nitro- was reacted by reacting ethyl 2-methylbenzylidene-acetoacetate with 2-amino-1-nitro-1-propene in ethanol. pyridine-5-carboxylic acid ethyl ester of mp 155 ° C (isopropanol).
  • Yield: 42% of theory.

Beispiel 33Example 33

2-Acetylamino-4,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsäurediethylester

Figure imgb0075
8 g (0,03 Mol) 2-Amino-4,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsäurediethylester werden in 100 ml Acetanhydrid 4 Stunden unter Rückfluss gekocht. Man engt im Vakuum zum Trockne ein und kristallisiert den Rückstand aus Ethanol um. Ausbeute: 5,4 g (58% der Theorie) vom Fp.: 105 °C.2-Acetylamino-4,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid diethyl ester
Figure imgb0075
8 g (0.03 mol) of 2-amino-4,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid diethyl ester are boiled under reflux in 100 ml of acetic anhydride for 4 hours. The mixture is concentrated to dryness in vacuo and the residue is recrystallized from ethanol. Yield: 5.4 g (58% of theory) of mp: 105 ° C.

Beispiel 34Example 34

2-Amino-6-methyl-1,4-dihydro-4-(2'-chlorphenyl)-pyridin-3-carbonsäureethylester

Figure imgb0076
Nach 2-stündigem Kochen einer Lösung von 18,1 g 2'-Chlorbenzylidenaceton und 13,0 g Amidinoessigsäureethylester in 150 ml Ethanol wird das Lösungsmittel im Vakuum abgezogen. Der Rückstand wird aus Ethanol umkristallisiert, Ausbeute 62% der Theorie, Fp.: 171 °C.2-Amino-6-methyl-1,4-dihydro-4- (2'-chlorophenyl) pyridine-3-carboxylic acid ethyl ester
Figure imgb0076
After boiling a solution of 18.1 g of 2'-chlorobenzylidene acetone and 13.0 g of ethyl amidinoacetate in 150 ml of ethanol for 2 hours, the solvent is removed in vacuo. The residue is recrystallized from ethanol, yield 62% of theory, mp: 171 ° C.

Beispiel 35Example 35

1,4-Dihydro-4-phenyl-2,3,6-trimethylpyridin-5-carbonsäuremethylester

Figure imgb0077
24,1 g (80 mmol) 1,4-Dihydro-2,6-dimethyl-4-phenyl-pyridin-3,5-dicarbonsäuremethylester werden bei 60 °C unter Rühren portionsweise in eine Lösung von 12,2 g (320 mmol) LiAIH4 in 400 ml abs. Tetrahydrofuran eingetragen (N2-Atm) und 6 bis 7 Stunden bei 60 °C nachgerührt. Nach dem Abkühlen werden nacheinander 19,7 ml Essigester, 15,9 ml Wasser, 19,6 ml N NaOH und 15,9 ml Wasser zugetropft. Anschliessend wird abgesaugt, gut mit Ether nachgewaschen und das Filtrat im Vakuum eingedampft. Der sirupöse Rückstand wird in 50 ml Ether gelöst und in der Kälte zur Kristallisation gestellt, 7,4 g d.s. 36% der Theorie. Nach Umkristallisation aus Acetonitril farblose Prismen; Schmp. 120 °C.1,4-Dihydro-4-phenyl-2,3,6-trimethylpyridine-5-carboxylic acid methyl ester
Figure imgb0077
24.1 g (80 mmol) of 1,4-dihydro-2,6-dimethyl-4-phenyl-pyridine-3,5-dicarboxylic acid methyl ester are added in portions at 60 ° C. with stirring in a solution of 12.2 g (320 mmol ) LiAIH 4 in 400 ml abs. Tetrahydrofuran registered (N 2 -Atm) and stirred at 60 ° C for 6 to 7 hours. After cooling, 19.7 ml of ethyl acetate, 15.9 ml of water, 19.6 ml of N NaOH and 15.9 ml of water are added dropwise in succession. It is then filtered off, washed well with ether and the filtrate evaporated in vacuo. The syrupy residue is dissolved in 50 ml of ether and made to crystallize in the cold, 7.4 g of ds 36% of theory. After recrystallization from acetonitrile, colorless prisms; Mp 120 ° C.

Beispiel 36Example 36

Figure imgb0078
Figure imgb0078

Analog Beispiel 35 wurde am 4-(2-Chlorphenyl)-1,4-dihydro-2,6-dimethyl- pyridin-3,5-dicarbonsäuremethylester durch Reduktion mit LiAIH4 in THF 4-(2-Chlorphenyl)-1,4-dihydro-2,3,6-trimethyl- pyridin-5-carbonsäuremethylester vom Schmp. 164 °C (Acetonitril) erhalten.

  • Ausbeute: 30% der Theorie.
Analogously to Example 35, methyl 4- (2-chlorophenyl) -1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate was obtained by reduction with LiAIH 4 in THF 4- (2-chlorophenyl) -1.4 -dihydro-2,3,6-trimethyl-pyridine-5-carboxylic acid methyl ester of mp. 164 ° C (acetonitrile) obtained.
  • Yield: 30% of theory.

Beispiel 37Example 37

1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-pyridin-3,5-dicarbonsäure-isopropyl-(2,2,2-trichlorethvll-ester

Figure imgb0079
Eine Lösung von 30,2 g (0,2 Mol) 3-Nitrobenzaldehyd, 46,6g g (0,2 Mol) Acetessigsäure-(2,2,2-trichlorethyl)-ester und 28,6 g (0,2 Mol) 3-Aminocrotonsäureisopropylester in 200 ml Ethanol wurde 12 Stunden unter Stickstoff zum Sieden erhitzt. Das Lösungsmittel wurde im Vakuum eingeengt, der feste Rückstand aus Ethanol umkristallisiert. Schmp.: 192 °C; Ausbeute: 46 g (47% der Theorie).1,4-Dihydro-2,6-dimethyl-4- (3-nitrophenyl) pyridine-3,5-dicarboxylic acid isopropyl (2,2,2-trichloroethyl) ester
Figure imgb0079
A solution of 30.2 g (0.2 mol) of 3-nitrobenzaldehyde, 46.6 g (0.2 mol) of acetoacetic acid (2,2,2-trichloroethyl) ester and 28.6 g (0.2 mol ) Isopropyl 3-aminocrotonic acid in 200 ml of ethanol was heated to boiling under nitrogen for 12 hours. The solvent was concentrated in vacuo, the solid residue was recrystallized from ethanol. Mp: 192 ° C; Yield: 46 g (47% of theory).

Beispiel 38Example 38

1,4-Dihydro-2,8-dimethyl-4-(3-nitrophenyl)-pyridin-3,5-dicarbonsäure-(c)-hexylisopropyl- ester

Figure imgb0080
Wurde analog Beispiel 32 hergestellt aus 0,2 Mol 3-Nitrobenzaldehyd, 0,2 Mol Acetessigsäure-(n-hexyl)-ester und 0,2 Mol 3-Aminocrotonsäureisopropylester. Schmp.: 87 °C; Ausbeute: 75%.1,4-dihydro-2,8-dimethyl-4- (3-nitrophenyl) pyridine-3,5-dicarboxylic acid (c) hexylisopropyl ester
Figure imgb0080
Was prepared analogously to Example 32 from 0.2 mol of 3-nitrobenzaldehyde, 0.2 mol of acetoacetic acid (n-hexyl) ester and 0.2 mol of 3-aminocrotonic acid isopropyl ester. Mp: 87 ° C; Yield: 75%.

Beispiel 39Example 39

1,4-Dihydro-2,6-dimethyl-4-(pyridyl-3)-pyridin-3,5-dicarbonsäuremonoethylester

Figure imgb0081
Hergestellt gemäss DE-OS 2 847 237 (Beispiel Nr. 14). Schmp.: 205 °C (Zers.); Ausbeute: 32% der Theorie.1,4-Dihydro-2,6-dimethyl-4- (pyridyl-3) pyridine-3,5-dicarboxylic acid monoethyl ester
Figure imgb0081
Manufactured according to DE-OS 2 847 237 (Example No. 14). Mp: 205 ° C (dec.); Yield: 32% of theory.

Beispiel 40Example 40

3-Cyano-1,4-dihydro-2,6-dimethyl-4-(2-trifluormethylphenyl)-pyridin-5-carbonsäuremethylester

Figure imgb0082
Hergestellt gemäss DE-OS 2 658 804 (Beispiel Nr. 17). Schmp.: 171 °C; Ausbeute: 42% der Theorie.3-Cyano-1,4-dihydro-2,6-dimethyl-4- (2-trifluoromethylphenyl) pyridine-5-carboxylic acid methyl ester
Figure imgb0082
Manufactured according to DE-OS 2 658 804 (Example No. 17). Mp: 171 ° C; Yield: 42% of theory.

Beispiel 41Example 41

2,6-Di-(4-nitrophanyl)-4-(4-ethoxycarbonyl- methoxy-1-methyl-1,4-dihydropyridin-3,5-dicarbonsäurediethylester

Figure imgb0083
100 mmol 4-(Ethoxycarbonylmethoxy)-benzalde- hyd wurden mit 200 mmol 4-Nitrobenzoylessigester, 100 mmol Methylamin-hydrochlorid in 60 ml Pyridin 5 Stunden auf 100 °C erhitzt. Es wurde auf Eiswasser gegossen und abgesaugt.

  • Ausbeute: 11 % der Theorie; Fp.: 136 °C.
2,6-Di- (4-nitrophanyl) -4- (4-ethoxycarbonyl-methoxy-1-methyl-1,4-dihydropyridine-3,5-dicarboxylic acid diethyl ester
Figure imgb0083
100 mmol of 4- (ethoxycarbonylmethoxy) benzaldehyde were heated at 100 ° C. for 5 hours with 200 mmol of 4-nitrobenzoyl acetate, 100 mmol of methylamine hydrochloride in 60 ml of pyridine. It was poured onto ice water and suction filtered.
  • Yield: 11% of theory; Mp: 136 ° C.

Beispiel 42Example 42

2,6-Dimethyl-4-(2-trifluormethylphenyl)-1-methyl-1,4-dihydropyridin-3,5-dicarbonsäure- diallylester

Figure imgb0084
100 mmol 2-Trifluormethylbenzaldehyd, 200 mmol Acetessigsäureallylester und 120 mmol Methylaminhydrochlorid wurden in 50 ml Pyridin 5 Stunden auf 110 °C erhitzt, auf Wasser gekippt und abgesaugt.

  • Ausbeute: 5% der Theorie; Fp.: 90 bis 91 °C.
2,6-Dimethyl-4- (2-trifluoromethylphenyl) -1-methyl-1,4-dihydropyridine-3,5-dicarboxylic acid diallyl ester
Figure imgb0084
100 mmol of 2-trifluoromethylbenzaldehyde, 200 mmol of acetoacetic acid allyl ester and 120 mmol of methylamine hydrochloride were heated in 50 ml of pyridine at 110 ° C. for 5 hours, poured over water and suction filtered.
  • Yield: 5% of theory; Mp .: 90 to 91 ° C.

Beispiel 43Example 43

2,6-Diphenyl-3-5-di(phenylcarbonyl)-1-methyl-4-(3-pyridiyl)-1,4-dihydropyridin

Figure imgb0085
1,3 ml Pyridin-3-aldehyd, 6 g Dibenzoylmethan und 1 g Methylaminhydrochlorid werden in 10 ml Pyridin über Nacht auf 100 °C erwärmt, anschliessend auf Eiswasser gegossen, abgesaugt und aus Methanol umkristallisiert.

  • Ausbeute: 15% der Theorie; Fp.: 238 °C.
2,6-diphenyl-3-5-di (phenylcarbonyl) -1-methyl-4- (3 - pyridiyl) -1,4-dihydropyridine
Figure imgb0085
1.3 ml of pyridine-3-aldehyde, 6 g of dibenzoylmethane and 1 g of methylamine hydrochloride are heated in 10 ml of pyridine at 100 ° C. overnight, then poured onto ice water, suction filtered and recrystallized from methanol.
  • Yield: 15% of theory; Mp: 238 ° C.

Beispiel 44Example 44

Bis-[2,6-dimethyl-5-ethoxycarbonyl-4-(3-nitrophenyl)-1,4-dihydropyridin-3-carbonsäure]-1,6-hexandiylester

Figure imgb0086
25 mmol Bis-(3-aminocrotonsäure)-1,6-hexandiylester werden zusammen mit 50 mmol 3-Nitrobenzylidenacetessigsäureethylester in 100 ml Ethanol 14 Stunden unter Rückfluss gekocht. Nach Erkalten wird das Lösungsmittel im Vakuum abdestilliert und mit 50%igem wässrigem Ethanol aufgenommen. Der halbfeste Rückstand wurde aus Methanol umkristallisiert.

  • Ausbeute: 37% der Theorie; Fp.: 177 bis 179 °C.
Bis- [2,6-dimethyl-5-ethoxycarbonyl-4- (3-nitrophenyl) -1,4-dihydropyridine-3-carboxylic acid] -1,6-hexanediyl ester
Figure imgb0086
25 mmol of bis- (3-aminocrotonic acid) -1,6-hexanediyl ester are boiled together with 50 mmol of 3-nitrobenzylideneacetoacetic acid ethyl ester in 100 ml of ethanol under reflux for 14 hours. After cooling, the solvent is distilled off in vacuo and taken up in 50% aqueous ethanol. The semi-solid residue was recrystallized from methanol.
  • Yield: 37% of theory; Mp .: 177 to 179 ° C.

Beispiel 45Example 45

Bis-[2,6-dimethyl-5-ethoxycarbonyl-4-(3-nitrophenyl)-1,4-dihydropyridin-3-carbonsäure]-1,12-dodecandiylester

Figure imgb0087
Darstellung analog Beispiel 44 mit Bis-(3-amino- crotonsäure)-1,12-dodecandiylester anstatt Bis-(3-aminocrotonsäure)-1,6-Hexandiylester.

  • Ausbeute: 10% der Theorie; Fp.: 103 bis 120 °C.
Bis- [2,6-dimethyl-5-ethoxycarbonyl-4- (3-nitrophenyl) -1,4-dihydropyridine-3-carboxylic acid] -1,12-dodecanediyl ester
Figure imgb0087
Representation analogous to Example 44 with bis- (3-amino-crotonic acid) -1,12-dodecanediyl ester instead of bis- (3-aminocrotonic acid) -1,6-hexanediyl ester.
  • Yield: 10% of theory; Mp .: 103 to 120 ° C.

Beispiel 46Example 46

Figure imgb0088
Figure imgb0088

Analog Beispiel 17 wurde durch Umsetzung von 2-(4-Methylbenzylthio)-benzaldehyd mit 2-Amino-1-nitro-1-propen und Acetessigsäuremethylester in Ethanol 1,4-Dihydro-2,6-dimethyl-4-[2-(4-methylbenzyl- thio)-phenyl]-3-nitropyridin-5-carbonsäuremethylester vom Schmp. 160 °C {Isopropanol) erhalten.

  • Ausbeute: 28% der Theorie.
Analogously to Example 17, by reaction of 2- (4-methylbenzylthio) benzaldehyde with 2-amino-1-nitro-1-propene and methyl acetoacetate in ethanol, 1,4-dihydro-2,6-dimethyl-4- [2- ( 4-methylbenzyl-thio) -phenyl] -3-nitropyridine-5-carboxylic acid methyl ester of mp. 160 ° C {isopropanol) obtained.
  • Yield: 28% of theory.

Beispiel 47Example 47

Figure imgb0089
Figure imgb0089

Analog Beispiel 16 wurde durch Umsetzung von 2-Trifluormethylbenzaldehyd mit ß-Aminocrotonsäuremethylester und 1-Nitrobutanon-2 in Ethanol 1,4-Dihydro-2-ethyl-6-methyl-3-nitro-4-(2-trifluormethylphenyl)-pyridin-5-carbonsäure-methylester vom Schmp. 199 °C (Iropropanol) erhalten.

  • Ausbeute: 31% der Theorie.
Analogously to Example 16, 1,4-dihydro-2-ethyl-6-methyl-3-nitro-4- (2-trifluoromethylphenyl) pyridine was used to react 2-trifluoromethylbenzaldehyde with methyl ß-aminocrotonic acid and 1-nitrobutanone-2 in ethanol. 5-carboxylic acid methyl ester of mp. 199 ° C (Iropropanol) obtained.
  • Yield: 31% of theory.

Beispiel 48Example 48

Figure imgb0090
Figure imgb0090

Analog Beispiel 16 wurde durch Umsetzung von 2-Benzylthiobenzaldehyd mit β-Aminocrotonsäuremethylester und 1-Nitrobutanon-2 in Ethanol 4-(2-Benzylthiophenyl)-1,4-dihydro-2-ethyl-6-methyl-3-nitro-pyridin-5-carbonsäuremethylester vom Schmp. 122 °C (lsopropanol) erhalten.

  • Ausbeute: 21 % der Theorie.
Analogously to Example 16, 4- (2-benzylthiophenyl) -1,4-dihydro-2-ethyl-6-methyl-3-nitro-pyridine was obtained by reacting 2-benzylthiobenzaldehyde with methyl β-aminocrotonic acid and 1-nitrobutanone-2 in ethanol. 5-carboxylic acid methyl ester of mp 122 ° C (isopropanol) obtained.
  • Yield: 21% of theory.

Beispiel 49Example 49

Figure imgb0091
Figure imgb0091

Analog Beispiel 16 wurde durch Umsetzung von 3-Benzylthiobenzaldehyd mit β-Aminocrotonsäuremethylester und Nitroaceton in Ethanol 4-(3-Benzylthiophenyl)-1,4-dihydro-2,6-dimethyl-3-nitropyridin-5-carbonsäuremethyl-ester vom Schmp. 155 °C (Ethanol) erhalten.

  • Ausbeute: 35% der Theorie.
Analogously to Example 16, 4- (3-benzylthiophenyl) -1,4-dihydro-2,6-dimethyl-3-nitropyridine-5-carboxylic acid methyl ester of mp. 4 was obtained by reacting 3-benzylthiobenzaldehyde with methyl β-aminocrotonic acid and nitroacetone in ethanol. Obtained 155 ° C (ethanol).
  • Yield: 35% of theory.

Beispiel 50Example 50

Figure imgb0092
Figure imgb0092

Analog Beispiel 17 wurde durch Umsetzung von 2-Trifluormethylbenzaldehyd mit y-Phenylacetessigsäureethylester und 2-Amino-1-nitro-1-propen in Ethanol 2-Benzyl-1,4-dihydro-6-methyl-3-nitro-4-(2-trifluormethylphenyl)-pyridin-5-carbonsäureethylester vom Schmp. 168 °C erhalten.

  • Ausbeute: 12% der Theorie.
Analogously to Example 17, 2-benzyl-1,4-dihydro-6-methyl-3-nitro-4- (2 -trifluoromethylphenyl) pyridine-5-carboxylic acid ethyl ester of mp. 168 ° C.
  • Yield: 12% of theory.

Beispiel 51Example 51

Figure imgb0093
Figure imgb0093

Analog Beispiel 17 wurde durch Umsetzung von 2-Trifluormethylbenzaldehyd mit 2-Amino-1-nitro-1-propen und 3-Oxo-hexansäuremethylester in Ethanol 1,4-Dihydro-2-methyl-3-nitro-6-propyl-4-(2-trifluormethyl-phenyl)-pyridin-5-carbonsäuremethylester vom Schmp. 168°C (Isopropanol) erhalten.

  • Ausbeute: 19% der Theorie.
Analogously to Example 17, 1,4-dihydro-2-methyl-3-nitro-6-propyl-4- was reacted with 2-amino-1-nitro-1-propene and methyl 3-oxo-hexanoate in ethanol by reaction of 2-trifluoromethylbenzaldehyde. (2-trifluoromethyl-phenyl) -pyridine-5-carboxylic acid methyl ester of mp. 168 ° C (isopropanol) obtained.
  • Yield: 19% of theory.

Beispiel 52Example 52

Figure imgb0094
Figure imgb0094

Analog Beispiel 16 wurde durch Umsetzung von 3-Ethoxybenzaldehyd mit Nitroaceton und β-Aminocrotonsäuremethylester in Ethanol 1,4-Dihydro-2,6-dimethyl-4-(3-ethoxyphenyl)-3-nitropyridin-5-carbonsäuremethylester vom Schmp. 127 °C erhalten.

  • Ausbeute: 42% der Theorie.
Analogously to Example 16, 1,4-dihydro-2,6-dimethyl-4- (3-ethoxyphenyl) -3-nitropyridine-5-carboxylic acid methyl ester of mp 127 ° was obtained by reacting 3-ethoxybenzaldehyde with nitroacetone and methyl β-aminocrotonic acid in ethanol C received.
  • Yield: 42% of theory.

Beispiel 53Example 53

Figure imgb0095
Figure imgb0095

Analog Beispiel 16 wurde durch Umsetzung von 2-Benzyl-thiobenzaldehyd mit Nitroaceton und β-Aminocrotonsäure-(β-cyanoethyl)ester in Ethanol-4-(2-Benzylthiophenyl)-1,4-dihydro-2,6-dimethyl-3-nitropyridin-5-carbonsäure-(ß-cyanoethyl)ester vom Schmp. 173 °C (Isopropanol) erhalten.

  • Ausbeute: 28% der Theorie.
Analogously to Example 16, the reaction of 2-benzylthiobenzaldehyde with nitroacetone and β-aminocrotonic acid (β-cyanoethyl) ester in ethanol-4- (2-benzylthiophenyl) -1,4-dihydro-2,6-dimethyl-3- Received nitropyridine-5-carboxylic acid (ß-cyanoethyl) ester of mp. 173 ° C (isopropanol).
  • Yield: 28% of theory.

Beispiel 54Example 54

Figure imgb0096
Figure imgb0096

Analog Beispiel 16 wurde durch Umsetzung von 2-Cyanobenzaldehyd mit Nitroaceton und β-Aminocrotonsäuremethylester in Ethanol 4-(2-Cyanophenyl)-1,4-dihydro-2,6-dimethyl-3-nitropyridin-5-carbonsäuremethylester vom Schmp. 182 °C (Isopropanol) erhalten.

  • Ausbeute: 28% der Theorie.
Analogously to Example 16, 4- (2-cyanophenyl) -1,4-dihydro-2,6-dimethyl-3-nitropyridine-5-carboxylic acid methyl ester of melting point 182 ° was obtained by reacting 2-cyanobenzaldehyde with nitroacetone and methyl β-aminocrotonic acid in ethanol C (isopropanol) obtained.
  • Yield: 28% of theory.

Beispiel 55Example 55

Figure imgb0097
Figure imgb0097

Analog Beispiel 16 wurde durch Umsetzung von 2,3-Dichlorbenzaldehyd mit Nitroaceton und ß-Aminocrotonsäuremethylester in Ethanol 4-(2,3-Dichlorphenyl)-1,4-dihydro-2,6-dimethyl-3-nitropyridin-5-carbonsäuremethylester vom Schmp. 184 °C erhalten.

  • Ausbeute: 39% der Theorie.
Analogously to Example 16, 4- (2,3-dichlorophenyl) -1,4-dihydro-2,6-dimethyl-3-nitropyridine-5-carboxylic acid methyl ester of 4- (2,3-dichlorophenyl) -1,4-dihydro-2,6-dimethyl-3-nitropyridine-5-carboxylic acid methyl ester was reacted by reacting 2,3-dichlorobenzaldehyde with nitroacetone and methyl β-aminocrotonate in ethanol Mp. 184 ° C obtained.
  • Yield: 39% of theory.

Beispiel 56Example 56

Figure imgb0098
Figure imgb0098

Analog Beispiel 16 wurde durch Umsetzung von 2-Trifluormethylbenzaldehyd mit Nitroaceton und β-Aminocrotonsäure-(6-hydroxyhexyl)ester in Ethanol 1,4-Dihydro-2,6-dimethyl-3-nitro-4-(2-trifluormethylphenyl)-pyridin-5-carbonsäure-(6-hydroxyhexyl)ester vom Schmp. 174 °C erhalten.

  • Ausbeute: 32% der Theorie.
Analogously to Example 16, 1,4-dihydro-2,6-dimethyl-3-nitro-4- (2-trifluoromethylphenyl) pyridine was reacted with 2-trifluoromethylbenzaldehyde with nitroacetone and β-aminocrotonic acid (6-hydroxyhexyl) ester in ethanol Obtained -5-carboxylic acid (6-hydroxyhexyl) ester of mp. 174 ° C.
  • Yield: 32% of theory.

Beispiel 57Example 57

Figure imgb0099
Figure imgb0099

Durch Umsetzung von 1 Äquivalent 1,4-Dihydro-2,6-dimethyl-3-nitro-4-(2-trifluormethylphenyl)-pyridin-5-carbonsäure-(6-hydroxyhexyl)-ester mit 1 Äquivalent 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3- . carboxymethylpyridin-5-carbonsäure und 1,1 Äquivalenten Dicyclohexylcarbodiimid im Methylenchlorid wird 5- 6-[2,6-Dimethyl-5-nitro-4-(2-trifluormethylphenyl)-1,4-dihydro-pyrid-3-yJcarboxy]-hexyloxy- carbonyl-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridin-3-carbonsäuremethylester als amorphe, gelbe Substanz erhalten.

  • Ausbeute: 68%
  • m/e: 756 ≙ M
    Figure imgb0100
By reacting 1 equivalent of 1,4-dihydro-2,6-dimethyl-3-nitro-4- (2-trifluoromethylphenyl) pyridine-5-carboxylic acid (6-hydroxyhexyl) ester with 1 equivalent of 1,4-dihydro -2,6-dimethyl-4- (3-nitrophenyl) -3-. carboxymethylpyridine-5-carboxylic acid and 1.1 equivalents of dicyclohexylcarbodiimide in methylene chloride is 5- 6- [2,6-dimethyl-5-nitro-4- (2-trifluoromethylphenyl) -1,4-dihydro-pyrid-3-yJcarboxy] - hexyloxycarbonyl-2,6-dimethyl-4- (3-nitrophenyl) -1,4-dihydropyridine-3-carboxylic acid methyl ester obtained as an amorphous, yellow substance.
  • Yield: 68%
  • m / e: 756 ≙ M
    Figure imgb0100

Beispiel 58Example 58

Figure imgb0101
Figure imgb0101

Analog dem vorhergehenden Beispiel erhält man durch Umsetzung von 1,4-Dihydro-2,6-dimethyl-3-nitro-4-(3-nitrophenyl)-pyridin-5-carbonsäure-(6-hydroxyhexylester) mit 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3-carboxymethyl-pyridin-5-carbonsäure und Dicyclohexylcarbodümid in Methylenchlorid wird 5- 6-[2,3-Dimethyl-5-nitro-4-(3-nitrophenyl)-1,4-dihydro-pyrid-3-ylcarboxy]-hexyloxycarbonyl-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridin-3-carbonsäuremethylester als amorphe, gelbe Substanz erhalten.

  • Ausbeute: 73%
  • m/e: 733 ≙ M
    Figure imgb0102
Analogously to the previous example, reaction of 1,4-dihydro-2,6-dimethyl-3-nitro-4- (3-nitrophenyl) pyridine-5-carboxylic acid (6-hydroxyhexyl ester) with 1,4-dihydro -2,6-dimethyl-4- (3-nitrophenyl) -3-carboxymethyl-pyridine-5-carboxylic acid and dicyclohexylcarbodiimide in methylene chloride becomes 5- 6- [2,3-dimethyl-5-nitro-4- (3-nitrophenyl ) -1,4-dihydro-pyrid-3-ylcarboxy] -hexyloxycarbonyl-2,6-dimethyl-4- (3-nitrophenyl) -1,4-dihydropyridine-3-carboxylic acid methyl ester was obtained as an amorphous, yellow substance.
  • Yield: 73%
  • m / e: 733 ≙ M
    Figure imgb0102

Beispiel 59Example 59

Figure imgb0103
Figure imgb0103

Analog Beispiel 16 wurde durch Umsetzung von 5-Chlor-2-nitrobenzaldehyd mit Nitroaceton und ß-Aminocrotonsäuremethylester in Ethanol 4-(5-Chlor-2-nitrophenyl)-2,4-dihydro-2,6-dimethyl-3-nitro-pyridin-5-carbonsäure-methylester vom Schmp. 221 °C (Isopropanol) erhalten.

  • Ausbeute: 43% der Theorie.
Analogously to Example 16, 4- (5-chloro-2-nitrophenyl) -2,4-dihydro-2,6-dimethyl-3-nitro- was obtained by reacting 5-chloro-2-nitrobenzaldehyde with nitroacetone and methyl ß-aminocrotonic acid in ethanol. pyridine-5-carboxylic acid methyl ester of mp. 221 ° C (isopropanol) obtained.
  • Yield: 43% of theory.

Beispiel 60Example 60

Figure imgb0104
Figure imgb0104

Analog Beispiel 16 wurde durch Umsetzung von 2-Chlor-5-nitrobenzaldehyd mit Nitroaceton und ß-Aminocrotonsäuremethylester in Ethanol 4-(2-Chlor-5-nitrophenyl)-1,4-dihydro-2,6-dimethyl-3-nitro-pyridin-5-carbonsäure-methylester vom Schmp. 219 °C erhalten.

  • Ausbeute: 39% der Theorie.
Analogously to Example 16, 4- (2-chloro-5-nitrophenyl) -1,4-dihydro-2,6-dimethyl-3-nitro- was obtained by reacting 2-chloro-5-nitrobenzaldehyde with nitroacetone and methyl ß-aminocrotonic acid in ethanol. pyridine-5-carboxylic acid methyl ester of melting point 219 ° C.
  • Yield: 39% of theory.

Beispiel 61Example 61

Figure imgb0105
Figure imgb0105

Analog Beispiel 16 wurde durch Umsetzung von 2-(3-Chlorbenzylthio)-benzaldehyd mit Nitroaceton und β-Aminocrotonsäure-n-hexylester in Ethanol 4-(3-Chlorbenzylthiophenyl)-1,4-dihydro-2,6-dimethyl-3-nitropyridin-5-carbonsäure-n-hexylester nach Chromatographie erhalten.

  • Ausbeute: 21 % der Theorie.
    Figure imgb0106
Analogously to Example 16, 4- (3-chlorobenzylthiophenyl) -1,4-dihydro-2,6-dimethyl-3- was reacted with 2- (3-chlorobenzylthio) benzaldehyde with nitroacetone and β-aminocrotonic acid n-hexyl ester in ethanol. Nitropyridine-5-carboxylic acid n-hexyl ester obtained after chromatography.
  • Yield: 21% of theory.
    Figure imgb0106

Beispiel 62Example 62

Figure imgb0107
Figure imgb0107

Durch Umsetzung von je 10 mmol 2-Trifluormethylbenzaldehyd, Nitroaceton, Amidinoessigesterhydrochlorid und Natriummethylat in 60 ml siedendem Ethanol wurde 6-Amino-1,4-dihydro-2-methyl-3-nitro-4-(2-trifluormethylphenyl)-pyridin-5-carbonsäuremethylester vom Schmp. 210 °C (Isopropanol) erhalten.

  • Ausbeute: 36% der Theorie.
6-Amino-1,4-dihydro-2-methyl-3-nitro-4- (2-trifluoromethylphenyl) pyridine-5 was obtained by reacting 10 mmol each of 2-trifluoromethylbenzaldehyde, nitroacetone, amidinoacetic ester hydrochloride and sodium methylate in 60 ml of boiling ethanol -carboxylic acid methyl ester of mp. 210 ° C (isopropanol) obtained.
  • Yield: 36% of theory.

Beispiel 63Example 63

Figure imgb0108
Figure imgb0108

Durch Umsetzung von je 10 mmol 2-Trifluormethylbenzaldehyd, Acetessigsäuremethylester, Nitroaceton und Methylaminhydrochlorid in 50 ml Eisessig bei 60 °C für 12 Stunden wurde 1,4-Dihydro-3-nitro-4-(2-trifluormethylphenyl)-1,2,6-trimethylpyridin-5-carbonsäuremethylester vom Schmp. 156 °C (Isopropanol) erhalten.

  • Ausbeute: 15% der Theorie.
By reacting 10 mmol of 2-trifluoromethylbenzaldehyde, methyl acetoacetate, nitroacetone and methylamine hydrochloride in 50 ml of glacial acetic acid at 60 ° C. for 12 hours, 1,4-dihydro-3-nitro-4- (2-trifluoromethylphenyl) -1,2,6 -Trimethylpyridine-5-carboxylic acid methyl ester of mp. 156 ° C (isopropanol) obtained.
  • Yield: 15% of theory.

Beispiel 64Example 64

Figure imgb0109
Figure imgb0109

Analog Beispiel 16 wurde durch Umsetzung von β-Naphthylaldehyd, β-Aminocrotonsäuremethylester und Nitroaceton in Ethanol 1,4-Dihydro-2,6-dimethyl-4-β-naphthyl-3-nitro- pyridin-5-carbonsäuremethylester vom Schmp. 163 °C (Isopropanol) erhalten.

  • Ausbeute: 42% der Theorie.
Analogously to Example 16, 1,4-dihydro-2,6-dimethyl-4-β-naphthyl-3-nitro-pyridine-5-carboxylic acid methyl ester of mp 163 ° was obtained by reacting β-naphthylaldehyde, β-aminocrotonic acid methyl ester and nitroacetone in ethanol C (isopropanol) obtained.
  • Yield: 42% of theory.

Beispiel 65Example 65

Figure imgb0110
Figure imgb0110

Analog Beispiel 16 wurde durch Umsetzung von Pentafluorbenzaldehyd mit Nitroaceton und β-Aminocrotonsäuremethylester in Ethanol 1,4-Dihydro-2,6-dimethyl-3-nitro-4-pentafluor- phenylpyridin-5-carbonsäuremethylester vom Schmp. 231 °C erhalten.

  • Ausbeute: 38% der Theorie.
Analogously to Example 16, 1,4-dihydro-2,6-dimethyl-3-nitro-4-pentafluorophenylpyridine-5-carboxylic acid methyl ester of melting point 231 ° C. was obtained by reacting pentafluorobenzaldehyde with nitroacetone and methyl β-aminocrotonic acid in ethanol.
  • Yield: 38% of theory.

Beispiel 66Example 66

Figure imgb0111
Figure imgb0111

Analog Beispiel 16 wurde durch Umsetzung von 2-Chlor-6-fluorbenzaldehyd mit Nitroaceton und β-Aminocrotonsäuremethylester 4-(2-Chlor-6-fluorphenyl)-1,4-dihydro-2,6-dimethyl-3-nitropyridin-5-carbonsäuremethylester vom Schmp. 190 °C erhalten.

  • Ausbeute: 28% der Theorie.
Analogously to Example 16, 4- (2-chloro-6-fluorophenyl) -1,4-dihydro-2,6-dimethyl-3-nitropyridine-5- was reacted with 2-chloro-6-fluorobenzaldehyde with nitroacetone and β-aminocrotonic acid methyl ester. carboxylic acid methyl ester of melting point 190 ° C.
  • Yield: 28% of theory.

Beispiel 67Example 67

Figure imgb0112
Figure imgb0112

Durch Umsetzung von je 1 Äquivalent 1,4-Dihydro-2,6-dimethyl-3-nitro-4-(2-trifluormethylphenyl)-pyridin-5-carbonsäure mit Dimethylaminoethanol und DCC im Methylenchlorid erhält man 1,4-Dihydro-2,6-dimethyl-3-nitro-4-(2-trifluormethylphenyl)-pyridin-5-carbonsäure-ß-dimethyl- aminoethylester

  • vom Schmp. 132 °C.
  • Ausbeute: 84% der Theorie.
By reacting 1 equivalent of 1,4-dihydro-2,6-dimethyl-3-nitro-4- (2-trifluoromethylphenyl) pyridine-5-carboxylic acid with dimethylaminoethanol and DCC in methylene chloride, 1,4-dihydro-2 is obtained , 6-dimethyl-3-nitro-4- (2-trifluoromethylphenyl) pyridine-5-carboxylic acid-β-dimethylaminoethyl ester
  • from mp. 132 ° C.
  • Yield: 84% of theory.

Beispiel 68Example 68

Figure imgb0113
Figure imgb0113

Analog Beispiel 16 erhält man durch Umsetzung von 3-Benzyloxybenzaldehyd mit Nitroaceton und β-Aminocrotonsäuremethylester 4-(3-Benzyloxyphenyl)-1,4-dihydro-2,6-dimethyl-3-nitropyridin-5-carbonsäuremethylester vom Schmp. 181 °C (Isopropanol).

  • Ausbeute: 34% der Theorie.
Analogously to Example 16, 4- (3-benzyloxyphenyl) -1,4-dihydro-2,6-dimethyl-3-nitropyridine-5-carboxylic acid methyl ester of melting point 181 ° C. is obtained by reacting 3-benzyloxybenzaldehyde with nitroacetone and methyl β-aminocrotonate (Isopropanol).
  • Yield: 34% of theory.

Beispiel 69Example 69

1,4-Dihydro-2,6-dimethyl-4-[2-(4-methylbenzyl- oxy)-phenyl]-pyridin-3-carbonsäure-methylester

Figure imgb0114
Methyl 1,4-dihydro-2,6-dimethyl-4- [2- (4-methylbenzyloxy) phenyl] pyridine-3-carboxylate
Figure imgb0114

A) Herstellung von a-Acetyl-2-(4-methylbenzyl- oxy)-zimtsäuremethylesterA) Preparation of methyl a-acetyl-2- (4-methylbenzyloxy) -cinnamate

25g g (110,6 mmol) 2-(4-Methylbenzyloxy)-benz- aldehyd werden mit 11,9 ml (110,6 mmol) Acetessigsäuremethylester in 66 ml Isopropanol verrührt und mit einer frisch zubereiteten Lösung von 0,64 ml Piperidin und 0,38 ml Eisessig in 5,5 ml Isopropanol versetzt. Es wird 1 Stunde bei 60 °C und 4 Stunden bei 40 °C gerührt, abgekühlt und eingeengt. Der Eindampfrückstand wird in Ether gelöst und nacheinander mit ca. 100 ml 1N Salzsäure, zweimal mit Wasser, mit gesättigter Natriumhydrogencarbonatlösung und wieder zweimal mit Wasser gewaschen. Die Etherphase wird getrocknet, filtriert und eingeengt. Man erhält 35,3 g (98,51% der Theorie) eines dunkelgelben Öles, welches roh weiter umgesetzt wird.25g g (110.6 mmol) of 2- (4-methylbenzyloxy) benzaldehyde are stirred with 11.9 ml (110.6 mmol) of methyl acetoacetate in 66 ml of isopropanol and with a freshly prepared solution of 0.64 ml of piperidine and 0.38 ml glacial acetic acid in 5.5 ml isopropanol. The mixture is stirred at 60 ° C. for 1 hour and at 40 ° C. for 4 hours, cooled and concentrated. The evaporation residue is dissolved in ether and washed successively with about 100 ml of 1N hydrochloric acid, twice with water, with saturated sodium bicarbonate solution and again twice with water. The ether phase is dried, filtered and concentrated. 35.3 g (98.51% of theory) of a dark yellow oil are obtained, which is further reacted raw.

B) 1,4-Dihydro-2,6-dimethyl-4-[2-(4-methyl- benzyloxy)-phenyl]-pyridin-3,5-dicarbonsäure- methyl-(2-cyanoethyl)-esterB) 1,4-Dihydro-2,6-dimethyl-4- [2- (4-methylbenzyloxy) phenyl] pyridine-3,5-dicarboxylic acid methyl (2-cyanoethyl) ester

Figure imgb0115
35,3 g (108,35 mmol) a-Acetyl-2-(4-methylbenzyl- oxy)-zimtsäuremethylester werden mit 16,8 g (108,95 mmol) ß-Aminocrotonsäure-2-cyanoethyl- ester in 160 ml Ethanol 18 Stunden zum Rückfluss gekocht. Es wird eingeengt, der Eindampfrückstand wird in Essigester aufgenommen und zweimal mit Wasser geschüttelt. Die Essigesterphase wird getrocknet, filtriert und eingeengt. Der erhaltene Eindampfrückstand kristallisiert beim Verrühren mit Methanol. Es wird abgesaugt und mit Methanol gewaschen. Man erhält 20,2 g (40,53% der Theorie) eines leicht gelbgefärbten Produktes vom Schmp. 165 °C unter Zersetzung.
Figure imgb0115
35.3 g (108.35 mmol) of methyl a-acetyl-2- (4-methylbenzyloxy) cinnamate are mixed with 16.8 g (108.95 mmol) of 2-cyanoethyl ß-aminocrotonic acid in 160 ml of ethanol Boiled to reflux for 18 hours. It is concentrated, the evaporation residue is taken up in ethyl acetate and shaken twice with water. The ethyl acetate phase is dried, filtered and concentrated. The evaporation residue obtained crystallizes on stirring with methanol. It is suctioned off and washed with methanol. 20.2 g (40.53% of theory) of a slightly yellow-colored product of melting point 165 ° C. are obtained with decomposition.

C) 1,4-Dihydro-2,6-dimethyl-4-[2-(4-methyl- benzyloxy)-phenyl]-pyridin-3,5-dicarbonsäure- monomethylesterC) 1,4-Dihydro-2,6-dimethyl-4- [2- (4-methylbenzyloxy) phenyl] pyridine-3,5-dicarboxylic acid monomethyl ester

Figure imgb0116
17,5 g (38 mmol) 1,4-Dihydro-2,6-dimethyl-4-[2-(4-methylbenzyloxy)-phenyl]-pyridin-3,5-dicarbonsäure-methyl-(2-cyanoethyl)-ester werden in einer Lösung von 4,6 g (115 mmol) Natriumhydroxid in 115 ml Wasser suspendiert und mit 57,5 ml Dimethoxyethan versetzt. Man erhält allmählich eine klare Lösung. Es wird 20 Stunden gerührt, mit 100 ml Wasser versetzt und dreimal mit Methylenchlorid extrahiert. Die wässrige Phase wird unter Rühren mit konz. Salzsäure tropfenweise sauer gestellt, wobei die Säure ausfällt. Es wird abgesaugt, mit Wasser gewaschen und getrocknet. Man erhält 12,2 g (78,9% der Theorie) eines beigefarbenen Festproduktes vom Schmp. ab 169 °C Zersetzung.
Figure imgb0116
17.5 g (38 mmol) 1,4-dihydro-2,6-dimethyl-4- [2- (4-methylbenzyloxy) phenyl] pyridine-3,5-dicarboxylic acid methyl- (2-cyanoethyl) - esters are suspended in a solution of 4.6 g (115 mmol) sodium hydroxide in 115 ml water and mixed with 57.5 ml dimethoxyethane. A clear solution is gradually obtained. The mixture is stirred for 20 hours, mixed with 100 ml of water and extracted three times with methylene chloride. The aqueous phase is stirred with conc. Hydrochloric acid acidified dropwise, whereby the acid fails. It is suctioned off, washed with water and dried. 12.2 g (78.9% of theory) of a beige solid product with a melting point of 169 ° C. and above are obtained.

D) 3 g 1,4-Dihydro-2,6-dimethyl-4-[2-(4-methyl- benzyloxy)-phenyl]-pyridin-3,5-dicarbonsäure- monomethylesterD) 3 g of 1,4-dihydro-2,6-dimethyl-4- [2- (4-methylbenzyloxy) phenyl] pyridine-3,5-dicarboxylic acid monomethyl ester

werden in 30 ml Diethylenglykol suspendiert und unter Rühren auf 170 bis 180 °C erwärmt, wobei unter Gasentwicklung eine klare Lösung entsteht. Es wird ca. 5 Minuten bei 180 °C gerührt und abgekühlt. Die viskose Lösung wird unter starkem Schütteln in einem Ether/Wasser-Gemisch gelöst, es wird getrennt, die wässrige Phase mit Ether extrahiert und die vereinten Etherphasen mit 1N Natronlauge und zweimal mit Wasser gewaschen. Es wird getrocknet, filtriert und eingeengt. Der erhaltene sirupöse Rückstand wird mit Isopropanol oder Acetonitril im Eisbad kristallisiert und abgesaugt. Es werden 1,6 g 1,4-Dihydro-2,6-dimethyl-4-[2-(4-methylbenzyloxy)-phenyl]-pyridin-3-carbonsäuremethylester vom Schmp. 107 °C bis 109 °C erhalten.


  • Analog wurden hergestellt:
are suspended in 30 ml of diethylene glycol and heated to 170 ° to 180 ° C. with stirring, a clear solution being formed with the evolution of gas. The mixture is stirred at 180 ° C. for about 5 minutes and cooled. The viscous solution is dissolved with vigorous shaking in an ether / water mixture, it is separated, the aqueous phase is extracted with ether and the combined ether phases are washed with 1N sodium hydroxide solution and twice with water. It is dried, filtered and concentrated. The syrupy residue obtained is crystallized with isopropanol or acetonitrile in an ice bath and suction filtered. 1.6 g of 1,4-dihydro-2,6-dimethyl-4- [2- (4-methylbenzyloxy) phenyl] pyridine-3-carboxylic acid methyl ester of mp 107 ° C. to 109 ° C. are obtained.

  • The following were produced analogously:

Beispiel 70Example 70

1,4-Dihydro-2,6-dimethyl-4-(2-trifluormethylphenyl)-pyridin-3-carbonsäureethylester vom Schmp. 125 bis 128 °C.1,4-Dihydro-2,6-dimethyl-4- (2-trifluoromethylphenyl) pyridine-3-carboxylic acid ethyl ester of mp. 125 to 128 ° C.

Beispiel 71Example 71

1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-pyridin-3-carbonsäureisopropylester, isoliert als Öl. Rf-Wert: 0,525; DC-Alurolle, Schichtdicke: 0,2 mm, Kieselgel: 60 F 254, Merck; Fliessmittel: Petrolether/Essigester im Volumenverhältnis 2: 1.1,4-Dihydro-2,6-dimethyl-4- (3-nitrophenyl) pyridine-3-carboxylic acid isopropyl ester, isolated as an oil. R f value: 0.525; DC aluminum roll, layer thickness: 0.2 mm, silica gel: 60 F 254, Merck; Eluent: petroleum ether / ethyl acetate in a volume ratio of 2: 1.

Beispiel 72Example 72

1,4-Dihydro-1,2,6-trimethyl-4-(2-chlorphenyl)-pyridin-3-carbonsäuremethylester vom Schmp. 142 bis 144 °C.1,4-Dihydro-1,2,6-trimethyl-4- (2-chlorophenyl) pyridine-3-carboxylic acid methyl ester, mp. 142 to 144 ° C.

Beispiel 73Example 73

1,4-Dihydro-2,6-dimethyl-4-(3-chlorphenyl)-pyridin-3-carbonsäuremethylester vom Schmp. 129 bis 133 °C.1,4-Dihydro-2,6-dimethyl-4- (3-chlorophenyl) pyridine-3-carboxylic acid methyl ester of mp. 129 to 133 ° C.

Beispiel 74Example 74

1,4-Dihydro-2,6-dimethyl-4-(2-methylphenyl)-pyridin-3-carbonsäuremethylester vom Schmp. 127 bis 130 °C.1,4-Dihydro-2,6-dimethyl-4- (2-methylphenyl) pyridine-3-carboxylic acid methyl ester of mp. 127 to 130 ° C.

Beispiel 75Example 75

1,4-Dihydro-2,6-dimethyl-4-(2-chlorphenyl)-pyridin-3-carbonsäuremethylester r

  • vom Schmp. 143-146 °C.
1,4-Dihydro-2,6-dimethyl-4- (2-chlorophenyl) pyridine-3-carboxylic acid methyl ester r
  • from mp. 143-146 ° C.

Beispiel 76Example 76

1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-pyridin-3-carbonsäuremethylester vom Schmp. 110 bis 112 °C.1,4-Dihydro-2,6-dimethyl-4- (3-nitrophenyl) pyridine-3-carboxylic acid, methyl ester, mp. 110 to 112 ° C.

Beispiel 77Example 77

1,4-Dihydro-2,6-dimethyl-4-(2-phenylthio- methyloxy-phenyl)-pyridin-3-carbonsäuremethylester als Öl.

Figure imgb0117
1,4-Dihydro-2,6-dimethyl-4- (2-phenylthiomethyloxyphenyl) pyridine-3-carboxylic acid methyl ester as an oil.
Figure imgb0117

Beispiel 78Example 78

1,4-Dihydro-2,6-dimethyl-4-(2-benzyloxy- phenyl)-pyridin-3-carbonsäuremethylester vom Schmp. 81 bis 83 °C.1,4-Dihydro-2,6-dimethyl-4- (2-benzyloxyphenyl) pyridine-3-carboxylic acid, methyl ester, melting point 81 to 83 ° C.

Beispiel 79Example 79

1,4-Dihydro-2,6-dimethyl-4-[2-(4-chlorbenzyl- oxy)-phenyl]-pyridin-3-carbonsäuremethylester vom Schmp. 90 bis 94 °C.1,4-Dihydro-2,6-dimethyl-4- [2- (4-chlorobenzyloxy) phenyl] pyridine-3-carboxylic acid, methyl ester, mp. 90 to 94 ° C.

Beispiel 80Example 80

1,4-Dihydro-2,6-dimethyl-4-[2-(2-chlorbenzyl- oxy)-phenyl]-pyridin-3-carbonsäuremethylester vom Schmp. 75 bis 77 °C.1,4-Dihydro-2,6-dimethyl-4- [2- (2-chlorobenzyloxy) phenyl] pyridine-3-carboxylic acid, methyl ester, mp. 75 to 77 ° C.

Beispiel 81Example 81

1,4-Dihydro-2,6-dimethyl-4-[2-(2,6-dichlor- benzyloxy)-phenyl]-pyridin-3-carbonsäuremethylester
vom Schmp. 125 bis 128 °C.
1,4-Dihydro-2,6-dimethyl-4- [2- (2,6-dichlorobenzyloxy) phenyl] pyridine-3-carboxylic acid methyl ester
from mp. 125 to 128 ° C.

Beispiel 82Example 82

1,4-Dihydro-2,6-dimethyl-4-[2-(3,4-dichlor- phenyloxy)-phenyl]-pyridin-3-carbonsäuremethylester,
isoliert als Schaum. RrWert: 0,65, DC-Fertigplatten Kieselgel 60 F 254, Fliessmittel: Chloroform/ Essigester im Volumenverhältnis 5:1.
1,4-dihydro-2,6-dimethyl-4- [2- (3,4-dichlorophenyloxy) phenyl] pyridine-3-carboxylic acid methyl ester,
isolated as foam. R r value: 0.65, ready-made DC silica gel 60 F 254 plates, eluent: chloroform / ethyl acetate in a volume ratio of 5: 1.

Beispiel 83Example 83

1,4-Dihydro-2,6-dimethyl-4-[2-(4-methyl- benzyloxy)-naphthyl]-pyridin-3-carbonsäuremethylester,
isoliert als Schaum.
1,4-dihydro-2,6-dimethyl-4- [2- (4-methylbenzyloxy) naphthyl] pyridine-3-carboxylic acid methyl ester,
isolated as foam.

Massenspektrum:Mass spectrum:

Die wichtigsten Peaks findet man bei m/e = 413 (Molpeak); m/e = 308; m/e = 248; m/e = 166.The most important peaks are found at m / e = 413 (Molpeak); m / e = 308; m / e = 248; m / e = 166.

Beispiel 84Example 84

1,4-Dihydro-2,6-dimethyl-4-[2-(4-methylbenzyl- oxy)-phenyl]-pyridin-3-carbonsäureisopropyl- ester
vom Schmp. ab 99 °C.
1,4-Dihydro-2,6-dimethyl-4- [2- (4-methylbenzyloxy) phenyl] pyridine-3-carboxylic acid isopropyl ester
from mp. from 99 ° C.

Beispiel 85Example 85

1,4-Dihydro-2,6-dimethyl-4-(2-(3-trifluormethyl- benzylthio)-phenyl]-pyridin-3-carbonsäuremethylester,
isoliert als Öl. RrWert: 0,84, DC-Alurolle, Schichtdicke: 0,2 mm, Kieselgel 60 F 254, Fliessmittel: Chloroform/Essigester im Volumenverhältnis 5: 1.
1,4-dihydro-2,6-dimethyl-4- (2- (3-trifluoromethyl-benzylthio) phenyl] pyridine-3-carboxylic acid methyl ester,
isolated as an oil. R r value: 0.84, DC aluminum roller, layer thickness: 0.2 mm, silica gel 60 F 254, eluent: chloroform / ethyl acetate in a volume ratio of 5: 1.

Beispiel 86Example 86

1,4-Dihydro-2,6-dimethyl-4-[2-(4-methylbenzyl- oxy)-phenyl]-pyridin-3-carbonsäureisobutylester vom Schmp. ab 57 °C.1,4-Dihydro-2,6-dimethyl-4- [2- (4-methylbenzyloxy) phenyl] pyridine-3-carboxylic acid isobutyl ester, melting point from 57 ° C.

Beispiel 87Example 87

1,4-Dihydro-2,6-dimethyl-4-naphthyl-pyridin-3-carbonsäuremethylester, isoliert als Schaum.1,4-Dihydro-2,6-dimethyl-4-naphthyl-pyridine-3-carboxylic acid methyl ester, isolated as a foam.

Massenspektrum:Mass spectrum:

Die wichtigsten Massenpeaks sind m/e = 293 (Molpeak); m/e = 166 (M - naphthyl).The most important mass peaks are m / e = 293 (mol peak); m / e = 166 (M - naphthyl).

Beispiel 88Example 88

1,4-Dihydro-2,6-dimethyl-4-[2-(3-trifluormethyl- benzyloxy)-phenyl]-pyridin-3-carbonsäuremethylester
vom Schmp. 134 °C.
1,4-Dihydro-2,6-dimethyl-4- [2- (3-trifluoromethyl-benzyloxy) phenyl] pyridine-3-carboxylic acid methyl ester
from mp. 134 ° C.

Beispiel 89Example 89

1,4-Dihydro-2,6-dimethyl-4-(2-(4-methylbenzyl- oxy)-phenyl]-pyridin-3-carbonsäure-sec.- butylester
vom Schmp. ab 78 °C.
1,4-Dihydro-2,6-dimethyl-4- (2- (4-methylbenzyloxy) phenyl] pyridine-3-carboxylic acid sec-butyl ester
from 78 ° C.

Beispiel 90Example 90

1,4-Dihydro-2,6-dimethyl-4-(3-benzyloxy- phenyl)-pyridin-3-carbonsäuremethylester, isoliert als Öl. RrWert: 0,69, DC-Alurolle, Schichtdicke 0,2 mm, Kieselgel 60 G 254, Merck; Fliessmittel: Chloroform/Essigester im Volumenverhältnis 7: 1.1,4-Dihydro-2,6-dimethyl-4- (3-benzyloxyphenyl) pyridine-3-carboxylic acid methyl ester, isolated as an oil. R r value: 0.69, DC aluminum roller, layer thickness 0.2 mm, silica gel 60 G 254, Merck; Superplasticizer: chloroform / ethyl acetate in a volume ratio of 7: 1.

Beispiel 91Example 91

1,4-Dihydro-2,6-dimethyl-4-[2-(3-trifluormethyl- benzyloxy)-phenyl]-pyridin-3-carbonsäure- isobutylester, isoliert als Öl.1,4-Dihydro-2,6-dimethyl-4- [2- (3-trifluoromethyl-benzyloxy) phenyl] pyridine-3-carboxylic acid isobutyl ester, isolated as an oil.

Massenspektrum:Mass spectrum:

Die wichtigsten Massenpeaks sind:

  • m/e = 459 (Molpeak);
  • m/e = 402
    Figure imgb0118
  • m/e = 208 (M-C14H10F3O).
The main mass peaks are:
  • m / e = 459 (mol peak);
  • m / e = 402
    Figure imgb0118
  • m / e = 208 (MC 14 H 10 F 3 O).

Beispiel 92Example 92

1,4-Dihydro-2,6-dimethyl-4-[2-(3-nitrobenzyl- oxy)-phenyl]-pyridin-3-carbonsäuremethylester vom Schmp. 117 bis 118 °C.1,4-Dihydro-2,6-dimethyl-4- [2- (3-nitrobenzyloxy) phenyl] pyridine-3-carboxylic acid, methyl ester, mp. 117 to 118 ° C.

Beispiel 93Example 93

1,4-Dihydro-2,6-dimethyl-4-[2-(3-nitrobenzyl- oxy)-phenyl]-pyridin-3-carbonsäureethylester vom Schmp. ab 107 bis 109 °C.1,4-Dihydro-2,6-dimethyl-4- [2- (3-nitrobenzyloxy) phenyl] pyridine-3-carboxylic acid ethyl ester of melting point from 107 to 109 ° C.

Beispiel 94Example 94

1,4-Dihydro-2,6-dimethyl-4-[2-(4-fluorbenzyl- oxy)-phenyl]-pyridin-3-carbonsäuremethylester vom Schmp. 68 bis 70 °C.1,4-Dihydro-2,6-dimethyl-4- [2- (4-fluorobenzyloxy) phenyl] pyridine-3-carboxylic acid, methyl ester, mp. 68 to 70 ° C.

Beispiel 95Example 95

1,4-Dihydro-2,6-dimethyl-4-[2-(3-trifluormethyl- benzyloxy)-phenyl]-pyridin-3-carbonsäure-sec.- butylester,
isoliert als Öl.
1,4-dihydro-2,6-dimethyl-4- [2- (3-trifluoromethyl-benzyloxy) phenyl] pyridine-3-carboxylic acid, sec-butyl ester,
isolated as an oil.

Massenspektrum:Mass spectrum:

Die wichtigsten Massenpeaks sind: m/e = 459 (Molpeak); m/e = 402 (M-57).The main mass peaks are: m / e = 459 (Molpeak); m / e = 402 (M-57).

Beispiel 96Example 96

1,4-Dihydro-2,6-dimethyl-4-[2-(4-fluorbenzyl- oxy)-phenyl]-pyridin-3-carbonsäureethylester vom Schmp. 122 bis 125 °C.1,4-Dihydro-2,6-dimethyl-4- [2- (4-fluorobenzyloxy) phenyl] pyridine-3-carboxylic acid ethyl ester of mp. 122 to 125 ° C.

Beispiel 97Example 97

1,4-Dihydro-2,6-dimethyl-4-[2-(3,5-dimethyl- benzyloxy)-phenyl]-pyridin-3-carbonsäuremethylester
vom Schmp. 127 bis 129 °C (kristallisiert mit 1 Mol Acetonitril).
1,4-Dihydro-2,6-dimethyl-4- [2- (3,5-dimethylbenzyloxy) phenyl] pyridine-3-carboxylic acid methyl ester
of mp 127 to 129 ° C (crystallized with 1 mole of acetonitrile).

Beispiel 98Example 98

1,4-Dihydro-2,6-dimethyl-4,(3-nitrophenyl)-pyridin-3-carbonsäureethylester vom Schmp. 107 bis 108 °C.1,4-Dihydro-2,6-dimethyl-4, (3-nitrophenyl) pyridine-3-carboxylic acid ethyl ester, mp. 107 to 108 ° C.

Beispiel 99Example 99

1,4-Dihydro-2,6-dimethyl-4-[2-(3,5-dimethyl- benzyloxy)-phenyl]-pyridin-3-carbonsäure-n-butylester,
isoliert als Öl.
1,4-dihydro-2,6-dimethyl-4- [2- (3,5-dimethylbenzyloxy) phenyl] pyridine-3-carboxylic acid n-butyl ester,
isolated as an oil.

Massenspektrum:Mass spectrum:

Die wichtigsten Peaks liegen bei:

  • m/e = 417 (M-2); m/e = 300 (M-119) und
  • m/e = 208.
The most important peaks are:
  • m / e = 417 (M-2); m / e = 300 (M-119) and
  • m / e = 208.

Beispiel 100Example 100

1,4-Dihydro-2,6-dimethyl-4-[2-(3-methylbenzyl- oxy)-phenyl]-pyridin-3-carbonsäure-n-butylester vom Schmp. 104 bis 10 °C.1,4-Dihydro-2,6-dimethyl-4- [2- (3-methylbenzyloxy) phenyl] pyridine-3-carboxylic acid n-butyl ester, mp. 104 to 10 ° C.

Beispiel 101Example 101

1,4-Dihydro-2,6-dimethyl-4-[2-(3-methylbenzyl- oxy)-phenyl]-pyridin-3-carbonsäuremethylester vom Schmp. 58 bis 62 °C, kristallisiert mit 1 Mol Acetonitril.1,4-Dihydro-2,6-dimethyl-4- [2- (3-methylbenzyloxy) phenyl] pyridine-3-carboxylic acid, methyl ester, mp. 58 to 62 ° C., crystallized with 1 mol of acetonitrile.

Beispiel 102Example 102

1,4-Dihydro-2,6-dimethyl-4-[2-(3-fluorbenzyl- oxy)-phenyl]-pyridin-3-carbonsäuremethylester vom Schmp. 109 bis 10 °C.1,4-Dihydro-2,6-dimethyl-4- [2- (3-fluorobenzyloxy) phenyl] pyridine-3-carboxylic acid, methyl ester, mp. 109 to 10 ° C.

Beispiel 103Example 103

1,4-Dihydro-2,6-dimethyl-4-[2-(3-fluorbenzyl- oxy)-phenyl]-pyridin-3-carbonsäure-n-butylester vom Schmp. 105 bis 106 °C.1,4-Dihydro-2,6-dimethyl-4- [2- (3-fluorobenzyloxy) phenyl] pyridine-3-carboxylic acid n-butyl ester, mp. 105 to 106 ° C.

Beispiel 104Example 104

1,4-Dihydro-2,6-dimethyl-4-(2-phenylpropyl- mercaptophenyl)-pyridin-3-carbonsäuremethylester,
isoliert als Öl.
1,4-dihydro-2,6-dimethyl-4- (2-phenylpropyl-mercaptophenyl) pyridine-3-carboxylic acid methyl ester,
isolated as an oil.

RrWert: 0,46, DC-Alurolle, Schichtdicke: 0,2 mm, Kieselgel 60 F 254 Merck, Fliessmittel: Chloroform.R r value: 0.46, DC aluminum roller, layer thickness: 0.2 mm, silica gel 60 F 254 Merck, eluent: chloroform.

Beispiel 105Example 105

1,4-Dihydro-2,6-dimethyl-4-[2-(3-methoxy- benzyloxy)-phenyl]-pyridin-3-carbonsäuremethylester
vom Schmp. ab 53 °C.
1,4-Dihydro-2,6-dimethyl-4- [2- (3-methoxybenzyloxy) phenyl] pyridine-3-carboxylic acid methyl ester
from 53 ° C.

Beispiel 106Example 106

1,4-Dihydro-2,6-dimethyl-4-(2-benzylthio- phenyl)-pyridin-3-carbonsäuremethylester.1,4-Dihydro-2,6-dimethyl-4- (2-benzylthiophenyl) pyridine-3-carboxylic acid methyl ester.

Massenspektrum:Mass spectrum:

Die wichtigsten Peaks findet man bei

  • m/e = 365 (Molpeak), m/e = 350 (M-15),
  • m/e = 306 (M-59), m/e = 274, m/e = 166.
The most important peaks can be found at
  • m / e = 365 (Molpeak), m / e = 350 (M-15),
  • m / e = 306 (M-59), m / e = 274, m / e = 166.

Beispiel 107Example 107

1,4-Dihydro-2,6-dimethy)-4-[2-(3-methoxy- benzyloxy)-phenyl]-pyridin-3-carbonsäure-n-butylester

  • vom Schmp. 144 bis 146 °C.
1,4-Dihydro-2,6-dimethy) -4- [2- (3-methoxybenzyloxy) phenyl] pyridine-3-carboxylic acid n-butyl ester
  • from mp. 144 to 146 ° C.

Beispiel 108Example 108

1,4-Dihydro-2,6-dimethyl-4-(2-chlorphenyl)-5-phenyl-ureidopyridin-3-carbonsäuremethylester

Figure imgb0119
9,65 g (30 mmol) 1,4-Dihydro-2,6-dimethyl-4-(2-chlorphenyl)-3,5-dicarbonsäuremonoethylester

  • werden mit 6,4 Mol (30 mmoi) Diphenylphosphorylazid und 4,2 ml (30 mmol) Triethylamin 1 Stunde zum Rückfluss erhitzt. Es wird abgekühlt, mit 2,8 ml (30 mmol) Anilin versetzt und 1 Stunde gekocht. Es wird eingeengt, der feste Eindampfrückstand wird in warmem Essigester gelöst, es wird mit 1N Salzsäure, Wasser, 2N Natronlauge und zweimal mit Wasser gewaschen, getrocknet und eingeengt. Der feste Eindampfrückstand wird mit 100 ml heissem Essigester versetzt, es wird unter Rühren abgekühlt, abgesaugt und mit Essigester gewaschen. Man erhält 4,6 g 1,4-Dihydro-2,6-dimethyl-4-(2-chlorphenyl)-5-phenyl-ureido-pyridin-3-carbonsäuremethylester vom Schmp. 203 bis 205 °C.
  • Analog wurden hergestellt:
1,4-Dihydro-2,6-dimethyl-4- (2-chlorophenyl) -5-phenyl-ureidopyridine-3-carboxylic acid methyl ester
Figure imgb0119
9.65 g (30 mmol) of 1,4-dihydro-2,6-dimethyl-4- (2-chlorophenyl) -3,5-dicarboxylic acid monoethyl ester
  • are heated with 6.4 mol (30 mmoi) of diphenylphosphoryl azide and 4.2 ml (30 mmol) of triethylamine to reflux for 1 hour. It is cooled, 2.8 ml (30 mmol) of aniline are added and the mixture is boiled for 1 hour. It is concentrated, the solid evaporation residue is dissolved in warm ethyl acetate, it is washed with 1N hydrochloric acid, water, 2N sodium hydroxide solution and twice with water, dried and concentrated. The solid evaporation residue is mixed with 100 ml of hot ethyl acetate, it is cooled with stirring, suction filtered and washed with ethyl acetate. 4.6 g of 1,4-dihydro-2,6-dimethyl-4- (2-chlorophenyl) -5-phenyl-ureido-pyridine-3-carboxylic acid methyl ester of melting point 203 to 205 ° C. are obtained.
  • The following were produced analogously:

Beispiel 109Example 109

1,4-Dihydro-2,6-dimethyl-4-[2-(4-methylbenzyl- oxy)-phenyl]-5-n-butylureido-pyridin-3-carbonsäuremethylester
vom Schmp. 194 bis 196 °C.

Figure imgb0120
1,4-Dihydro-2,6-dimethyl-4- [2- (4-methylbenzyloxy) phenyl] -5-n-butylureidopyridine-3-carboxylic acid methyl ester
from mp. 194 to 196 ° C.
Figure imgb0120

Beispiel 110Example 110

1,4-Dihydro-2,6-dimethyl-4-(2-chlorphenyl)-5-N-morpholinyl)-carbonylamino-pyridin-3-carbonsäuremethylester
vom Schmp. 245 bis 249 °C.

Figure imgb0121
1,4-Dihydro-2,6-dimethyl-4- (2-chlorophenyl) -5-N-morpholinyl) carbonylamino-pyridine-3-carboxylic acid methyl ester
from mp. 245 to 249 ° C.
Figure imgb0121

Beispiel 111Example 111

1,4-Dihydro-2;6-dimethyl-4-(2-chlorphenyl)-5-(4-N-methylpiperazinyl-carbonylamino)-pyridin-3-carbonsäuremethylester
vom Schmp. 231 °C.

Figure imgb0122
1,4-Dihydro-2; 6-dimethyl-4- (2-chlorophenyl) -5- (4-N-methylpiperazinylcarbonylamino) pyridine-3-carboxylic acid methyl ester
from mp. 231 ° C.
Figure imgb0122

Beispiel 112Example 112

1,4-Dihydro-2,6-dimethyl-4-(2-benzyloxy- phenyl)-pyridin-3,5-dicarbonsäure-monomethylester

Figure imgb0123
10,6 g (24 mmol) 1,4-Dihydro-2,6-dimethyl-4-(2-benzyloxyphenyl)-pyridin-3,5-dicarbonsäure- methyl-(ß-cyanoethyl)-ester
werden in einer Lösung von 2,88 g (72 mmol) Natriumhydroxid in 72 ml Wasser suspendiert und mit 45 ml Dimethoxyethan versetzt. Es wird über Nacht gerührt, mit 100 ml Wasser versetzt und dreimal mit Ether extrahiert. Die wässrige Phase wird am Rotationsverdampfer kurz andestilliert und anschliessend unter Rühren tropfenweise mit konzentrierter Salzsäure angesäuert. Das ausgefallene Produkt wird abgesaugt, mit Wasser gewaschen und getrocknet. Man erhält 6,2 g eines beigegefärbten Produktes vom Schmp. 160 °C unter Zersetzung.
Analog Beispiel 112 wurden hergestellt:1,4-Dihydro-2,6-dimethyl-4- (2-benzyloxyphenyl) pyridine-3,5-dicarboxylic acid monomethyl ester
Figure imgb0123
10.6 g (24 mmol) of 1,4-dihydro-2,6-dimethyl-4- (2-benzyloxyphenyl) pyridine-3,5-dicarboxylic acid methyl (β-cyanoethyl) ester
are suspended in a solution of 2.88 g (72 mmol) of sodium hydroxide in 72 ml of water and mixed with 45 ml of dimethoxyethane. The mixture is stirred overnight, mixed with 100 ml of water and extracted three times with ether. The aqueous phase is briefly distilled on a rotary evaporator and then acidified dropwise with concentrated hydrochloric acid while stirring. The precipitated product is filtered off, washed with water and dried. 6.2 g of a colored product of mp 160 ° C. are obtained with decomposition.
The following were prepared as in Example 112:

Beispiel 113Example 113

1,4-Dihydro-2,6-dimethyl-4-(2-(4-methylbenzyl- oxy)-phenyl]-pyridin-3,5- dicarbonsäure-monomethylester
vom Schmp. 169 °C unter Zersetzung.
1,4-Dihydro-2,6-dimethyl-4- (2- (4-methylbenzyloxy) phenyl] pyridine-3,5-dicarboxylic acid monomethyl ester
of mp 169 ° C with decomposition.

Beispiel 114Example 114

1,4-Dihydro-2,6-dimethyl-4-[2-(4-chlorbenzyl)-phenyl]-pyridin-3,5-dicarbonsäure-monomethylester
vom Schmp. 156 °C unter Zersetzung.
1,4-Dihydro-2,6-dimethyl-4- [2- (4-chlorobenzyl) phenyl] pyridine-3,5-dicarboxylic acid monomethyl ester
of mp. 156 ° C with decomposition.

Beispiel 115Example 115

1,4-Dihydro-2,6-dimethyl-4-[2-(2-chlorbenzyl- oxy)-phenyl]-pyridin-3,5-dicarbonsäure-monomethylester
vom Schmp. 153 °C unter Zersetzung.
1,4-Dihydro-2,6-dimethyl-4- [2- (2-chlorobenzyloxy) phenyl] pyridine-3,5-dicarboxylic acid monomethyl ester
of melting point 153 ° C with decomposition.

Beispiel 116Example 116

1,4-Dihydro-2,6-dimethyl-4-(2-phenylmercapto- methoxyphenyl)-pyridin-3,5-dicarbonsäure-monomethylester
vom Schmp. 95 °C unter Zersetzung.
1,4-Dihydro-2,6-dimethyl-4- (2-phenylmercapto-methoxyphenyl) pyridine-3,5-dicarboxylic acid monomethyl ester
95 ° C with decomposition.

Beispiel 117Example 117

1,4-Dihydro-2,6-dimethyl-4-(2-phenethyloxy- phenyl)-pyridin-3,5-dicarbonsäure-monomethylester
vom Schmp. 100 bis 103 °C unter Zersetzung.
1,4-Dihydro-2,6-dimethyl-4- (2-phenethyloxyphenyl) pyridine-3,5-dicarboxylic acid monomethyl ester
from mp. 100 to 103 ° C with decomposition.

Beispiel 118Example 118

1,4-Dihydro-2,6-dimethyl-4-[2-(2,6-dichlor- benzyloxy)-phenyl]-pyridin-3,5-dicarbonsäure- monomethylester
vom Schmp. 198 bis 201 °C unter Zersetzung.
1,4-Dihydro-2,6-dimethyl-4- [2- (2,6-dichlorobenzyloxy) phenyl] pyridine-3,5-dicarboxylic acid monomethyl ester
from mp 198 to 201 ° C with decomposition.

Beispiel 119Example 119

1,4-Dihydro-2,6-dimethyl-4-[2-(3,4-dichlor- benzyloxy)-phenyl]-pyridin-3,5-dicarbonsäure- monomethylester
vom Schmp. 138 bis 140 °C unter Zersetzung.
1,4-Dihydro-2,6-dimethyl-4- [2- (3,4-dichlorobenzyloxy) phenyl] pyridine-3,5-dicarboxylic acid monomethyl ester
from mp. 138 to 140 ° C with decomposition.

Beispiel 120Example 120

1,4-Dihydro-2,6-dimethyl-4-(3-propoxyphenyl)-pyridin-3,5-dicarbonsäure-monomethylester
vom Schmp. 175 bis 177°C unter Zersetzung.
1,4-Dihydro-2,6-dimethyl-4- (3-propoxyphenyl) pyridine-3,5-dicarboxylic acid monomethyl ester
from mp. 175 to 177 ° C with decomposition.

Beispiel 121Example 121

1,4-Dihydro-2,6-dimethyl-4-(3-benzyloxyphe- nyl)-pyridin-3,5-dicarbonsäure-monomethylester vom Schmp. 148 °C unter Zersetzung.1,4-Dihydro-2,6-dimethyl-4- (3-benzyloxyphenyl) pyridine-3,5-dicarboxylic acid monomethyl ester, mp. 148 ° C. with decomposition.

Beispiel 122Example 122

1,4-Dihydro-2,6-dimethyl-4-[2-(4-methylbenzyl- oxy)-naphthyl]-pyridin-3,5-dicarbonsäure-monomethylester
vom Schmp. 171 bis 179 °C unter Zersetzung.
1,4-Dihydro-2,6-dimethyl-4- [2- (4-methylbenzyloxy) naphthyl] pyridine-3,5-dicarboxylic acid monomethyl ester
from mp. 171 to 179 ° C with decomposition.

Beispiel 123Example 123

1,4-Dihydro-2,6-dimethyl-4-naphthyl-pyridin-3,5-dicarbonsäure-monomethylester
vom Schmp. 175 bis 179 °C unter Zersetzung.
1,4-Dihydro-2,6-dimethyl-4-naphthyl-pyridine-3,5-dicarboxylic acid monomethyl ester
from mp. 175 to 179 ° C with decomposition.

Beispiel 124Example 124

1,4-Dihydro-2,6-dimethyl-4-[2-(4-methylbenzyl- oxy)-phenyl]-pyridin-3,5-dicarbonsäure-mono- isopropylester
vom Schmp. 101 °C unter Zersetzung.
1,4-Dihydro-2,6-dimethyl-4- [2- (4-methylbenzyloxy) phenyl] pyridine-3,5-dicarboxylic acid monoisopropyl ester
from mp. 101 ° C with decomposition.

Beispiel 125Example 125

1,4-Dihydro-2,6-dimethyl-4-[2-(3-trifluormethyl- benzylthio)-phenyl]-pyridin-3,5-dicarbonsäure- monomethylester
vom Schmp. 90 °C unter Zersetzung.
1,4-Dihydro-2,6-dimethyl-4- [2- (3-trifluoromethyl-benzylthio) phenyl] pyridine-3,5-dicarboxylic acid monomethyl ester
of mp 90 ° C with decomposition.

Beispiel 126Example 126

1,4-Dihydro-2,6-dimethyl-4-[2-(4-methylbenzyl- oxy)-phenyi]-pyridin-3,5-dicarbonsäure-monoisobutylester
vom Schmp. 85 °C unter Zersetzung.
1,4-Dihydro-2,6-dimethyl-4- [2- (4-methylbenzyloxy) phenyi] pyridine-3,5-dicarboxylic acid monoisobutyl ester
of melting point 85 ° C with decomposition.

Beispiel 127Example 127

1,4-Dihydro-2,6-dimethyl-4-[2-(4-methylbenzyl- oxy)-phenyl]-pyridin-3,5-dicarbonsäure-mono- sec.-butylester
vom Schmp. 133 bis 140 °C unter Zersetzung.
1,4-Dihydro-2,6-dimethyl-4- [2- (4-methylbenzyloxy) phenyl] pyridine-3,5-dicarboxylic acid mono-sec-butyl ester
from mp. 133 to 140 ° C with decomposition.

Beispiel 128Example 128

1,4-Dihydro-2,6-dimethyl-4-[2-(3-trifluormethyl- benzyloxy)-phenyl]-pyridin-3,5-dicarbonsäure- monomethylester
vom Schmp. 182 °C unter Zersetzung.
1,4-Dihydro-2,6-dimethyl-4- [2- (3-trifluoromethyl-benzyloxy) phenyl] pyridine-3,5-dicarboxylic acid monomethyl ester
of mp. 182 ° C with decomposition.

Beispiel 129Example 129

1,4-Dihydro-2,6-dimethyl-4-(2-(3-trifluormethyl- benzyloxy)-phenyl]-pyridin-3,5-dicarbonsäure- monoisobutylester
vom Schmp. 150 bis 153 °C unter Zersetzung.
1,4-Dihydro-2,6-dimethyl-4- (2- (3-trifluoromethyl-benzyloxy) phenyl] pyridine-3,5-dicarboxylic acid monoisobutyl ester
from mp. 150 to 153 ° C with decomposition.

Beispiel 130Example 130

1,4-Dihydro-2,6-dimethyl-4-(2-(3-trifluormethyl- benzyloxy)-phenyl]-pyridin-3,5-dicarbonsäure- mono-sec.-butylester
vom Schmp. 144 °C unter Zersetzung.
1,4-Dihydro-2,6-dimethyl-4- (2- (3-trifluoromethyl-benzyloxy) phenyl] pyridine-3,5-dicarboxylic acid mono-sec.-butyl ester
of mp. 144 ° C with decomposition.

Beispiel 131Example 131

1,4-Dihydro-2,6-dimethyl-4-(2-(3-nitrobenzyl- oxy)-phenyl]-pyridin-3,5-dicarbonsäure-monomethylester
vom Schmp. 167 °C unter Zersetzung.
1,4-Dihydro-2,6-dimethyl-4- (2- (3-nitrobenzyloxy) phenyl] pyridine-3,5-dicarboxylic acid monomethyl ester
of mp. 167 ° C with decomposition.

Beispiel 132Example 132

1,4-Dihydro-2,6-dimethyl-4-[2-(3-nitrobenzyl- oxy)-phenyl]-pyridin-3,5-dicarbonsäure-mono- ethylester
vom Schmp. 172 °C unter Zersetzung.
1,4-Dihydro-2,6-dimethyl-4- [2- (3-nitrobenzyloxy) phenyl] pyridine-3,5-dicarboxylic acid monoethyl ester
of mp 172 ° C with decomposition.

Beispiel 133Example 133

1,4-Dihydro-2,6-dimethyl-4-[2-(4-fluorbenzyl- oxy)-phenyl]-pyridin-3,5-dicarbonsäure-mono- ethylester
vom Schmp. 154 bis 156 °C unter Zersetzung.
1,4-Dihydro-2,6-dimethyl-4- [2- (4-fluorobenzyloxy) phenyl] pyridine-3,5-dicarboxylic acid monoethyl ester
from mp. 154 to 156 ° C with decomposition.

Beispiel 134Example 134

1,4-Dihydro-2,6-dimethyl-4-[2-(4-fluorbenzyl- oxy)-phenyl]-pyridin-3,5-dicarbonsäure-monomethylester
vom Schmp. 181 bis 186 °C unter Zersetzung.
1,4-Dihydro-2,6-dimethyl-4- [2- (4-fluorobenzyloxy) phenyl] pyridine-3,5-dicarboxylic acid monomethyl ester
from mp. 181 to 186 ° C with decomposition.

Beispiel 135Example 135

1,4-Dihydro-2,6-dimethyl-4-(2-phenylpropyl- mercaptophenyl)-pyridin-3,5-dicarbonsäure- monomethylester
vom Schmp. ab 94 °C unter Zersetzung.
1,4-Dihydro-2,6-dimethyl-4- (2-phenylpropyl-mercaptophenyl) pyridine-3,5-dicarboxylic acid monomethyl ester
from mp. 94 ° C with decomposition.

Beispiel 136Example 136

1,4-Dihydro-2,6-dimethyl-4-[2-(3,5-dimethyl- benzyloxy)-phenyl]-pyridin-3,5-dicarbonsäure- monomethylester
vom Schmp. ab 98 °C unter Zersetzung.
1,4-Dihydro-2,6-dimethyl-4- [2- (3,5-dimethylbenzyloxy) phenyl] pyridine-3,5-dicarboxylic acid monomethyl ester
from mp. 98 ° C with decomposition.

Beispiel 137Example 137

1,4-Dihydro-2,6-dimethyl-4-[2-(3,5-dimethyl- benzyioxy)-phenyi]-pyridin-3,5-dicarbonsäure- mono-n-butylester
vom Schmp. ab 85 °C unter Zersetzung.
1,4-Dihydro-2,6-dimethyl-4- [2- (3,5-dimethyl-benzyioxy) phenyi] pyridine-3,5-dicarboxylic acid mono-n-butyl ester
from mp. from 85 ° C with decomposition.

Beispiel 138Example 138

1,4-Dihydro-2,6-dimethyl-4-[3-methylbenzyl- oxy)-phenyl]-pyridin-3,5-dicarbonsäure-monomethylester vom Schmp. 140 bis 145 °C unter Zersetzung.1,4-Dihydro-2,6-dimethyl-4- [3-methylbenzyloxy) phenyl] pyridine-3,5-dicarboxylic acid monomethyl ester of melting point 140 to 145 ° C. with decomposition.

Beispiel 139Example 139

1,4-Dihydro-2,6-dimethyl-4-[2-(3-methylbenzyl- oxy)-phenyl]-pyridin-3,5-dicarbonsäure-mono-n-butylester
vom Schmp. 132 bis 139 °C unter Zersetzung.
1,4-Dihydro-2,6-dimethyl-4- [2- (3-methylbenzyloxy) phenyl] pyridine-3,5-dicarboxylic acid mono-n-butyl ester
from mp. 132 to 139 ° C with decomposition.

Beispiel 140Example 140

1,4-Dihydro-2,6-dimethyl-4-[2-(3-fluorbenzyl- oxy)-phenyl]-pyridin-3,5-dicarbonsäure-monomethylester
vom Schmp. 146 bis 149 °C unter Zersetzung.
1,4-Dihydro-2,6-dimethyl-4- [2- (3-fluorobenzyloxy) phenyl] pyridine-3,5-dicarboxylic acid monomethyl ester
from mp. 146 to 149 ° C with decomposition.

Beispiel 141Example 141

1,4-Dihydro-2,6-dimethyl-4-[2-(3-fluorbenzyl- oxy)-phenyl]-pyridin-3,5-dicarbonsäure-mono-n-butylester
vom Schmp. 141 bis 144 °C unter Zersetzung.
1,4-Dihydro-2,6-dimethyl-4- [2- (3-fluorobenzyloxy) phenyl] pyridine-3,5-dicarboxylic acid mono-n-butyl ester
from mp. 141 to 144 ° C with decomposition.

Beispiel 142Example 142

1,4-Dihydro-2,6-dimethyl-4-[2-(3-methoxy- benzyloxy)-phenyl]-pyridin-3,5-dicarbonsäure- monomethylester
vom Schmp. 155 bis 160 °C unter Zersetzung.
1,4-Dihydro-2,6-dimethyl-4- [2- (3-methoxybenzyloxy) phenyl] pyridine-3,5-dicarboxylic acid monomethyl ester
from mp 155 to 160 ° C with decomposition.

Beispiel 143Example 143

1,4-Dihydro-2,6-dimethyl-4-[2-(3-methoxy- benzyloxy)-phenyl]-pyridin-3,5-dicarbonsäure- mono-n-butylester
vom Schmp. 145 bis 149 °C unter Zersetzung.
1,4-Dihydro-2,6-dimethyl-4- [2- (3-methoxybenzyloxy) phenyl] pyridine-3,5-dicarboxylic acid mono-n-butyl ester
from mp. 145 to 149 ° C with decomposition.

Beispiel 144Example 144

1-Ethyl-2-methyl-4-[2-(3-trifluormethylbenzyl- thio)-phenyl]-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]-pyridin-3-carbonsäureethylester.
Fp.: 117 bis 119 °C.
1-Ethyl-2-methyl-4- [2- (3-trifluoromethylbenzylthio) phenyl] -5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid ethyl ester .
Mp .: 117 to 119 ° C.

Beispiel 145Example 145

2-Methyl-4-[2-(3-trifluormethylbenzylthio)-phenyl]-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]-pyridin-3-carbonsäure-2-methoxyethylester. Fp.: 124 bis 125 °C.2-Methyl-4- [2- (3-trifluoromethylbenzylthio) phenyl] -5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid 2-methoxyethyl ester. Mp .: 124 to 125 ° C.

Beispiel 146Example 146

2-Methyl-4-[2-(3-trifluormethylbenzylthio)-phenyl]-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]-pyridin-3-carbonsäurebutylester.
Fp.: 112 bis 120°C.
2-Methyl-4 - [ 2- (3-trifluoromethylbenzylthio) phenyl] -5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid butyl ester.
Mp .: 112 to 120 ° C.

Beispiel 147Example 147

2-Methyl-4-[2-(3-trifluormethylbenzyloxy)-phenyl]-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]-pyridin-3-carbonsäureethylester.
Fp.: 180 bis 183 °C.
2-Methyl-4- [2- (3-trifluoromethylbenzyloxy) phenyl] -5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid ethyl ester.
Mp .: 180 to 183 ° C.

Beispiel 148Example 148

2-Methyl-4-[2-(3-nitrobenzylthio)phenyl]-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäureethylester.
Fp.: 164 bis 166 °C.
2-Methyl-4- [2- (3-nitrobenzylthio) phenyl] -5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid ethyl ester.
Mp .: 164 to 166 ° C.

Beispiel 149Example 149

2-Methyl-4-[2-(3-nitrobenzylthio)phenyl]-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäure-n-butylester.
Fp.: 137 bis 139 °C.
2-Methyl-4- [2- (3-nitrobenzylthio) phenyl] -5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid n-butyl ester.
Mp .: 137 to 139 ° C.

Beispiel 150Example 150

2-Methyl-4-[2-(3-methylbenzylsulfinyl)phenyl]-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäureethylester.
Fp.:243-245 °C.
2-Methyl-4- [2- (3-methylbenzylsulfinyl) phenyl] -5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid ethyl ester.
Mp: 243-245 ° C.

Beispiel 151Example 151

4-[2-(Benzylthio)phenyl]-2-methyl-5-oxo-4,5,6,7-tetrahydro-1 H-pyrrolo[3,4-b]pyridin-3-carbonsäureethylester.
Fp.: 243 bis 246 °C.
Ethyl 4- [2- (benzylthio) phenyl] -2-methyl-5-oxo-4,5,6,7-tetrahydro-1H-pyrrolo [3,4-b] pyridine-3-carboxylate.
Mp: 243 to 246 ° C.

Beispiel 152Example 152

4-[2-(Benzylsulfonyl)phenyl]-2-methyl-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäureethylester.
Fp.: 150 bis 152 °C.
4- [2- (Benzylsulfonyl) phenyl] -2-methyl-5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid ethyl ester.
Mp .: 150 to 152 ° C.

Beispiel 153Example 153

2-Methyl-4-[2-(3-trifluormethylbenzylthio)phenyl]-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]-3-carbonsäuremethylester.
Fp.: 178 bis 181 °C.
2-Methyl-4- [2- (3-trifluoromethylbenzylthio) phenyl] -5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] -3-carboxylic acid methyl ester.
Mp .: 178 to 181 ° C.

Beispiel 154Example 154

4-[2-(4-tert.-Butylbenzylthio)phenyl]-2-methyl-5-oxo-1,4,5,7-tetrahyd rofuro[3,4-b] pyrid i n-3-carbonsäurebutylester.
Fp.: 103 °C.
4- [2- (4-tert-Butylbenzylthio) phenyl] -2-methyl-5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyride in 3-carboxylic acid butyl ester.
Mp .: 103 ° C.

Beispiel 155Example 155

2-Methyl-4-[2-(3-trifluormethylbenzyl)phenyl]-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäureethylester.
Fp.: 189 °C.
2-Methyl-4- [2- (3-trifluoromethylbenzyl) phenyl] -5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid ethyl ester.
Mp: 189 ° C.

Beispiel 156Example 156

2-Methyl-4-[2-(3-methylbenzylthio)phenyl]-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäureethylester.
Fp.: 150 bis 155 °C.
2-Methyl-4- [2- (3-methylbenzylthio) phenyl] -5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid ethyl ester.
Mp .: 150 to 155 ° C.

Beispiel 157Example 157

4-[2-(3-Chlorbenzylthio)phenyl]-2-methyl-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäurebutylester.
Fp.: 167 bis 170 °C.
4- [2- (3-Chlorobenzylthio) phenyl] -2-methyl-5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid butyl ester.
Mp .: 167 to 170 ° C.

Beispiel 158Example 158

4-[2-(4-Ethoxycarbonylbenzylthio)phenyl]-2-methyl-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]-pyridin-3-carbonsäureethylester.
Fp.: 157 bis 160 °C.
4- [2- (4-Ethoxycarbonylbenzylthio) phenyl] -2-methyl-5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid ethyl ester.
Mp .: 157 to 160 ° C.

Beispiel 159Example 159

4-[2-(Benzylthio)phenyl]-2-propyl-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäureethylester.
Fp.: 167 bis 169 °C.
Ethyl 4- [2- (benzylthio) phenyl] -2-propyl-5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylate.
Mp .: 167 to 169 ° C.

Beispiel 160Example 160

4-[2-(Chlorbenzylthio)phenyl]-2-methyl-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäureethylester.
Fp.: 87 bis 89 °C.
Ethyl 4- [2- (chlorobenzylthio) phenyl] -2-methyl-5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylate.
Mp .: 87 to 89 ° C.

Beispiel 161Example 161

4-[2-Benzylthio)phenyl]-2-ethyl-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäuremethylester.
Fp.: 174 bis 176 °C.
4- [2-Benzylthio) phenyl] -2-ethyl-5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid methyl ester.
Mp .: 174 to 176 ° C.

Beispiel 162Example 162

4-[2-(4-tert.-Butylbenzylthio)phenyl]-2-methyl-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]-pyridin-3-carbonsäureethylester.
Fp.: 127 bis 130 °C.
4- [2- (4-tert-Butylbenzylthio) phenyl] -2-methyl-5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid ethyl ester.
Mp .: 127 to 130 ° C.

Beispiel 163Example 163

2-Methyl-4-[2-(3-methylbenzylthio)phenyl]-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäureethylester.
Fp.: 114 bis 116°C.
2-Methyl-4- [2- (3-methylbenzylthio) phenyl] -5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid ethyl ester.
Mp .: 114 to 116 ° C.

Beispiel 164Example 164

4-[2-(4-tert.-Butylbenzylthio)phenyl]-2-methyl-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]-pyridin-3-carbonsäuremethylester.
Fp.: 112 bis 113°C.
4- [2- (4-tert-Butylbenzylthio) phenyl] -2-methyl-5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid methyl ester.
Mp .: 112 to 113 ° C.

Beispiel 165Example 165

2-Methyl-4-[2-(3-methylbenzylthio)phenyl]-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäuremethylester.
Fp.: 166 bis 168 °C.
2-Methyl-4- [2- (3-methylbenzylthio) phenyl] -5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid methyl ester.
Mp .: 166 to 168 ° C.

Beispiel 166Example 166

4-[2-(3-Chlorbenzylthio)phenyl]-2-methyl-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäuremethylester.
Fp.: 209 bis 211 °C.
4- [2- (3-Chlorobenzylthio) phenyl] -2-methyl-5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid methyl ester.
Mp: 209-211 ° C.

. Beispiel 167. Example 167

2-Methyl-4-[2-(4-methylbenzylthio)phenyl]-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbon- säureoctylester.

  • 1H-NMR (CDCl3): δ = 0,9 (t, J = 7 Hz, 3H), 1,0-1,5 (m, 12H), 2,3 und 2,35 (2s, je 3H), 3,75-4,1 (m, 2H), 4,1 und 4,15 (2d, J = 14 Hz, je 1H), 4,45 (s, 2H), 5,5 (s, 1H) 7,0-7,4 (m, 8H), 8,1 (s, NH) ppm.
2-Methyl-4- [2- (4-methylbenzylthio) phenyl] -5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid octyl ester.
  • 1 H-NMR (CDCl 3 ): δ = 0.9 (t, J = 7 Hz, 3H), 1.0-1.5 (m, 12H), 2.3 and 2.35 (2s, each 3H ), 3.75-4.1 (m, 2H), 4.1 and 4.15 (2d, J = 14 Hz, each 1H), 4.45 (s, 2H), 5.5 (s, 1H ) 7.0-7.4 (m, 8H), 8.1 (s, NH) ppm.

Beispiel 168Example 168

2-Methyl-4-[2-(4-methylbenzylthio)phenyl]-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäurebutylester.
Fp.: 87 bis 89 °C.
2-Methyl-4- [2- (4-methylbenzylthio) phenyl] -5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid butyl ester.
Mp .: 87 to 89 ° C.

Beispiel 169Example 169

4-[2-(Benzylthio)phenyl]-2-methyl-5-oxo-1-propyl-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäureethylester.
Fp.: 132 °C.
Ethyl 4- [2- (benzylthio) phenyl] -2-methyl-5-oxo-1-propyl-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylate.
Mp: 132 ° C.

Beispiel 170Example 170

1-Allyl-4-[2-(benzylthio)phenyl]-2-methyl-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäureethylester.
Fp.: 115 bis 177 °C.
1-Allyl-4- [2- (benzylthio) phenyl] -2-methyl-5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid ethyl ester.
Mp .: 115 to 177 ° C.

Beispiel 171Example 171

2-Methyl-4-[2-(4-methylbenzylthio)phenyl]-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäure-(2-methoxy)-ethylester.
Fp.: 137 bis 139 °C.
2-Methyl-4- [2- (4-methylbenzylthio) phenyl] -5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid (2-methoxy) ethyl ester .
Mp .: 137 to 139 ° C.

Beispiel 172Example 172

2-Methyl-4-[2-(4-methylbenzyloxy)phenyl]-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäureethylester.
Fp.: 208 bis 209 °C.
2-Methyl-4- [2- (4-methylbenzyloxy) phenyl] -5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid ethyl ester.
Mp .: 208 to 209 ° C.

Beispiel 173Example 173

4-[2-(benzylthio)phenyl]-1-ethyl-2-methyl-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäureethylester.
Fp.: 80 bis 82 °C.
Ethyl 4- [2- (benzylthio) phenyl] -1-ethyl-2-methyl-5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylate.
Mp .: 80 to 82 ° C.

Beispiel 174Example 174

4-[2-(Benzylthio)phenyl]-1,2-dimethyl-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäureethylester.
Fp.: 188-190 °C.
4- [2- (Benzylthio) phenyl] -1,2-dimethyl-5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid ethyl ester.
Mp: 188-190 ° C.

Beispiel 175Example 175

4-[3-(Benzylthio)phenyl]-2-methyl-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäureethylester.
Fp.: 183 bis 185 °C.
4- [3- (Benzylthio) phenyl] -2-methyl-5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid ethyl ester.
Mp .: 183 to 185 ° C.

Beispiel 176Example 176

4-[2-(4-Methoxycarbonylbenzylthio)phenyl]-2-methyl-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]-pyridin-3-carbonsäureethylester.
Fp.: 102 bis 110 °C.
4- [2- (4-Methoxycarbonylbenzylthio) phenyl] -2-methyl-5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid ethyl ester.
Mp .: 102 to 110 ° C.

Beispiel 177Example 177

2-Methyl-4-[2-(1-phenylethylthio)phenyl]-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäureethylester.
Fp.: 93 bis 110 °C (2 : 3-Diastereomerengemisch).
2-Methyl-4- [2- (1-phenylethylthio) phenyl] -5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid ethyl ester.
Mp .: 93 to 110 ° C (2: 3 mixture of diastereomers).

Beispiel 178Example 178

2-Methyl-4-[2-(2-methylbenzylthio)phenyl]-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäureethylester.
Fp.: 217 bis 219 °C.
2-Methyl-4- [2- (2-methylbenzylthio) phenyl] -5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid ethyl ester.
Mp .: 217 to 219 ° C.

Beispiel 179Example 179

2-Methyl-5-oxo-4-[3-phenylpropylsulfinyl)-phenyl]-1,4,5,7-tetrahydrofuro(3,4-b]pyridin-3-carbonsäureethylester.
Fp.: 185 bis 186 °C.
2-Methyl-5-oxo-4- [3-phenylpropylsulfinyl) phenyl] -1,4,5,7-tetrahydrofuro (3,4-b] pyridine-3-carboxylic acid, ethyl ester.
Mp .: 185 to 186 ° C.

Beispiel 180Example 180

2-Methyl-4-[2-(4-nitrobenzylthio)phenyl]-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäureethylester.
Fp.: 168 bis 170 °C.
2-Methyl-4- [2- (4-nitrobenzylthio) phenyl] -5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid ethyl ester.
Mp .: 168 to 170 ° C.

Beispiel 181Example 181

4-[2-(Methoxycarbonyl)phenyl]-2-methyl-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäureethylester.
Fp.: 240 bis 249 °C.
Ethyl 4- [2- (methoxycarbonyl) phenyl] -2-methyl-5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylate.
Mp .: 240 to 249 ° C.

Beispiel 182Example 182

4-[2-(Butylthio)phenyl]-2-methyl-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäureethylester.
Fp.: 163 bis 167 °C.
Ethyl 4- [2- (butylthio) phenyl] -2-methyl-5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylate.
Mp: 163 to 167 ° C.

Beispiel 183Example 183

4-[2-(2,5-Dichlorbenzylthio)phenyl]-2-methyl-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]-pyridin-3-carbonsäureethylester.
Fp.: 244 bis 250 °C.
Ethyl 4- [2- (2,5-dichlorobenzylthio) phenyl] -2-methyl-5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylate.
Mp .: 244 to 250 ° C.

Beispiel 184Example 184

4-[2-(4-Methoxybenzylthio)phenyl]-2-methyl-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäureethylester.
Fp.: 83 bis 85 °C.
Ethyl 4- [2- (4-methoxybenzylthio) phenyl] -2-methyl-5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylate.
Mp .: 83 to 85 ° C.

Beispiel 185Example 185

4-[2-(4-Chlorbenzylthio)phenyl]-2-methyl-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäureethylester.
Fp.: 97 bis 99 °C.
Ethyl 4- [2- (4-chlorobenzylthio) phenyl] -2-methyl-5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylate.
Mp .: 97 to 99 ° C.

Beispiel 186Example 186

2-Methyl-4-[2-(1-methylethylthio)phenyl]-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäureethylester.
Fp.: 193 bis 194 °C.
2-Methyl-4- [2- (1-methylethylthio) phenyl] -5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid ethyl ester.
Mp: 193 to 194 ° C.

Beispiel 187Example 187

2-Methyl-5-oxo-4-[2-(3-phenylpropylthio)-phenyl]-1,4,5,7-tetrahydro[3,4-b]pyridin-3-carbonsäureethylester.
Fp.: 179 bis 180 °C.
2-Methyl-5-oxo-4- [2- (3-phenylpropylthio) phenyl] -1,4,5,7-tetrahydro [3,4-b] pyridine-3-carboxylic acid ethyl ester.
Mp .: 179 to 180 ° C.

Beispiel 188Example 188

2-Methyl-5-oxo-4-[2-(tetralin-2-yl-methylthio)-phenyl]-1,4,5,7-tetrahydrofuro-[3,4-b]pyridin-3-carbonsäureethylester.
Fp.: 102 bis 104 °C.
2-Methyl-5-oxo-4- [2- (tetralin-2-yl-methylthio) phenyl] -1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid, ethyl ester.
Mp .: 102 to 104 ° C.

Beispiel 189Example 189

4-(2,3-Dimethylphenyl)-2-methyl-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäureethylester.
Fp.: 225 bis 227 °C.
4- (2,3-Dimethylphenyl) -2-methyl-5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid ethyl ester.
Mp .: 225 to 227 ° C.

Beispiel 190Example 190

2-Methyl-5-oxo-[2-(2-[phenylcarbonyloxy]-ethylthio)-phenyl]-1,4,5,7-tetrahydrofuro-[3,4-b]pyridin-3-carbonsäureethylester.
Fp.: 190 bis 196 °C.
2-Methyl-5-oxo [2- (2- [phenylcarbonyloxy] ethylthio) phenyl] -1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid ethyl ester.
Mp .: 190 to 196 ° C.

Beispiel 191Example 191

2-Methyl-4-[2-(1-naphthylmethylthio)phenyl]-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäureethylester.
Fp.: 93 bis 100 °C.
2-Methyl-4- [2- (1-naphthylmethylthio) phenyl] -5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid ethyl ester.
Mp .: 93 to 100 ° C.

Beispiel 192Example 192

4-[2-(Benzylsulfinylthio)phenyl]-2-methyl-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b] pyridin-3-carbonsäureethylester.
Fp.: 250 °C.
4- [2- (Benzylsulfinylthio) phenyl] -2-methyl-5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid ethyl ester.
Mp .: 250 ° C.

Beispiel 193Example 193

4-[2-(3,4-Dichlorbenzylthio)phenyl]-2-methyl-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]-pyridin-3-carbonsäureethylester.
Fp.: 90 bis 95 °C.
Ethyl 4- [2- (3,4-dichlorobenzylthio) phenyl] -2-methyl-5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylate.
Mp .: 90 to 95 ° C.

Beispiel 194Example 194

4-[3-Benzyloxyphenyl]-2-methyl-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäureethylester.
Fp.: 103 bis 104 °C.
4- [3-Benzyloxyphenyl] -2-methyl-5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid ethyl ester.
Mp .: 103 to 104 ° C.

Beispiel 195Example 195

4-[2-(2-Hydroxyethylthio)phenyl]-2-methyl-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäureethylester.
Fp.: 130 bis 134 °C.
4- [2- (2-Hydroxyethylthio) phenyl] -2-methyl-5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid ethyl ester.
Mp .: 130 to 134 ° C.

Beispiel 196Example 196

4-(2-Benzylphenyl)-2-methyl-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäureethylester.
Fp.: 239 bis 240 °C.
4- (2-Benzylphenyl) -2-methyl-5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid ethyl ester.
Mp: 239 to 240 ° C.

Beispiel 197Example 197

4-(2-Ethylthio)phenyl-2-methyl-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäureethylester.
Fp.: 235 bis 236 °C.
4- (2-Ethylthio) phenyl-2-methyl-5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid ethyl ester.
Mp .: 235 to 236 ° C.

Beispiel 198Example 198

2-Methyl-4-[2-(methylthio)phenyl]-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäureethylester.
Fp.: 233 bis 234 °C.
2-Methyl-4- [2- (methylthio) phenyl] -5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid ethyl ester.
Mp: 233 to 234 ° C.

Beispiel 199Example 199

2-Methyl-4-[2-(2-phenylethylthio)phenyl]-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäureethylester.
Fp.: 184 bis 185 °C.
2-Methyl-4- [2- (2-phenylethylthio) phenyl] -5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid ethyl ester.
Mp .: 184 to 185 ° C.

Beispiel 200Example 200

2-Methyl-4-[2-(4-methylbenzylthio)phenyl]-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäureethylester.
Fp.: 132 bis 134 °C.
2-Methyl-4- [2- (4-methylbenzylthio) phenyl] -5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid ethyl ester.
Mp: 132 to 134 ° C.

Beispiel 201Example 201

4-(2-Benzyloxyphenyl)-2-methyl-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäuremethylester.
Fp.: 245 bis 246 °C.
4- (2-Benzyloxyphenyl) -2-methyl-5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid methyl ester.
Mp .: 245 to 246 ° C.

Beispiel 202Example 202

4-(2-Ethylphenyl)-2-methyl-5-oxo-1,4,5,7-tetra- hydrofuro[3,4-b]pyridin-3-carbonsäureethylester. Fp.: 197 bis 200 °C.4- (2-Ethylphenyl) -2-methyl-5-oxo-1,4,5,7-tetra-hydrofuro [3,4-b] pyridine-3-carboxylic acid ethyl ester. Mp .: 197 to 200 ° C.

Beispiel 203Example 203

4-(2-Benzylthiophenyl)-2-methyl-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäure- octylester.
Fp.: 212 °C.
4- (2-Benzylthiophenyl) -2-methyl-5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid octyl ester.
Mp: 212 ° C.

Beispiel 204Example 204

4-(2-Benzylthiophenyl)-2-methyl-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäurebutylester (amorphe Substanz).4- (2-Benzylthiophenyl) -2-methyl-5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid butyl ester (amorphous substance).

Beispiel 205Example 205

4-(2-Benzyloxyphenyl)-2-methyl-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäureethylester.
Fp.: 177 °C.
4- (2-Benzyloxyphenyl) -2-methyl-5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid ethyl ester.
Mp: 177 ° C.

Beispiel 206Example 206

4-(2-Benzylthiophenyl)-2-methyl-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäuremethylester.
Fp.: 215 °C.
4- (2-Benzylthiophenyl) -2-methyl-5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid methyl ester.
Mp: 215 ° C.

Beispiel 207Example 207

2-Mefhyl-5-oxo-4-(2-trifluormethylphenyl)-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäureethylester.
Fp.: 228 bis 230 °C.
2-Methyl-5-oxo-4- (2-trifluoromethylphenyl) -1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid ethyl ester.
Mp .: 228 to 230 ° C.

Beispiel 208Example 208

4-(2-Benzylthiophenyl)-2-methyl-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäureiso- propylester.
Fp.: 158 bis 161 °C.
Isopropyl 4- (2-benzylthiophenyl) -2-methyl-5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylate.
Mp 158-161 ° C.

Beispiel 209Example 209

2-Methyl-5-oxo-4-(2-phenylphenyl)-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäureethylester.
Fp.: 217 bis 220 °C.
2-Methyl-5-oxo-4- (2-phenylphenyl) -1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid ethyl ester.
Mp .: 217 to 220 ° C.

Beispiel 210Example 210

2-Methyl-4-(2-methylphenyl)-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäure- isopropylester.
Fp.: 208 °C.
2-Methyl-4- (2-methylphenyl) -5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid isopropyl ester.
Mp: 208 ° C.

Beispiel 211Example 211

2-Methyl-4-(2-methylphenyl)-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäurebutylester.
Fp.: 167 bis 176 °C.
2-Methyl-4- (2-methylphenyl) -5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid butyl ester.
Mp .: 167 to 176 ° C.

Beispiel 212Example 212

2-Methyl-4-(2-methylphenyl)-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäure- allylester.
Fp.: 170 bis 175 °C.
2-Methyl-4- (2-methylphenyl) -5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid allyl ester.
Mp .: 170 to 175 ° C.

Beispiel 213Example 213

3-Acetyl-4-(2-benzylthiophenyl)-2-methyl-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin.
Fp.: 212 °C.
3-acetyl-4- (2-benzylthiophenyl) -2-methyl-5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine.
Mp: 212 ° C.

Beispiel 214Example 214

2-Methyl-5-oxo-4-(2-trifluormethylphenyl)-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäuremethylester.
Fp.: 229 bis 233 °C.
2-Methyl-5-oxo-4- (2-trifluoromethylphenyl) -1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid methyl ester.
Mp: 229 to 233 ° C.

Beispiel 215Example 215

2-Methyl-5-oxo-4-(2-methylphenyl)-1,4,5,7-tetrahyd rofu ro[3,4-b] pyrid i n-3-carbonsäu remethylester.
Fp.: 196 bis 201 °C.
2-Methyl-5-oxo-4- (2-methylphenyl) -1,4,5,7-tetrahydrofuran [3,4-b] pyride in 3-carboxylic acid, remethyl ester.
Mp .: 196 to 201 ° C.

Beispiel 216Example 216

4-(3-Chlorphenyl)-1,2-dimethyl-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäure-2-methoxyethylester.
Fp.: 128 bis 133 °C.
4- (3-Chlorophenyl) -1,2-dimethyl-5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid 2-methoxyethyl ester.
Mp .: 128 to 133 ° C.

Beispiel 217Example 217

3-Acetyl-2-methyl-5-oxo-4-[2-trifluormethylphenyl]-tetrahydrofuro[3,4-b]pyridin.
Fp.: 212 bis 213 °C.
3-acetyl-2-methyl-5-oxo-4- [2-trifluoromethylphenyl] tetrahydrofuro [3,4-b] pyridine.
Mp .: 212 to 213 ° C.

Beispiel 218Example 218

2-Methoxymethyl-5-oxo-4-(2-trifluormethylphenyl)-1,4,5,7-tetrahydrofuro-[3,4-b]pyridin-3-carbonsäureethylester.
Fp.: 218 bis 219 °C.
2-Methoxymethyl-5-oxo-4- (2-trifluoromethylphenyl) -1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid ethyl ester.
Mp .: 218 to 219 ° C.

Beispiel 219Example 219

4-(3-Chlorphenyl)-1,2-dimethyl-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäureethylester.
Fp.: 188 bis 190 °C.
4- (3-Chlorophenyl) -1,2-dimethyl-5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid ethyl ester.
Mp .: 188 to 190 ° C.

Beispiel 220Example 220

4-(3-Chlorphenyl)-2-methyl-5-oxo-1,4,5,7-tetra- hydrofuro[3,4-b]pyridin-3- carbonsäurebutylester. Fp.: 142 bis 144 °C.4- (3-chlorophenyl) -2-methyl-5-oxo-1,4,5,7-tetra-hydrofuro [3,4-b] pyridine-3-carboxylic acid butyl ester. Mp .: 142 to 144 ° C.

Beispiel 221Example 221

4-(3-Chlorphenyl)-2-methyl-5-oxo-1,4,5,7-tetra- hydrofuro[3,4-b]pyridin-3-carbonsäureallylester. Fp.: 164-167 °C.4- (3-Chlorophenyl) -2-methyl-5-oxo-1,4,5,7-tetra-hydrofuro [3,4-b] pyridine-3-carboxylic acid allyl ester. Mp: 164-167 ° C.

Beispiel 222Example 222

2-Methyl-5-oxo-4-(2-trifluormethylphenyl)-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäure-82-pyridyl)-methylester.
Fp.: 209 bis 210 °C.
2-Methyl-5-oxo-4- (2-trifluoromethylphenyl) -1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid-82-pyridyl) methyl ester.
Mp .: 209 to 210 ° C.

Beispiel 223Example 223

2-Methyl-5-oxo-1-propyl-4-(2-trifluormethylphenyl)-1,4,5,7-tetrahydrofuro-[3,4-b]pyridin-3-carbonsäureethylester.
Fp.: 106 bis 107 °C.
2-Methyl-5-oxo-1-propyl-4- (2-trifluoromethylphenyl) -1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid ethyl ester.
Mp .: 106 to 107 ° C.

Beispiel 224Example 224

2-Methyl-5-oxo-4-(2-trifluormethylphenyl)-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbon- säurebenzylester.
Fp.: 218 bis 219 °C.
2-methyl-5-oxo-4- (2-trifluoromethylphenyl) -1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid benzyl ester.
Mp .: 218 to 219 ° C.

Beispiel 225Example 225

4-(3-Chlorphenyl)-2-methyl-5-oxo-1,4,5,7-tetra- hydrofuro[3,4-b]pyridin-3-carbonsäurehexy)ester. Fp.: 130 bis 133 °C.4- (3-chlorophenyl) -2-methyl-5-oxo-1,4,5,7-tetra-hydrofuro [3,4-b] pyridine-3-carboxylic acid hexy) ester. Mp .: 130 to 133 ° C.

Beispiel 226Example 226

1-Ethyl-2-methyl-5-oxo-4-(2-trifluormethylphenyl)-1,4,5,7-tetrahydrofuro-[3,4-b]pyridin-3-carbonsäureethylester.
Fp.: 157 bis 160 °C.
1-Ethyl-2-methyl-5-oxo-4- (2-trifluoromethylphenyl) -1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid ethyl ester.
Mp .: 157 to 160 ° C.

Beispiel 227Example 227

2-Methyl-5-oxo-4-(2-trifluormethylphenyl)-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbon- säureoctylester.
Fp.: 119 bis 120 °C.
2-Methyl-5-oxo-4- (2-trifluoromethylphenyl) -1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid octyl ester.
Mp .: 119 to 120 ° C.

Beispiel 228Example 228

4-(2,3-Dichlorphenyl)-2-methyl-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäureethylester.
Fp.: 249 bis 251 °C.
Ethyl 4- (2,3-dichlorophenyl) -2-methyl-5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylate.
Mp: 249 to 251 ° C.

Beispiel 229Example 229

2-Methyl-5-oxo-4-(3-pyridyl)-1,4,5,7-tetrahydro- furo[3,4-b]pyridin-3-carbonsäureethylester.
Fp.: 192 bis 194 °C.
2-Methyl-5-oxo-4- (3-pyridyl) -1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid ethyl ester.
Mp: 192 to 194 ° C.

Beispiel 230Example 230

2-Methyl-5-oxo-4-(2-trifluormethoxyphenyl)-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäureethylester.
Fp.: 174 bis 176 °C.
2-Methyl-5-oxo-4- (2-trifluoromethoxyphenyl) -1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid ethyl ester.
Mp .: 174 to 176 ° C.

Beispiel 231Example 231

2-Methyl-4-(2-naphthyl)-5-oxo-1,4,5,7-tetra- hydrofuro[3,4-b]pyridin-3-carbonsäureethylester. Fp.: >270°C.2-Methyl-4- (2-naphthyl) -5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid ethyl ester. Mp .:> 270 ° C.

Beispiel 232Example 232

5-Oxo-4-(2-trifluormethylphenyl)-1,2,7-trimethyl-1,4,5,7-tetrahydrofuro[3,4-b]-pyridin-3-carbonsäureethylester.
Fp.: 171 bis 172 °C.
5-Oxo-4- (2-trifluoromethylphenyl) -1,2,7-trimethyl-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid ethyl ester.
Mp .: 171 to 172 ° C.

Beispiel 233Example 233

2-Methyl-5-oxo-4-(3-trifluormethylphenyl)-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäureethylester.
Fp.: 180 bis 182 °C.
2-Methyl-5-oxo-4- (3-trifluoromethylphenyl) -1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid ethyl ester.
Mp .: 180 to 182 ° C.

Beispiel 234Example 234

2-Ethyl-5-oxo-4-(2-trifluormethylphenyl)-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäureethylester.
Fp.: 237 bis 239 °C.
2-Ethyl-5-oxo-4- (2-trifluoromethylphenyl) -1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid ethyl ester.
Mp .: 237 to 239 ° C.

Beispiel 235Example 235

2-Methyl-5-oxo-4-(2-trifluormethylphenyl)-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbon- säureallylester.
Fp.: 190 bis 192 °C.
2-methyl-5-oxo-4- (2-trifluoromethylphenyl) -1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carbon acid allyl ester.
Mp .: 190 to 192 ° C.

Beispiel 236Example 236

1,2-Dimethyl-5-oxo-4-(2-trifluormethylphenyl)-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäureethylester.
Fp.: 196 bis 197 °C.
1,2-Dimethyl-5-oxo-4- (2-trifluoromethylphenyl) -1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid ethyl ester.
Mp .: 196 to 197 ° C.

Beispiel 237Example 237

4-[(2-Fluor-3-chlor)phenyl]-2-methyl-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäuremethylester.
Fp.: 220 bis 223 °C.
4 - [(2-Fluoro-3-chloro) phenyl] -2-methyl-5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid methyl ester.
Mp .: 220 to 223 ° C.

Beispiel 238Example 238

4-[2-(Cyclohexylmethylthio)phenyl]-2-methyl-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäurebutylester.
Fp.: 123 bis 128 °C.
4- [2- (Cyclohexylmethylthio) phenyl] -2-methyl-5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid butyl ester.
Mp .: 123 to 128 ° C.

Beispiel 239Example 239

4-[2-(Cyclohexylmethylthio)phenyl]-2-methyl-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäureethylester.
Fp.: 77 bis 82 °C.
4- [2- (Cyclohexylmethylthio) phenyl] -2-methyl-5-oxo-1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid ethyl ester.
Mp .: 77 to 82 ° C.

Beispiel 240Example 240

2-Methyl-5-oxo-4-(2-trifluormethylphenyl)-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbon- säurehexylester.
Fp.: 164 bis 165 °C.
2-Methyl-5-oxo-4- (2-trifluoromethylphenyl) -1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid hexyl ester.
Mp .: 164 to 165 ° C.

Beispiel 241Example 241

2-Methyl-5-oxo-4-(2-phenylthiophenyl)-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-3-carbonsäureethylester.
Fp.: 191 bis 192 °C.
2-Methyl-5-oxo-4- (2-phenylthiophenyl) -1,4,5,7-tetrahydrofuro [3,4-b] pyridine-3-carboxylic acid ethyl ester.
Mp: 191 to 192 ° C.

Beispiel 242Example 242

4-(2-Chlorphenyl)-2-methyl-5-oxo-1,4,5,7-tetra- hydrofuro[3,4-b)pyridin-3-carbonsäureallylester.
Fp.: 206 °C.
4- (2-Chlorophenyl) -2-methyl-5-oxo-1,4,5,7-tetrahydrofuro [3,4-b) pyridine-3-carboxylic acid allyl ester.
Mp .: 206 ° C.

Beispiel 243Example 243

Analog zu dem Verfahren gemäss Beispiel Nr. 35 werden die folgenden Verbindungen durch Hydrierung mit Lithium-Aluminium-Hydrid aus den entsprechenden Diestern erhalten. 1,4-Dihydro-2,3,6-trimethyl-4-(2-chlorphenyl)-pyridin-5-carbonsäureethylester
vom Schmp. 112 °C.
Analogously to the process according to Example No. 35, the following compounds are obtained from the corresponding diesters by hydrogenation with lithium aluminum hydride. 1,4-Dihydro-2,3,6-trimethyl-4- (2-chlorophenyl) pyridine-5-carboxylic acid ethyl ester
from mp. 112 ° C.

Beispiel 244Example 244

1,4-Dihydro-2,3,6-trimethyl-4-(4-chlorphenyl)-pyridin-5-carbonsäuremethylester
vom Schmp. 94 °C.
1,4-Dihydro-2,3,6-trimethyl-4- (4-chlorophenyl) pyridine-5-carboxylic acid methyl ester
from mp. 94 ° C.

Beispiel 245Example 245

1,4-Dihydro-2,3,6-trimethyl-4-(2-methylphenyl)-pyridin-5-carbonsäuremethylester
vom Schmp. 147 bis 153 °C.
1,4-Dihydro-2,3,6-trimethyl-4- (2-methylphenyl) pyridine-5-carboxylic acid methyl ester
from mp. 147 to 153 ° C.

Beispiel 246Example 246

1,4-Dihydro-2,3,6-trimethyl-4-[2-(4-methyl- benzylthio)-phenyl]-pyridin-5-carbonsäuremethylester

  • vom Schmp.
  • 109 bis 111 °C.
1,4-Dihydro-2,3,6-trimethyl-4- [2- (4-methylbenzylthio) phenyl] pyridine-5-carboxylic acid methyl ester
  • from Schmp.
  • 109 to 111 ° C.

Beispiel 247Example 247

1,4-Dihydro-2,3,6-trimethyl-4-(2-trifluormethylphenyl)-pyridin-5-carbonsäuremethylester
vom Schmp. 145 bis 149 °C.
1,4-Dihydro-2,3,6-trimethyl-4- (2-trifluoromethylphenyl) pyridine-5-carboxylic acid methyl ester
from mp. 145 to 149 ° C.

Beispiel 248Example 248

1,4-Dihydro-2,3,6-trimethyl-4-(4-methylphenyl)-pyridin-5-carbonsäuremethy!ester
vom Schmp. 146 bis 150 °C.
1,4-Dihydro-2,3,6-trimethyl-4- (4-methylphenyl) pyridine-5-carboxylic acid methyl ester
from mp. 146 to 150 ° C.

Beispiel 249Example 249

1,4-Dihydro-2,3,6-trimethyl-4-(3-thienyl)-pyridin-5-carbonsäuremethylester
vom Schmp. 150 bis 158 °C.
1,4-Dihydro-2,3,6-trimethyl-4- (3-thienyl) pyridine-5-carboxylic acid methyl ester
from mp. 150 to 158 ° C.

Beispiel 250Example 250

1,4-Dihydro-2;3,6-trimethyl-4-(2-benzyloxy- phenyl)-pyridin-5-carbonsäuremethylester, isoliert als farbloses Harz.
Massenspektrum: Die wichtigsten Peaks findet man bei:

  • m/e = 363, 348, 304, 272, 180.
1,4-dihydro-2 ; 3,6-trimethyl-4- (2-benzyloxyphenyl) pyridine-5-carboxylic acid methyl ester, isolated as a colorless resin.
Mass spectrum: The most important peaks can be found at:
  • m / e = 363, 348, 304, 272, 180.

Beispiel 251Example 251

1,4-Dihydro-2,3,6-trimethyl-4-[2-(4-chlorbenzyl- oxy)-phenyl]-pyridin-5-carbonsäuremethylester, isoliert als farbloses Harz.
Massenspektrum: m/e = 396 (180).
1,4-Dihydro-2,3,6-trimethyl-4- [2- (4-chlorobenzyloxy) phenyl] pyridine-5-carboxylic acid methyl ester, isolated as a colorless resin.
Mass spectrum: m / e = 396 (180).

Beispiel 252Example 252

1,4-Dihydro-2,3,6-trimethyl-4-[2-(2,6-dichlor- benzyloxy)-phenyl]-pyridin-5-carbonsäuremethylester,
isoliert als Öl.
1,4-dihydro-2,3,6-trimethyl-4- [2- (2,6-dichlorobenzyloxy) phenyl] pyridine-5-carboxylic acid methyl ester,
isolated as an oil.

Beispiel 253Example 253

1,4-Dihydro-2,3,6-trimethyl-4-[2-(4-methyl- benzyloxy)-phenyl]-pyridin-5-carbonsäuremethylester,
isoliert als Öl.
1,4-dihydro-2,3,6-trimethyl-4- [2- (4-methylbenzyloxy) phenyl] pyridine-5-carboxylic acid methyl ester,
isolated as an oil.

Beispiel 254Example 254

1,4-Dihydro-2,3,6-trimethyl-4-(2-phenethyloxy- phenyl)-pyridin-5-carbonsäuremethylester, isoliert als gelbes Öl.1,4-Dihydro-2,3,6-trimethyl-4- (2-phenethyloxyphenyl) pyridine-5-carboxylic acid methyl ester, isolated as a yellow oil.

Beispiel 255Example 255

1,4-Dihydro-2,3,6-trimethyl-4-(2-phenyl- mercaptomethoxyphenyl)-pyridin-5-carbonsäuremethylester,

  • isoliert als gelbes Öl.
  • Massenspektrum: m/e = 395 (180).
1,4-dihydro-2,3,6-trimethyl-4- (2-phenyl-mercaptomethoxyphenyl) pyridine-5-carboxylic acid methyl ester,
  • isolated as a yellow oil.
  • Mass spectrum: m / e = 395 (180).

Beispiel 256Example 256

1,4-Dihydro-2,3,6-trimethyl-4-[3-(4-methyl- benzyloxy)-phenyl]-pyridin-5-carbonsäuremethylester,
isoliert als gelbes Öl.
1,4-dihydro-2,3,6-trimethyl-4- [3- (4-methyl-benzyloxy) -phenyl] - pyridin-5-carbonsäuremethylester,
isolated as a yellow oil.

Beispiel 257Example 257

Figure imgb0124
Figure imgb0124

Analog Beispiel 18 erhält man aus 0,1 Mol 2-Amino-1-nitro-1-propen und 0,1 Mol 2-Chlor-1-phenyl-buten-1-on-3 durch Erhitzen in siedendem Ethanol das 3-Chlor-1,4-dihydro-2,6-dimethyl-5-nitro-4-phenyl- pyridin

  • vom Schmelzpunkt 192 °C (Isopropanol).
  • Ausbeute: 28% der Theorie.
Analogously to Example 18, 3-chloro is obtained from 0.1 mol of 2-amino-1-nitro-1-propene and 0.1 mol of 2-chloro-1-phenyl-buten-1-one-3 by heating in boiling ethanol -1,4-dihydro-2,6-dimethyl-5-nitro-4-phenylpyridine
  • melting point 192 ° C (isopropanol).
  • Yield: 28% of theory.

Beispiel 258Example 258

Figure imgb0125
Figure imgb0125

Analog Beispiel 18 werden 0,1 Mol 2-Amino-1-nitro-1-propen und 0,1 Mol 2-Chlor-1-(3-nitrophenyl)-buten-1-on-3 in siedendem Ethanol erhitzt. Man erhält 3-Chlor-1,4-dihydro-2,6-dimethyl-5-nitro-4-(3-nitrophenyl)-pyridin

  • vom Schmp. 198 °C (Zers.).
  • Ausbeute:
Analogously to Example 18, 0.1 mol of 2-amino-1-nitro-1-propene and 0.1 mol of 2-chloro-1- (3-nitrophenyl) -buten-1-one-3 are heated in boiling ethanol. 3-Chloro-1,4-dihydro-2,6-dimethyl-5-nitro-4- (3-nitrophenyl) pyridine is obtained
  • of melting point 198 ° C (dec.).
  • Yield:

Beispiel 259Example 259

Figure imgb0126
Figure imgb0126

Analog Beispiel 18 werden 0,1 Mol Aminocrotonsäuremethylester und 2-Chlor-1-phenyl-buten-1-on-3 in siedendem Ethanol erhitzt. Man erhält 3-Chlor-1,4-dihydro-2,6-dimethyl-4-phenyl- pyridin-5-carbonsäuremethylester

  • vom Schmp. 147 °C.
  • Ausbeute: 23% der Theorie.
Analogously to Example 18, 0.1 mol of aminocrotonic acid methyl ester and 2-chloro-1-phenyl-buten-1-one-3 are heated in boiling ethanol. 3-Chloro-1,4-dihydro-2,6-dimethyl-4-phenyl-pyridine-5-carboxylic acid methyl ester is obtained
  • from mp. 147 ° C.
  • Yield: 23% of theory.

Beispiel 260Example 260

Figure imgb0127
Figure imgb0127

Analog Beispiel 18 wurde duch Umsetzung von 2-Nitro-1-(2-trifluormethylphenyl)-buten-1-on-3 und Amidinoessigsäureethylester in Ethanol 2-Amino-1,4-dihydro-6-methyl-5-nitro-4-(2-trifluormethylphenyl)-pyridin-5-carbon-säureester vom Schmp. 210 °C (Isopropanol) erhalten. Ausbeute: 32% der Theorie.Analogously to Example 18, 2-amino-1,4-dihydro-6-methyl-5-nitro-4- (2-trifluoromethylphenyl) pyridine-5-carbon acid ester of mp. 210 ° C (isopropanol) obtained. Yield: 32% of theory.

Beispiel 261Example 261

4-(2-Benzylthiophenyl)-3-cyano-1,4-dihydro-2,6-dimethyl-pyridin-5-carbonsäuremethylester

Figure imgb0128
Eine Lösung von 22,7 g (69 mMol) 2-(2-Benzylthio- benzyliden)-acetessigsäuremethylester und 5,7 g (69 mMol) β-Aminocrotonsäurenitril in 80 ml Methanol wurde 12 Stunden unter Stickstoff zum Sieden erhitzt. Anschliessend wurde das Lösungsmittel i.V. eingeengt und der ölige Rückstand durch Verreiben mit wenig Ether zur Kristallisation gebracht. Das Rohprodukt wurde abgesaugt und aus Methanol umkristallisiert.

  • Schmelzpunkt: 183-185 °C.
  • Ausbeute: 15,7 g (58%).
4- (2-Benzylthiophenyl) -3-cyano-1,4-dihydro-2,6-dimethyl-pyridine-5-carboxylic acid methyl ester
Figure imgb0128
A solution of 22.7 g (69 mmol) of methyl 2- (2-benzylthio-benzylidene) -acetoacetate and 5.7 g (69 mmol) of β-aminocrotonitrile in 80 ml of methanol was heated to boiling under nitrogen for 12 hours. The solvent was then evaporated down in vacuo and the oily residue was crystallized by trituration with a little ether. The crude product was filtered off and recrystallized from methanol.
  • Melting point: 183-185 ° C.
  • Yield: 15.7 g (58%).

Beispiel 262Example 262

Figure imgb0129
Figure imgb0129

Analog Beispiel 261 wurde durch Umsetzung von 2-(2-(3-Chlorbenzylthio)-benzyliden)-acetessigsäuremethylester und β-Aminocrotonsäurenitril in Methanol der 4-(2-(3-Chlorbenzylthio)-phenyl)-3-cyano-1,4-dihydro-2,6-dimethy)pyridin-5-carbonsäuremethylester

  • vom Fp.: 155 °C (Methanol) erhalten.
  • Ausbeute: 51% der Theorie.
Analogously to Example 261, the 4- (2- (3-chlorobenzylthio) phenyl) -3-cyano-1,4-was reacted by reacting methyl 2- (2- (3-chlorobenzylthio) benzylidene) -acetoacetate and β-aminocrotonitrile in methanol -dihydro-2,6-dimethy) pyridine-5-carboxylic acid methyl ester
  • obtained from mp: 155 ° C (methanol).
  • Yield: 51% of theory.

Beispiel 263Example 263

Figure imgb0130
Figure imgb0130

Analog Beispiel 261 wurde durch Umsetzung von 2-(2-Benzylthiobenzyliden)-acetessigsäureethylester und β-Aminocrotonsäurenitril in Ethanol der 4-(2-Benzylthiophenyl)-3-cyano-1,4-dihydro-2,6-dimethyl-pyridin-5-carbonsäureethylester

  • vom Fp.: 127 °C erhalten.
  • Ausbeute: 49% der Theorie.
Analogously to Example 261, the 4- (2-benzylthiophenyl) -3-cyano-1,4-dihydro-2,6-dimethyl-pyridine-5 was obtained by reacting ethyl 2- (2-benzylthiobenzylidene) -acetoacetate and β-aminocrotonitrile in ethanol -carboxylic acid ethyl ester
  • obtained from mp: 127 ° C.
  • Yield: 49% of theory.

Beispiel 264Example 264

Figure imgb0131
Figure imgb0131

Analog Beispiel 261 wurde durch Umsetzung von 2-(2-Benzylthiobenzyliden)-acetessigsäure-n-propylester und β-Aminocrotonsäurenitril in Ethanol der 4-(2-Benzylthiophenyl)-3-cyano-1,4-dihydro-2,6-dimethyl-pyridin-5-carbonsäure-n-propylester

  • vom Fp.: 101 °C erhalten.
  • Ausbeute: 45% der Theorie.
Analogously to Example 261, the 4- (2-benzylthiophenyl) -3-cyano-1,4-dihydro-2,6-dimethyl was obtained by reacting n-propyl 2- (2-benzylthiobenzylidene) -acetoacetate and β-aminocrotonitrile in ethanol -pyridine-5-carboxylic acid n-propyl ester
  • obtained from mp: 101 ° C.
  • Yield: 45% of theory.

Beispiel 265Example 265

Figure imgb0132
Figure imgb0132

Analog Beispiel 261 wurde durch Umsetzung von 2-(2-Benzylthiobenzyliden)-acetessigsäure- isopropylester und ß-Aminocrotonsäurenitril in Ethanol der 4-(2-Benzylthiophenyl)-3-cyano-1,4-dihydro-2,6-dimethylpyridin-5-carbonsäureisopropylester

  • vom Fp.: 152 °C erhalten.
  • Ausbeute: 61 % der Theorie.
Analogously to Example 261, the 4- (2-benzylthiophenyl) -3-cyano-1,4-dihydro-2,6-dimethylpyridine-5 was obtained by reacting isopropyl 2- (2-benzylthiobenzylidene) -acetoacetate and β-aminocrotonitrile in ethanol -carboxylic acid isopropyl ester
  • obtained from mp: 152 ° C.
  • Yield: 61% of theory.

Claims (19)

1. Use of 1,4-dihydropyridines of the general formula (I)
Figure imgb0176
in which
n represents 0, 1 or 2,
R' a) represents hydrogen, a straight-chain, branched, cyclic, saturated or unsaturated aliphatic hydrocarbon radical which optionally contains 1 to 3 identical or different hetero chain members from the group comprising 0, CO, SOm (m = 0, 1 or 2), = N-, NRI and SiRIIRIII, this hydrocarbon radical optionally being substituted by halogen, N02, CN, N3, hydroxyl, aryl or heteroaryl or
b) represents an aryl or heteroaryl radical, these radicals optionally carrying 1 to 5 identical or different substituents from the group comprising aryl, alkyl, alkenyl, alkinyl, alkenoxy, alkinoxy, aralkyl, acyl, alkylene, dioxyalkylene, halogen, CF3, OCF3, SCF3, NO2, NO, CN, N3, CORIV, COORV, ORVI, NRI or NRVIIRVIII, it being possible for the alkyl, alkoxy and aryl radicals of the abovementioned substituents in their turn also to be substituted by halogen, COORV or NRVII RVIII or
c) represents the radical NRVIIRI, the radicals R', RII, RIII, RIV, RV, RVI, RVIII and RVIII mentioned under a), b) and c) having the meaning given below,
R2
a) represents one of the substituents mentioned under R1 but does not have to be identical thereto, or
b) represents the radicals NHRI or
Figure imgb0177
RI, RIX and RX having the meaning given below, or the substituents R1 and R2 together form a 5- to 8-membered, saturated or unsaturated ring which optionally contains 1, 2 or 3 identical or different ring members from the group comprising O, S, NRI and CO and which optionally contains 1 to 3 identical or different substituents from the group comprising halogen, hydroxyl, alkyl, alkoxy, aryl or . aralkyl,

R3 represents one of the substituents mentioned under R2 and is identical thereto or differs therefrom, only one of the two substituents
R2 or R3 in each case representing alkoxy, alkylthio or NHR!,
R4
a) represents hydrogen, NO2, NO, CN, SOmRXI (m = 0, 1 or 2), halogen
Figure imgb0178
or
Figure imgb0179
RIRVII, RVIII, RXI and RXIII having the meaning given below, or
b) represents a branched or unbranched, cyclic, saturated or unsaturated aliphatic hydrocarbon radical which is optionally substituted by halogen, OH, CN, alkoxy, alkylthio, aryloxy, COORV or
Figure imgb0180
RV, RVII and RVIII having the meaning given below, or
c) represents an aromatic hydrocarbon radical or a 5- to 7-membered saturated or unsaturated hetero ring with 1 to 4 identical or different hetero members from the group comprising 0, S, -N= and NRI, this hetero ring being linked to the dihydropyridine ring either via a carbon atom or a nitrogen atom, the aromatic hydrocarbon radical and the hetero rings optionally carrying 1 to 3 identical or different substituents from the group comprising halogen, OH, CN, CF3, OCF3, SCF3, N02, alkyl, alkoxy, aryl and
Figure imgb0181
or
d) represents the radical
Figure imgb0182
wherein X denotes oxygen, sulphur or NRI, and Y represents a single bond, 0, S or NRI, and R8 has the meaning given for R1 and is identical to the substituent R1 or differs therefrom, or
e) represents the radical
Figure imgb0183
wherein
n', R1', R2', R3', R5', R6' and R7' have the meaning given for n, R1, R2, R3, R5, R6 and R7 and are identical thereto or differ therefrom, and
R4* and R4** are identical or different and each represent a radical, minus one hydrogen, of the substituents mentioned for R4 under a) to d), or R2 and R4 together form a branched, unbranched, saturated or unsaturated 5- to 8-membered ring which optionally contains 1, 2 or 3 identical or different ring members from the group comprising O, CO, CS, C=NRI, = N-, NRI, SOm (m = 0, 1 or2) and SiRIIRIII, and which is optionally substituted by halogen, hydroxyl, alkoxy, aryl, aralkyl or
Figure imgb0184
or disubstituted by a straight-chain or branched alkylene chain with 3 to 8 carbon atoms, it being possible for this common ring of R2 and R4 also to be directly fused to the common ring of F1 and R2, the radicals RI, RII, RIII, RVII and RVIII having the meaning given below,
R5 has the meaning given for R4 and is identical to R4 or different therefrom, or
R5 and R3 together form a ring which is identical to the ring formed by R2 and R4 or differs therefrom, or
R6 represents hydrogen, alkyl or halogenoalkyl, and
R7
a) represents a saturated, unsaturated, cyclic, straight-chain or branched aliphatic hydrocarbon radical which is optionally substituted by halogen, aryl or heteroaryl, or
b) represents an aryl or heteroaryl radical which optionally contains 1 to 5 identical or different substituents from the group comprising NO2, CN, N3, NO, CF3, halogen, CORIV, CORV, ORVI,
Figure imgb0185
alkyl, aryl, alkenyl, alkinyl, alkenoxy, alkinoxy, aralkyl, acyl, alkylene and dioxyalkylene, it being possible for the abovementioned alkyl and aryl substituents in their turn also to be substituted by halogen, COORV or
Figure imgb0186
and in the abovementioned definitions of the substituents R1 to R8
RI represents hydrogen, alkyl, aryl, aralkyl, heteroaryl or acyl,
R" and Rill are identical or different and each represent alkyl, aryl, aralkyl or heteroaryl, RIV, RV and
RVI are in each case identical or different and represent hydrogen, alkyl, aryl, aralkyl or heteroaryl, the alkyl and aryl radicals optionally being substituted by halogen, nitro, trifluoromethyl, alkoxy, alkylthio or alkyl,
RVII and RVIII are in each case identical or different and represent hydrogen, aryl or aralkyl, or represent alkyl which is optionally interrupted by 0, S or NR', or, together with the nitrogen atom, form a 5- to 7-membered ring which can contain 1 or 2 identical or different hetero ring members from the group comprising O, S and NR', or
one of the radicals RVII or RVIII represents an aliphatic acyl group with up to 6 carbon atoms, R'x, RX, RXI, RXII and RXIII are in each case identical or different and represent alkyl, aryl or aralkyl,
the alkyl, aryl, aralkyl, heteroaryl and acyl radicals mentioned under R1 to R8 and under RI to RXIII, and the hetero ring formed with RVII and RVIII, in their turn optionally being substituted by OH, CF3, OCF3, CN, N02, halogen, lower thioalkyl, lower alkyl, lower alkoxy, aryl or aralkyl,
and the following substituents being mentioned as heteroaryl:
thienyl, fuyl, pyryl, pyridyl, quinolyl, isoquinolyl, pyrimidyl, pyradazinyl, quinazolyl, quinoxalyl, benzothienyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, oxydiazolyl, pyrazinyl, oxazinyl, thiazinyl, indolizinyl, indolyl, benzofuranyl, indazolyl, benzothienyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzthiazolyl, benztriazolyl, benzoxadiazolyl, cinnolinyl, phthalazinyl, naphthyridinyl, or benzotriazinyl,

in the form of isomers, isomer mixtures, racemates and optical antipodes, and of their pharmaceutically acceptable salts, which, from a concentration of 10-5 g/ml upwards, cause an at least 25% augmentation of the contraction of the isolated left atrium of the guinea pig heart, for the preparation of medicaments which increase the influx of Ca++ into the cell.
2. Use according to Claim 1 of compounds of the general formula (I) for the preparation of medicaments with a positive inotropic action.
3. Use according to Claim 1 of compounds of the general formula (I) for the preparation of medicaments with a cardiotonic action.
4. Use according to Claim 1 of compounds of the general formula (I) for the preparation of medicaments with an antihypotonic action.
5. Use according to Claim 1 of compounds of the general formula (I) for the preparation of medicaments for reducing blood-sugar.
6. Use according to Claim 1 of compounds of the general formula (I) for the preparation of medicaments for decreasing the swelling of mucous membranes.
7. Use according to Claim 1 of compounds of the general formula (I) for the preparation of medicaments for influencing the salt and liquid balance.
8. Use according to Claims 1 to 7 of compounds of the general formual (I) according to Claim 1, in which
n represents 0, 1 or 2,
R1
a) represents hydrogen, a straight-chain, branched cyclic saturated or unsaturated aliphatic hydrocarbon radical with up to 10 C atoms which optionally contains 1 or 2 identical or different hetero chain members from the group comprising 0, CO, S, SO2, =N- and NRI, this hydrocarbon radical optionally being substituted by halogen, N02, CN, N3, hydroxyl, with 1 to 4 C atoms, phenyl, naphthyl or heteroaryl or
b) represents a phenyl, naphthyl or heteroaryl radical, these radicals optionally carrying 1 to 3 identical or different substituents from the group comprising phenyl, alkyl, alkenyl, alkinyl, alkenoxy, alkinoxy with in each case up to 4 C atoms, aralkyl with 7 to 14 C atoms, acyl with up to 6 C atoms, alkylene, dioxyalkylene with up to 4 carbon atoms in the alkylene chain, halogen, CF3, OCF3, SCF3, NO2, CN, N3, CORIV, COORV, ORVI, NRI or NRVIIRVIII, it being possible for the alkyl, alkoxy and aryl radicals of the abovementioned substituents in their turn also to be substituted by halogen, COORV or NRVIIRVIII or
c) represents the radical NRVIIRI, the radicals RI, RII, RIII, RIV, RV, RVI, RVII and RVIII mentioned under a), b) and c) having the meaning given below,
R2 an
a) represents one of the substituents mentioned under R1 but does not have to be identical thereto or
b) represents the radicals NHRI or
Figure imgb0187
RI, RIX and RX having the meaning given below, or the substitutents
R1 and R2 together form a 5- to 7-membered saturated or unsaturated ring which optionally contains one or two identical or different ring members from the group comprising 0, S, NR' and CO and which optionally contains one to three identical or different substituents from the group comprising halogen, hydroxyl, alkyl, alkoxy with in each case 1 to 4 C atoms, phenyl, naphthyl or aralkyl with 7 to 14 C atoms, R3 represents one of the substituents mentioned under R2 and is identical thereto or differs therefrom, only one of the two substituents R2 or R3 in each case representing alkoxy, alkyathio or NHRI,
R4 a) represents hydrogen, NO2, NO, CN, SOm-RIX (m = 0 or 2), halogen,
Figure imgb0188
or
Figure imgb0189
RI, RVII, RVIII, RXII and RXIII having the meaning given below, or
b) represents a branched or unbranched, cyclic, saturated or unsaturated aliphatic hydrocarbon radical with up to 10 C atoms, which is optionally substituted by halogen, OH, CN, alkoxy, alkylthio with in each case 1 to 4 carbon atoms, phenyloxy, naphthoxy, COORV or
Figure imgb0190
RV, RVII and RVIII having the meaning given below, or
c) represents an aromatic hydrocarbon radical with 6 to 10 C atoms or a 5- to 7-membered saturated or unsaturated hetero ring with 1 to 3 identical or different hetero members from the group comprising O, S, -N= and NRI, this hetero ring being linked to the dihydropyridine ring either via a carbon atom or a nitrogen atom and the aromatic hydrocarbon radical and the hetero rings optionally carrying 1 to 3 identical or different substituents from the group comprising halogen, OH, CN, CF3, OCF3, SCF3, NO2, alkyl, alkoxy with in each case 1 to 4 C atoms, phenyl, naphthyl and
Figure imgb0191
or
d) represents the radical
Figure imgb0192
wherein X denotes oxygen, sulphur or NRI, and Y represents a single bond, 0, S or NR', and R8 has the meaning given for R1 and is identical to the substituent R1 or differs therefrom, or
e) represents the radical
Figure imgb0193
wherein
n', R1', R2', R3', R5', R6' and R7' have the meaning given for n, R1, R2, R3, R5, R6 and R7 and are identical thereto or differ therefrom, and
R4* and R4** are identical or different and each represent a radical, minus one hydrogen, of the substituents mentioned for R4 under a) to d), or R2 and R4 together form a branched, unbranched, saturated or unsaturated 5- to 7-membered ring which optionally contains 1, 2 or 3 identical or different ring members from the group comprising 0, CO, CS, C=NRI, =N-, NRI and SOm (m = 0 or 2) and which is optionally substituted by halogen, hydroxyl, alkoxy with 1 to 4 C atoms, phenyl, naphthyl, aralkyl with 7 to 14 C atoms, or
Figure imgb0194
or disubstituted by a straight-chain or branched alkylene chain with 3 to 6 carbon atoms, it being possible for this common ring of R2 and R4 also to be directly fused to the common ring of R1 and R2, the radicals RI, R", RIII, RVII and RVIII having the meaning given below,
R5 has the meaning given for R4 and is identical to R4 or differs therefrom,
R6 represents hydrogen, alkyl or halogenoalkyl with in each case 1 to 4 C atoms and
R7
a) represents a saturated, unsaturated cyclic, straight-chain or branched aliphatic hydrocarbon radical with up to 10 C atoms, which is optionally substituted by halogen, phenyl, naphthyl or heteroaryl or
b) represents a phenyl, naphthyl or heteroaryl radical which optionally contains 1 to 3 identical or different substituents from the group comprising N02, halogen, CN, N3, NO, CF3, CORIV, COORV, ORVI,
Figure imgb0195
alkyl with 1 to 4 C atoms, phenyl, naphthyl, alkenyl, alkinyl, alkenoxy, alkinoxy with in each case up to 4 C atoms, aralkyl with 7 to 14 C atoms, acyl with 1 to 4 C atoms, alkylene and dioxyalkylene with in each case up to 4 C atoms, it being possible for the abovementioned alkyl and aryl substituents in their turn also to be substituted by halogen, COORV or
Figure imgb0196
and in the abovementioned definitions of the substituents R1 to R 7
R1 represents hydrogen, alkyl with 1 to 6 C atoms, phenyl, naphthyl, aralkyl with 7 to 12 C atoms, heteroaryl or acyl with up to 7 C atoms, R" and Rill are identical or different and each represent alkyl with 1 to 6 C atoms, phenyl, naphthyl, aralkyl with 7 to 12 C atoms or heteroaryl,
RVII, RV and RVI are in each case identical or different and represent hydrogen, alkyl with 1 to 6 C atoms, phenyl, naphthyl, aralkyl with 7 to 12 C atoms or heteroaryl, the alkyl and aryl radicals optionally being substituted by halogen, nitro, trifluoromethyl, alkoxy, alkylthio and alkyl with in each case 1 to 4 C atoms,
RVII and RVIII are in each case identical or different and represent hydrogen, phenyl, naphthyl or aralkyl with 7 to 12 C atoms or represent alkyl with 1 to 6 C atoms which is optionally interrupted by 0, S or NRI, or, together with the nitrogen atom, from a 5- to 7-membered ring which can contain 1 or 2 identical or different hetero ring members from the group comprising 0, S and NRI, or
one of the radicals RVII and RVIII represents an aliphatic acyl group with up to 6 carbon atoms, Rlx, R X, RX" and RXIII are in each case identical or different and represent alkyl with 1 to 6 C atoms, phenyl, naphthyl or aralkyl with 7 to 12 C atoms, the alkyl, aryl, aralkyl, heteroaryl and acyl radicals mentioned under R1 to R8 and under RI to RVIII and the hetero ring formed with R6 and R7 in their turn optionally being substituted by OH, CF3, OCF3, CN, NO2, halogen, alkyl with 1 to 4 C atoms, alkoxy, alkylthio with in each case 1 to 4 C atoms, phenyl or benzyl,
and the following substituents being mentioned as heteroaryl:
thienyl, furyl, pyryl, pyridyl, quinolyl,
isoquinolyl, pyrimidyl, pyridazinyl,
quinazolyl, quinoxalyl, benzothienyl,
pyrazolyl, imidazolyl, oxazolyl, isoxazolyl,
thiazolyl, triazolyl, oxydiazolyl, pyrazinyl,
oxazinyl, thiazinyl, indolizinyl, indolyl,
benzofuranyl, indazolyl, benzothienyl,
benzimidazolyl, benzoxazolyl, benzisoxazolyl,
benzthiazolyl, benztriazolyl, benzoxadiazolyl,
cinnolinyl, phthalazinyl, naphthyridinyl or benzotriazinyl,

in the form of isomers, isomer mixtures, racemates and optical antipodes and of their pharmaceutically acceptable salts.
9. Use according to Claims 1 to 7 of compounds of the general formula (I) according to Claim 1, in which n represents 0 or 1,
R'
a) represents hydrogen, a straight-chain, branched cyclic saturated or unsaturated aliphatic hydrocarbon radical with up to 10 C atoms which optionally contains by one or two identical or different hetero chain members from the group comprising 0, CO, S, =N- and NR', this hydrocarbon radical optionally being substituted by F, Cl, Br, N02, CN, OH, phenyl or pyridyl or
b) represents a phenyl, naphthyl or pyridyl radical, these radicals optionally carrying 1 or 2 identical or different substituents from the group comprising phenyl, alkyl, alkenyl, alkoxy, alkenoxy with in each case up to 4 C atoms, benzyl,acetyl, alkylene, dioxyalkylene with 2 to 4 C atoms, fluorine, chlorine, bromine, CF3, OCF3, SCF3, NO2, CN, COORV, ORVI, NR' and NRVIIRVIII, it being possible for the alkyl, alkoxy and aryl radicals of the abovementioned substituents in their turn also to be halogen substituted or
c) represents the radical NRVIIRVIII, the radicals RI to RVIII mentioned under a), b) and
c) having the meaning given below,
R2
a) represents one of the substituents mentioned under R' but does not have to be identical thereto or
b) represents the radicals NHR' or
Figure imgb0197
R', RIX and RX having the meaning given below, or the substituents,
R' and R2 together form a 5- to 7-membered saturated or unsaturated ring which optionally contains 1 or 2 identical or different ring members from the group comprising 0, S, NR' and CO and which optionally contains 1 or 2 identical or different substituents from the group comprising halogen, hydroxyl, alkyl, alkoxy each with 1 to 4 C atoms, phenyl and benzyl,
R3 represents one of the substituents mentioned under
R2 and is identical thereto or differs therefrom, only one of the two substituents R2 or R3 in each case representing alkoxy, alkylthio or NHRI,
R4
a) represents hydrogen, N02, CN, SRXI, SO2RXI,
Figure imgb0198
or
Figure imgb0199
R', RVI, RVII, RVIII and R'x having the meaning given below,
b) represents a branched or unbranched alkyl or cycloalkyl radical with up to 8 C atoms, which is optionally substituted by halogen, hydroxyl, cyano, alkoxy with 1 to 4 C atoms, phenyloxy, COORV or
Figure imgb0200
RV, RVII and RVIII having the meaning given below or
c) represents an aromatic hydrocarbon radical with 6 to 10 C atoms or a 5- to 7-membered saturated or unsaturated hetero ring with 1 to 3 identical or different hetero members from the group comprising 0, S, =N- and NRI, this hetero ring being linked to the dihydropyridine ring either via a carbon atom or a nitrogen atom, and the aromatic hydrocarbon radical and the hetero rings optionally carrying 1 or 2 identical or different substituents from the group comprising halogen, hydroxyl, cyano, CF3, NO2, phenyl, alkyl and alkoxy each with 1 to 4 C atoms, or
d) represents the radical
Figure imgb0201
wherein X represents oxygen or NR' and Y represents a single bond, oxygen or NRI and R8 has for meaning given for R1 and is identical to the substituent or differs therefrom, or
e) represents the radical
Figure imgb0202
wherein n', R1', R2', R3', R5', R6' and R7' have the meaning given for n, R1, R2, R3, R5, R6 and R7 and are identical thereto or differ therefrom, and
R4* and R4** are identical or different and each represent a radical, minus one hydrogen, of the substituents mentioned for R4 under a) to d), or
R2 and R4 together form a branched unbranched saturated or unsaturated 5- to 7-membered ring which optionally contains 1 or 2 identical or different ring members from the group comprising 0, CO, CS, C=NRI, = N- and NRI and which is optionally substituted by halogen or hydroxyl
R1 having the meaning given below,
R5 has the meaning given for R4 and is identical to R4 or differs therefrom or
R5 and R3 together form a ring of the kind defined for R2 and R4 and is identical thereto or differs therefrom,
R6 represents hydrogen or alkyl with 1 to 4 C atoms which is optionally substituted by fluorine, chlorine or bromine and
R 7
a) represents a saturated, unsaturated cyclic, straight-chain or branched aliphatic hydrocarbon radical with up to 8 C atoms, which is optionally substituted by halogen, or
b) represents a phenyl or heteroaryl radical which optionally contains 1 to 3 identical or different substituents from the group comprising NO2, CN, N3, CF3, halogen, CORIV, CORV, ORVI, SRXI,
Figure imgb0203
phenyl, alkyl with 1 to 4 C atoms, benzyl

and acyl with 1 to 4 C atoms,
and in the abovementioned definitions of the substituents R1 to R8
RI represents hydrogen, alkyl with 1 to 6 C atoms, phenyl, naphthyl, benzyl, phenethyl, heteroaryl or acyl with up to 4 C atoms,
R" and RIII are identical or different and in each case represent alkyl with 1 to 6 C atoms, phenyl, naphthyl, benzyl or heteroaryl,
RIV, RV and RVI are in each case identical or different and represent hydrogen, alkyl with 1 to 6 C atoms, phenyl, naphthyl, benzyl or heteroaryl, the alkyl, phenyl and benzyl radicals optionally being substituted by fluorine, chlorine, nitro, CF3, methyl, methoxy and methylthio,
RVII and RVIII are in each case identical or different and represent hydrogen, phenyl or benzyl or rep- resent alkyl with 1 to 6 carbon atoms, which is optionally interrupted by 0 or NRI, or
together with the nitrogen atom, form a 5- to 7- membered ring which can contain 1 or 2 identical different hetero ring members from the group comprising 0, S and NR',
or
one of the radicals RVII or RVIII represents an aliphatic acyl group with up to 6 carbon atoms and RIX, R X, RXI, RXII and RXIII are in each case identical or different and represent alkyl with 1 to 6 C atoms, phenyl or benzyl, the following substituents being mentioned as heteroaryl:
thienyl, furyl, pyryl, pyridyl, quinolyl,
isoquinolyl, pyrimidyl, pyridazinyl,
quinazolyl, quinoxalyl, benzothienyl,
pyrazolyl, imidazolyl, oxazolyl, isoxazolyl,
thiazolyl, triazolyl, oxydiazolyl, pyrazinyl,
oxazinyl, thiazinyl, indolyl, benzofuranyl,
indazolyl, benzothienyl, benzimidazolyl,
benzoxazolyl, benzisoxazolyl, benzthiazolyl,
benztriazolyl or benzoxadiazolyl.
10. Use according to Claims 1 to 7 of compounds of the general formula (I) according to Claim 1 in which n represents 0,
R1
a) represents hydrogen, an aliphatic hydrocarbon radical with up to 6 C atoms, which optionally contains a hetero chain member from the group comprising 0, CO, =N- and NR' and which is optionally substituted by halogen, nitro, hydroxyl or phenyl or
b) represents a phenyl or pyridyl radical which are optionally substituted by halogen, N02, CF3, OCF3 , CN, COORV or NRVIIRVIII,
R2 represents one of the substituents mentioned under
R1 but does not have to be identical thereto or represents one of the radicals NHR' or N=CRXRXI, R3 represents one of the substituents mentioned under
R2 and is identical thereto or differs therefrom,
R4 a) represents hydrogen, N02, NRVIIRVIII,
Figure imgb0204
or halogen, or
b) represents an alkyl radical with 1 to 4 C atoms, which is optionally substituted by halogen, OH, CN, alkoxy with 1 to 4 C atoms, COORV or NRVIIRVIII or
c) represents phenyl, pyridyl orthienyl, which are optionally substituted by halogen, OH, CN, alkyl or alkoxy with in each case 1 to 4 C atoms or by NRVIIIRVIII or
d) represents the radical
Figure imgb0205
wherein X denotes oxygen and Y represents a single bond, oxygen or NRI and R8 has the meaning given for R1 and is identical to the substituent R1 or differs therefrom or
e) represents the radical
Figure imgb0206
wherein n', R1', R2', R3', R5', R6' and R7' have the meaning given for n, R1, R2, R3, R5, R6 and R7 and are identical thereto or differ therefrom, and
R4' and R4" are identical or different and each represent a radical, minus one hydrogen, of the substituents mentioned for R4 under a) to d), or
R2 and R4 together form a 5- to 7-membered ring which optionally contains 1 to 2 different ring members from the group comprising 0, CO, CS and C=NRI and which is optionally substituted by halogen,
R5 has the meaning given for R4 and is identical to R4 or differs therefrom,
R6 represents hydrogen or alkyl with 1 to 4 C atoms and R7 has the abovementioned meaning, the substituents R' to RVIII marked with Roman numerals in the abovementioned definitions having the meaning given in Claim 4.
11. Use according to Claims 1 to 7 of compounds of the general formula (I) according to Claim 1, in which at least one of the substituents R4 and R5 represents N02 and/or in which R2 and R4 together or R3 and R5 together form a lactone ring.
12. Compounds of the general formula (I)
Figure imgb0207
in which at least one of the substituents R4 and R5 represents the group
Figure imgb0208
wherein RVIII and RVII and the substituents R1, R2, R3, R6, R7 and n and the remaining radical of R4 and R5 have the meaning given in Claims 1 and 8 to 11.
13. Compounds of the general formula (I)
Figure imgb0209
in which at least one of the substituents R4 and R5 represents methyl, wherein R1, R2, R3, R6, R7 and n and the remaining radical of R4 and R5 have the meaning given in Claims 1 and 8 to 11.
14. Compounds of the general formula (I)
Figure imgb0210
in which one of the radical R4 or R5 denotes hydrogen, R' represents hydrogen and n represents 0 and R2, R3, R6 and R7 and the other radical of R 4 and R5 have the meaning given in Claims 1 and 8 to 11.
15. Compounds of the general formula (I)
Figure imgb0211
in which one of the radicals R4 and R5 denotes halogen and R1, R2, R3, R6 and R7 and n and the other radical of R4 or R5 have the meaning given in Claim 1 and 8 to 11.
16. Compounds according to Claim 15, in which one of the radicals R4 or R5 represents fluorine or chlorine.
17. Process for the preparation of compounds according to Claims 12 to 16, characterised in that
a) carbonyl compounds of the general formula (II)
Figure imgb0212
are reacted with ketones of the formulae (III) and (IV)
Figure imgb0213
and primary amines of the formula (V)
Figure imgb0214
in which n is 0,
if appropriate in the presence of inert solvents, or
b) carbonyl compounds of the formula (II)
Figure imgb0215
are reacted with enamines of the formula (VI)
Figure imgb0216
and ketones of the formula (IV)
Figure imgb0217
if appropriate in the presence of inert solvents or
c) enamines of the formula (VI)
Figure imgb0218
are reacted with ylidene compounds of the formula (VIII)
Figure imgb0219
if appropriate in the presence of inert solvents, or
d) one or more functional groups of dihydropyridines are modified by customary methods of hydrolysis, esterification, transesterification, lac- tonisation, condensation, acylation, reduction or cyclisation.
18. Medicaments containing at least one compound according to Claims 12 to 16.
19. Process for the preparation of medicaments, characterised in that at least one compound according to Claims 12 to 16 is converted into a suitable form of administration, if appropriate using inert auxiliaries and excipients.
EP82106537A 1981-07-30 1982-07-20 Dihydropyridines with a positive inotropic activity, their use in pharmaceutical preparations, and processes for their preparation Expired - Lifetime EP0071819B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT82106537T ATE26706T1 (en) 1981-07-30 1982-07-20 DIHYDROPYRIDINES WITH POSITIVE INOTROPIC ACTION, NEW COMPOUNDS, THEIR USE IN PHARMACEUTICALS AND PROCESSES FOR THEIR PRODUCTION.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE3130041 1981-07-30
DE19813130041 DE3130041A1 (en) 1981-07-30 1981-07-30 Dihydropyridines having a positive inotropic effect, novel compounds, their use in medicaments, and processes for their preparation
DE19823206671 DE3206671A1 (en) 1982-02-25 1982-02-25 Dihydropyridines having positively inotropic action, novel compounds, their use in medicaments and processes for their preparation
DE3206671 1982-02-25

Publications (3)

Publication Number Publication Date
EP0071819A1 EP0071819A1 (en) 1983-02-16
EP0071819B1 true EP0071819B1 (en) 1987-04-22
EP0071819B2 EP0071819B2 (en) 1992-06-10

Family

ID=25794943

Family Applications (1)

Application Number Title Priority Date Filing Date
EP82106537A Expired - Lifetime EP0071819B2 (en) 1981-07-30 1982-07-20 Dihydropyridines with a positive inotropic activity, their use in pharmaceutical preparations, and processes for their preparation

Country Status (21)

Country Link
US (1) US4532248A (en)
EP (1) EP0071819B2 (en)
JP (2) JPH066535B2 (en)
KR (2) KR890001566B1 (en)
AU (1) AU566502B2 (en)
CA (1) CA1212672A (en)
CH (1) CH656530A5 (en)
DE (1) DE3276112D1 (en)
DK (1) DK339782A (en)
ES (1) ES8305716A1 (en)
FI (1) FI822643L (en)
FR (1) FR2511247B1 (en)
GB (1) GB2105989B (en)
HK (1) HK19389A (en)
IE (1) IE54259B1 (en)
IL (1) IL66405A (en)
IT (1) IT1190929B (en)
NL (1) NL8202958A (en)
NZ (1) NZ201395A (en)
PH (1) PH23086A (en)
SG (1) SG52988G (en)

Cited By (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2514761A1 (en) * 1981-10-19 1983-04-22 Maruko Pharmaceutical Co NEW 1,4-DIHYDROPYRIDINES, USEFUL AS HYPOTENSEURS
EP0104550A2 (en) * 1982-09-23 1984-04-04 Bayer Ag Condensed 1,4-dihydropyridines, process for their preparation and their application as pharmaceutical products
EP0106276A2 (en) * 1982-10-15 1984-04-25 Kyowa Hakko Kogyo Co., Ltd. 1,4-Dihydropyridine derivatives
EP0106275A3 (en) * 1982-10-15 1984-05-23 Kyowa Hakko Kogyo Co., Ltd. 1,4-dihydropyridine derivatives
EP0111453A1 (en) * 1982-12-10 1984-06-20 Ciba-Geigy Ag Amide derivatives
EP0111455A2 (en) * 1982-12-10 1984-06-20 Ciba-Geigy Ag Unsaturated lactones
EP0123095A2 (en) * 1983-03-25 1984-10-31 Bayer Ag Chromone- and thiochromone-substited 1,4-dihydropyridine lactones, processes for their preparation and their use as pharmaceutical preparations
FR2545826A1 (en) * 1982-03-22 1984-11-16 Bristol Myers Co CYCLIC DIHYDROPYRIDYLIMIDATES, AND THEIR PHARMACOLOGICAL APPLICATION
EP0125803A2 (en) * 1983-04-27 1984-11-21 FISONS plc Pharmaceutically active dihydropyridines
EP0132375A2 (en) * 1983-07-23 1985-01-30 Pfizer Limited Dihydropyridine anti-ischaemic and antihypertensive agents
FR2554109A1 (en) * 1983-11-01 1985-05-03 Sandoz Sa NOVEL 1,4-DIHYDROPYRIDINE DERIVATIVES, THEIR PREPARATION AND USE IN THERAPEUTICS AS MEDICAMENTS
EP0141221A1 (en) * 1983-09-26 1985-05-15 Nissan Chemical Industries Ltd. 1,4-Dihydropyridine-5-phosphonic acid ester
EP0141222A1 (en) * 1983-09-26 1985-05-15 Nissan Chemical Industries Ltd. Dihydropyridine-5-phosphonic acid cyclic ester
EP0151006A2 (en) * 1984-01-25 1985-08-07 Yamanouchi Pharmaceutical Co., Ltd. Dihydropyridine compounds, their production, pharmaceutical compositions containing them, and methods of producing these compositions
EP0153016A2 (en) * 1984-02-14 1985-08-28 RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY Asymmetrical diesters of 1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylic acid
EP0164010A2 (en) * 1984-06-04 1985-12-11 Bayer Ag 3-Nitro-dihydropyridines, process for their preparation and their pharmaceutical use
EP0165032A2 (en) * 1984-06-15 1985-12-18 Pfizer Limited Dihydropyridine anti-ischaemic and antihypertensive agents
EP0167371A2 (en) * 1984-06-28 1986-01-08 Yamanouchi Pharmaceutical Co. Ltd. Dihydropyridine compounds, their production, and pharmaceutical compositions containing them
EP0183091A2 (en) * 1984-11-27 1986-06-04 CASSELLA Aktiengesellschaft 1,4-Dihydropyridines, process for their preparation and their use
EP0186028A2 (en) * 1984-12-22 1986-07-02 Bayer Ag Optically active nitrodihydropyridines, process for their preparation and their use in medicines
EP0189057A2 (en) * 1985-01-22 1986-07-30 Bayer Ag 5-Aryl-dihydropyridines, process for their preparation as well as use in medicaments
EP0214437A2 (en) * 1985-08-09 1987-03-18 Bayer Ag Preparation of 1,4-Dihydropyridine derivatives using novel Intermediates
EP0237695A2 (en) * 1986-01-17 1987-09-23 MERCK PATENT GmbH 1,4-Dihydropyridines
EP0241281A2 (en) * 1986-04-09 1987-10-14 Ortho Pharmaceutical Corporation Substituted thiacycloalkeno [3,2-b] pyridines, methods of preparation, compositions and method of use
EP0244713A2 (en) * 1986-05-07 1987-11-11 Bayer Ag 3-Amino-dihydropyridines, process for their preparation and their use as medicaments
EP0299727A1 (en) * 1987-07-17 1989-01-18 Pfizer Limited Therapeutic agents
EP0308608A1 (en) * 1987-07-28 1989-03-29 Bayer Ag Substituted nitro-dihydropyridines, process for their preparation and their use
US4904665A (en) * 1987-02-26 1990-02-27 Bayer Aktiengesellschaft Benzylaminoaryl-dihydropyridinelactones and their use in medicaments
EP0432751A2 (en) * 1989-12-14 1991-06-19 Marion Merrell Dow Inc. Isomers of 1-azabicyclo[2.2.2]oct-3-yl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-5-nitropyridine-3-carboxylate
EP0515940A1 (en) * 1991-05-30 1992-12-02 Bayer Ag New 2-amino-5-cyano-1,4-dihydropyridines, process for their preparation and use in pharmaceutical compositions
WO1994022829A2 (en) * 1993-04-05 1994-10-13 Synaptic Pharmaceutical Corporation Dihydropyridines and new uses thereof
EP0622363A2 (en) * 1993-04-27 1994-11-02 Bayer Ag 2-amino-5-cyano-4-quinolyldihydropyridine esters, process for their preparation and their use in medicine for the treatment of heart-circulatory illnesses
EP0622364A2 (en) * 1993-04-27 1994-11-02 Bayer Ag 2,6-Disubstituted-4-quinolyl-dihydropyridines
EP0622369A2 (en) * 1993-04-27 1994-11-02 Bayer Ag 2-Amino-4-quinoline-dihydropyridine, process for preparation and use thereof
US5508406A (en) * 1993-04-27 1996-04-16 Bayer Aktiengesellschaft Quinolyl-dihydropyridine esters, processes for their preparation, and their use in medicaments
US5550245A (en) * 1993-04-27 1996-08-27 Bayer Aktiengesellschaft 3-quinolyl-substituted dihydropyridines, processes for their preparation and their use in medicaments
US5606066A (en) * 1992-07-10 1997-02-25 Goldmann; Siegfried Light activable "caged" 1-(2-nitrobenzyl)-substituted 1,4-dihydropyridines
US5767131A (en) * 1993-04-05 1998-06-16 Synaptic Pharmaceutical Corporation Dihydropyridines and new uses thereof
AU709190B2 (en) * 1996-01-29 1999-08-26 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Dihydropyridine-, pyridine-, benzopyran- one- and triazoloquinazoline derivative, their preparation and their use as adenosine receptor antagonists
US6211198B1 (en) 1993-04-05 2001-04-03 Synaptic Pharmaceutical Corporation Dihydropyridines and new uses thereof

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3269219D1 (en) * 1981-11-17 1986-03-27 Fisons Plc Dihydropyridines, methods for their production and their formulation and use as pharmaceuticals
DE3207982A1 (en) * 1982-03-05 1983-09-08 Bayer Ag, 5090 Leverkusen NEW 1,4-DIHYDROPYRIDINE, METHOD FOR THE PRODUCTION AND USE THEREOF IN MEDICINAL PRODUCTS
DE3209274A1 (en) * 1982-03-13 1983-09-15 Bayer Ag, 5090 Leverkusen PYRIDINE CARBONIC ACID ESTER, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A MEDICINAL PRODUCT
EP0100189B1 (en) * 1982-07-22 1986-05-28 Pfizer Limited Dihydropyridine anti-ischaemic and antihypertensive agents
US4656181A (en) * 1982-11-24 1987-04-07 Cermol S.A. Esters of 1,4-dihydropyridines, processes for the preparation of the new esters, and medicaments containing the same
GR79111B (en) * 1982-12-20 1984-10-02 Lepetit Spa
DE3319956A1 (en) * 1983-06-01 1984-12-06 Bayer Ag, 5090 Leverkusen 1,4-DIHYDROPYRIDINE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE IN MEDICINAL PRODUCTS
JPS60120861A (en) * 1983-12-02 1985-06-28 Otsuka Pharmaceut Co Ltd Dihydropyridine derivative
DE3343658A1 (en) * 1983-12-02 1985-06-13 Bayer Ag, 5090 Leverkusen HYDROXY-TETRAHYDROPYRIDINLACTONE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE IN MEDICINAL PRODUCTS
US5137889A (en) * 1983-12-02 1992-08-11 Otsuka Pharmaceutical Co., Ltd. Dihydropyridine derivatives and process for preparing the same
DE3410645A1 (en) * 1984-03-23 1985-09-26 Bayer Ag, 5090 Leverkusen L-ALKYL-SUBSTITUTED 1,4-DIHYDROPYRIDINE LACTONE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE IN MEDICINAL PRODUCTS
IE57810B1 (en) * 1984-03-27 1993-04-21 Delagrange Lab 1,4-dihydropyridine derivatives,their preparation and their use
US4567268A (en) * 1984-04-03 1986-01-28 Merck & Co., Inc. Process for preparation of certain tetrahydrofuro[3,4-b]pyridines
DE3414801A1 (en) * 1984-04-19 1985-10-24 Bayer Ag, 5090 Leverkusen 4- (NITROPHENYL) TETRAHYDROPYRIDINE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A MEDICINAL PRODUCT
US4672068A (en) * 1984-05-04 1987-06-09 Fujirebio Kabushiki Kaisha Antihypertensive 1,4-dihydropyridines having a conjugated ester
GB8412208D0 (en) * 1984-05-12 1984-06-20 Pfizer Ltd Quinolone inotropic agents
US4731370A (en) * 1984-06-25 1988-03-15 Toyama Chemical Co., Ltd. Pyridyl ester containing 1,4-dihydropyridine derivatives and salts thereof and pharmaceutical composition containing the same
GB2162513B (en) * 1984-06-25 1988-01-20 Toyama Chemical Co Ltd Dihydropyridine derivatives
FI852359L (en) * 1984-06-27 1985-12-28 Hoffmann La Roche DIHYDROPYRIDINDERIVAT.
GB8421039D0 (en) * 1984-08-17 1984-09-19 Wyeth John & Brother Ltd Heterocyclic compounds
NZ212895A (en) * 1984-08-22 1988-07-28 Glaxo Spa 1,4-dihydropyridine derivatives and pharmaceutical compositions
DE3431152A1 (en) * 1984-08-24 1986-03-06 Cassella Ag, 6000 Frankfurt METHOD FOR PRODUCING OPTICALLY ACTIVE, SUBSTITUTED 1,4-DIHYDROPYRIDINE AND THEIR USE AS A MEDICINAL PRODUCT
DE3587851D1 (en) * 1984-09-28 1994-07-21 Byk Gulden Lomberg Chem Fab New diaryl compounds.
JPS6191185A (en) * 1984-10-11 1986-05-09 Sumitomo Seiyaku Kk Novel oxadiazolyl-1,4-dihydropyridine derivative
US4994476A (en) * 1984-10-31 1991-02-19 Bristol-Myers Company Dihydropyridin-3,5-dicarboxylates incorporating aryloxypropanolamine moieties
US4616002A (en) * 1984-11-09 1986-10-07 Ciba-Geigy Corporation Dihydro pyridine compounds, compositions and use
US4678796A (en) * 1984-11-30 1987-07-07 Warner-Lambert Company 2-alkylidene derivatives of 1,2,3,4-tetrahydropyridine-2,5-pyridine carboxylic acid dialkyl esters useful for treatment of cardiovascular disorders
HUT39179A (en) * 1984-12-10 1986-08-28 Sandoz Ag Process for production of derivatives of 1,4-dihydro-piridin
JPH0676405B2 (en) * 1986-06-13 1994-09-28 日清製粉株式会社 1,4-Dihydropyridine derivative and pharmaceutical composition containing the same
US4833150A (en) * 1985-03-14 1989-05-23 Nelson Research & Development Co. 1,4-dihydropyridines
US4652573A (en) * 1985-03-14 1987-03-24 Nelson Research & Development Co. Calcium antagonist N-hetero ester 1,4-dihydropyridines
JPH0742276B2 (en) * 1985-03-15 1995-05-10 サントリー株式会社 Novel N-substituted 3,4-dihydropyrimidine derivative and vasodilator
DE3517473A1 (en) * 1985-05-15 1986-11-20 Bayer Ag, 5090 Leverkusen PYRIMIDINYL-DIHYDROPYRIDINE, METHOD FOR THE PRODUCTION AND THEIR USE IN MEDICINAL PRODUCTS
US4728652A (en) * 1985-05-20 1988-03-01 E. R. Squibb & Sons, Inc. 2-substituted thio or oxy-4-aryl or heterocyclo-5-carboxy-1,4-dihydropyrimidines, composition containing them, and method of using them to reduce blood pressure
CA1267416A (en) * 1985-06-17 1990-04-03 Ila Sircar 1,4-dihydropyridine derivatives useful for the treatment of cardiovascular disorders
DE3521761A1 (en) * 1985-06-19 1987-01-02 Bayer Ag NEW 1,4-DIHYDROPYRIDINE, METHOD FOR THE PRODUCTION AND THEIR USE IN MEDICINAL PRODUCTS
ZA863578B (en) * 1985-06-21 1987-02-25 Hoffmann La Roche Dihydropyridine derivatives
JPS6210087A (en) * 1985-07-03 1987-01-19 Shionogi & Co Ltd 4,7-dihydrothieno(2,3-b)pyridine derivative, production thereof and remedy for circulatory disease
IT1215298B (en) * 1985-08-06 1990-01-31 Boehringer Biochemia Srl 2- (ETEROALCHIL) -1,4-DIHYDROPYRIDINE AND A PROCESS FOR THEIR PRODUCTION.
IT1201454B (en) * 1985-08-19 1989-02-02 Boehringer Biochemia Srl 1,4-dihydropyridine-2-SUBSTITUTED
EP0226271B1 (en) * 1985-08-21 1990-11-22 GLAXO S.p.A. 1,4-dihydropyridine compounds and their preparation and pharmaceutical formulation
IT1190405B (en) * 1985-10-22 1988-02-16 Recordati Chem Pharm FLAVONE DERIVATIVES
GB8527698D0 (en) * 1985-11-09 1985-12-11 Pfizer Ltd Dihydropyridine antiischaemic & antihypertensive agents
US4788203A (en) * 1985-11-26 1988-11-29 Merck & Co., Inc. Cyclized N-substituted-tetrahydropyridine compounds, useful in the treatment of cardiovascular disorders
DE3544693A1 (en) * 1985-12-18 1987-06-19 Bayer Ag 4-THIENYL-DIHYDROPYRIDINE, METHOD FOR THE PRODUCTION AND THEIR USE IN MEDICINAL PRODUCTS
DE3600596A1 (en) * 1986-01-11 1987-07-16 Bayer Ag 4-AMINOARYLDIHYDROPYRIDINLACTONE, METHOD FOR THE PRODUCTION AND THEIR USE IN MEDICINAL PRODUCTS
DE3600594A1 (en) * 1986-01-11 1987-07-16 Bayer Ag METHIONINE SUBSTITUTED 1,4-DIHYDROPYRIDINE, METHOD FOR THE PRODUCTION AND THEIR USE
US5162338A (en) * 1986-01-11 1992-11-10 Bayer Aktiengesellschaft Circulation active 4-aminoaryldihydropryidine lactones
IT1204461B (en) * 1986-02-20 1989-03-01 Glaxo Spa HETEROCYCLIC DERIVATIVES
IT1204462B (en) * 1986-02-20 1989-03-01 Glaxo Spa HETEROCYCLIC DERIVATIVES
IT1204460B (en) * 1986-02-20 1989-03-01 Glaxo Spa HETEROCYCLIC DERIVATIVES
IT1204459B (en) * 1986-02-20 1989-03-01 Glaxo Spa HETEROCYCLIC DERIVATIVES
US4689414A (en) * 1986-02-24 1987-08-25 E. R. Squibb & Sons, Inc. 2-(substituted imino)-6-aryl-3,6-dihydro-4-substituted-1,5(2H)-pyrimidinecarboxylic acids and analogs
US4849436A (en) * 1986-03-11 1989-07-18 Nelson Research & Development Co. 1,4-dihydropyridines
US4684656A (en) * 1986-03-14 1987-08-04 E. R. Squibb & Sons, Inc. 1,2,3,4-tetrahydro-6-substituted-4-aryl-3-(substituted sulfonyl)-2-thioxo(or oxo)-5-pyrimidinecarboxylic acids and esters and method of using them to lower blood pressure
US4855301A (en) * 1986-10-09 1989-08-08 E. R. Squibb & Sons, Inc. 1,2,3,4-Tetrahydro-6-substituted-4-aryl(or heterocyclo)-3-((substituted amino)carbonyl)-2-thioxo (or oxo)-5-pyrimidinecarboxylic acids and esters
US4684655A (en) * 1986-03-14 1987-08-04 E. R. Squibb & Sons, Inc. 1,2,3,4-tetrahydro-6-substituted-4-aryl-3-substituted-2-thioxo(or oxo)-5-pyrimidinecarboxylic acids and esters and use thereof to lower blood pressure
US4845225A (en) * 1986-04-09 1989-07-04 Ortho Pharmaceutical Corporation Substituted thiacycloalkeno [3,2-b] pyridines
US4705785A (en) * 1986-04-09 1987-11-10 Ortho Pharmaceutical Corporation Substituted thiacycloalkeno (3,2-b) pyridines and pharmaceutical compositions and method of use
IT1197012B (en) * 1986-07-29 1988-11-25 Boehringer Biochemia Srl 2- (ACYLTI) METHYL DIHYDROPYRIDINE, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US4868181A (en) * 1986-08-04 1989-09-19 E. I. Du Pont De Nemours And Company 1,4-dihydropyridine derivatives with calcium agonist and alpha1 -antagonist activity
DE3634066A1 (en) * 1986-10-07 1988-04-21 Boehringer Mannheim Gmbh NEW 5-ALKYLBENZIMIDAZOLES, PROCESS FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS
JPS63112560A (en) * 1986-10-29 1988-05-17 Green Cross Corp:The Dihydropyridine derivative
IT1213555B (en) * 1986-12-11 1989-12-20 Boehringer Biochemia Srl 2 METHYLOMETHYL HYDROPYRIDINE, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
IT1213440B (en) * 1986-12-24 1989-12-20 Boehringer Biochemia Srl 2-DITHIOALKYL-DIHYDROPYRIDINE, A METHOD FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS WHICH CONTAIN.
JPH0688973B2 (en) * 1987-03-12 1994-11-09 京都薬品工業株式会社 1,4-dihydropyridine derivative
IT1203900B (en) * 1987-04-15 1989-02-23 Lagor Spa POLES 1,4-DIHYDRO-2,6-DIMETHYLPYRIDIN 3,5-DICARBOXYESTERS USEFUL AS THERMAL STABILIZERS FOR SYNTHETIC POLYMERS
GB8709447D0 (en) * 1987-04-21 1987-05-28 Pfizer Ltd Dihydropyridines
IT1205114B (en) * 1987-05-29 1989-03-15 Boehringer Biochemia Srl 2-SELENOMETHYL-1,4-DIHYDROPYRIDINE, PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
DE3732380A1 (en) * 1987-09-25 1989-04-06 Bayer Ag DIHYDROPYRIDINETHER, METHOD FOR THEIR PRODUCTION AND THEIR USE
US5177211A (en) * 1988-01-21 1993-01-05 Alter, S.A. 4-alkyl-1,4-dihydropyridines with PAF-antagonist activity
US4879384A (en) * 1988-06-15 1989-11-07 Ortho Pharmaceutical Corporation Preparation of thiocycloalkno [3,2-b] pyridines
US5075440A (en) * 1990-05-03 1991-12-24 Ortho Pharmaceutical Corporation Novel pyrido[2,3-f](1,4)thiazepines and pyrido[3,2-b](1,5)benzothiazepines
US5260444A (en) * 1990-05-07 1993-11-09 Wakunaga Seiyaku Kabushiki Kaisha Dihydropyridine derivative
JPH0413679A (en) * 1990-05-07 1992-01-17 Wakunaga Pharmaceut Co Ltd Novel dihydropyridine derivative
US5166148A (en) * 1990-07-09 1992-11-24 The Du Pont Merck Pharmaceutical Company 2-amino-1,4-dihydropyridine derivatives with calcium agonist and alpha1 -antagonist activity
US5100892A (en) * 1990-11-13 1992-03-31 Glaxo Inc. Dihydropyridine vasodilator agents
US5258519A (en) * 1990-11-13 1993-11-02 Glaxo Inc. Dihydropyridine vasodilators agents
AU2603197A (en) 1996-04-10 1997-10-29 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Use of an a1 adenosine receptor agonist to treat cerebral ischaemia
US6265417B1 (en) * 1997-12-18 2001-07-24 Abbott Laboratories Potassium channel openers
US6593335B1 (en) * 1997-12-18 2003-07-15 Abbott Laboratories Potassium channel openers
AU4549399A (en) * 1998-06-08 1999-12-30 Theravance, Inc. Novel calcium channel drugs and uses
US6897305B2 (en) 1998-06-08 2005-05-24 Theravance, Inc. Calcium channel drugs and uses
US7101909B2 (en) * 1998-10-12 2006-09-05 Theravance, Inc. Calcium channel drugs and uses
CZ20014518A3 (en) 1999-06-14 2003-02-12 Ortho-Mcneil Pharmaceutical, Inc. Dithiepino[6,5-b]pyridines, compositions containing these compounds and process of their preparation
DE60022056T2 (en) 1999-07-12 2006-06-08 Ortho-Mcneil Pharmaceutical, Inc. Oxathiophene [6,5-B] dihydropyridine and related compounds and processes
AU7102700A (en) 1999-09-22 2001-04-24 Ortho-Mcneil Pharmaceutical, Inc. Benzo-fused dithiepino[6,5-b]pyridines, and related compositions and methods
AU783470B2 (en) 2000-01-12 2005-10-27 Ortho-Mcneil Pharmaceutical, Inc. Benzosulfones with calcium antagonist activity
WO2001055152A1 (en) * 2000-01-27 2001-08-02 Ortho-Mcneil Pharmaceutical, Inc.. BENZOXATHIEPINO[3,4-b]PYRIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS
US6538004B2 (en) 2000-03-03 2003-03-25 Abbott Laboratories Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers
CA2403808A1 (en) 2000-03-23 2001-09-27 Ortho-Mcneil Pharmaceutical, Inc. Thiepino [3,2-b] dihydropyridines and related compositions and methods
EP1296990A2 (en) 2000-05-30 2003-04-02 Ortho-McNeil Pharmaceutical, Inc. Dihydropyridine compounds for the inhibition of calcium-influx
KR100428398B1 (en) * 2002-01-23 2004-04-28 김관진 Slide fastener of stop pin manufactory machine
MXPA05000200A (en) * 2002-07-02 2005-06-06 Schering Corp New neuropeptide y y5 receptor antagonists.
EP1663227A2 (en) * 2003-09-10 2006-06-07 Synta Pharmaceuticals Corporation Dihydropyridine compounds for treating or preventing metabolic disorders
WO2009006580A1 (en) * 2007-07-05 2009-01-08 Cv Therapeutics, Inc. Optionally condensed dihydropyridine, dihydropyrimidine and dihydropyrane derivatives acting as late sodium channel blockers
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
WO2014083383A1 (en) * 2012-11-28 2014-06-05 Stichting Dienst Landbouwkundig Onderzoek Substituted dihydropyrtoines for somatic embryogenesis iν plants
WO2021253180A1 (en) * 2020-06-15 2021-12-23 Novartis Ag Methyl (r) -2- (fluoromethyl) -5-oxo-4-phenyl-4, 5, 6, 7-tetrahydro-1h-cyclopenta [b] pyridine-3-carboxylate and methyl (r) -2- (fluoromethyl) -5-oxo-4-phenyl-1, 4, 5, 7-tetrahydrofuro [3, 4-b] pyridine-3-carboxylate as cav1.2 activators
AU2021291799A1 (en) 2020-06-16 2023-01-19 Novartis Ag Methyl 2-methyl-5-oxo-1,4,5,7-tetradhydrofuro(3,4- b)pyridine-3-carboxylate compounds as Cav1.2 activators
WO2023111799A1 (en) * 2021-12-13 2023-06-22 Novartis Ag PYRIDINE-3-CARBOXYLATE COMPOUNDS AS CaV1.2 ACTIVATORS

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1923990C3 (en) * 1969-05-10 1978-11-23 Bayer Ag Process for the preparation of N-substituted M-dihydropyridine-S.S-dicarboxylic acid esters
US3932645A (en) * 1971-04-10 1976-01-13 Farbenfabriken Bayer Ag Pharmaceutical compositions containing unsymmetrical esters of 1,4-dihydropyridine 3,5-dicarboxylic acid
DE2117571C3 (en) * 1971-04-10 1979-10-11 Bayer Ag, 5090 Leverkusen Asymmetrical 1,4-dihydropyridine-33-dicarboxylic acid esters, process for their preparation and their use as pharmaceuticals
DE2218644C3 (en) * 1972-04-18 1982-08-19 Bayer Ag, 5090 Leverkusen Basic esters of 1,4-dihydropyridines, processes for their preparation and their use as pharmaceuticals
JPS4935277A (en) * 1972-08-07 1974-04-01
DE2242786A1 (en) * 1972-08-31 1974-03-14 Bayer Ag PROCESS FOR THE MANUFACTURING OF NEW 2-AMINO-1,4-DIHYDROPYRIDINES WITH A CARBONYL FUNCTION AND THEIR USE AS A MEDICINAL PRODUCT
GB1552911A (en) * 1975-07-02 1979-09-19 Fujisawa Pharmaceutical Co 1,4 dihydropyridine derivatives and the preparation thereof
DD122524A1 (en) * 1975-10-17 1976-10-12
DE2658804A1 (en) * 1976-12-24 1978-07-06 Bayer Ag Compsn. with circulatory and cardiac activity - contains a 3-cyano-1,2-di:hydro-pyridine deriv.
DE2659665A1 (en) * 1976-12-30 1978-07-13 Nattermann A & Cie NEW 1,4-DIHYDROPYRIDINE DERIVATIVES
DE2752820A1 (en) * 1977-11-26 1979-05-31 Bayer Ag NEW NITRO-SUBSTITUTED 1,4-DIHYDROPYRIDINE, THE METHOD FOR THEIR MANUFACTURING AND THEIR USE AS A MEDICINAL PRODUCT
NO780094L (en) * 1978-01-11 1979-05-21 Finn Hallingstad Procedure for the production of feed for feeding fish in salt water
CA1110234A (en) * 1978-01-18 1981-10-06 Hoffmann-La Roche Limited 4-pyridone-3-carboxylic acids and process for the preparation thereof
JPS5527054A (en) * 1978-08-15 1980-02-26 Gen Foods Corp Adsorption method
DE2847237A1 (en) * 1978-10-31 1980-05-14 Bayer Ag Cardiovascular 1,4-di:hydro-pyridine-3-carboxylic acids prodn. - by alkaline hydrolysis of ester(s) with electron withdrawing substit.
US4285955A (en) * 1978-10-31 1981-08-25 Bayer Aktiengesellschaft 1,4-Dihydropyridinecarboxylic acids
DE2935451A1 (en) * 1979-09-01 1981-03-19 Bayer Ag, 5090 Leverkusen OPTICALLY ACTIVE 1,4-DIHYDROPYRIDINE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A MEDICINAL PRODUCT

Cited By (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2514761A1 (en) * 1981-10-19 1983-04-22 Maruko Pharmaceutical Co NEW 1,4-DIHYDROPYRIDINES, USEFUL AS HYPOTENSEURS
FR2545826A1 (en) * 1982-03-22 1984-11-16 Bristol Myers Co CYCLIC DIHYDROPYRIDYLIMIDATES, AND THEIR PHARMACOLOGICAL APPLICATION
EP0104550A2 (en) * 1982-09-23 1984-04-04 Bayer Ag Condensed 1,4-dihydropyridines, process for their preparation and their application as pharmaceutical products
EP0104550A3 (en) * 1982-09-23 1986-11-26 Bayer Ag Condensed 1,4-dihydropyridines, process for their preparation and their application as pharmaceutical products
EP0106276A2 (en) * 1982-10-15 1984-04-25 Kyowa Hakko Kogyo Co., Ltd. 1,4-Dihydropyridine derivatives
EP0106276A3 (en) * 1982-10-15 1984-05-23 Kyowa Hakko Kogyo Co., Ltd. 1,4-dihydropyridine derivatives
EP0106275A3 (en) * 1982-10-15 1984-05-23 Kyowa Hakko Kogyo Co., Ltd. 1,4-dihydropyridine derivatives
EP0111453A1 (en) * 1982-12-10 1984-06-20 Ciba-Geigy Ag Amide derivatives
EP0111455A2 (en) * 1982-12-10 1984-06-20 Ciba-Geigy Ag Unsaturated lactones
EP0111455A3 (en) * 1982-12-10 1984-07-25 Ciba-Geigy Ag Unsaturated lactones
EP0123095A2 (en) * 1983-03-25 1984-10-31 Bayer Ag Chromone- and thiochromone-substited 1,4-dihydropyridine lactones, processes for their preparation and their use as pharmaceutical preparations
EP0123095A3 (en) * 1983-03-25 1986-12-03 Bayer Ag Chromone- and thiochromone-substited 1,4-dihydropyridine lactones, processes for their preparation and their use as pharmaceutical preparations
EP0125803A2 (en) * 1983-04-27 1984-11-21 FISONS plc Pharmaceutically active dihydropyridines
EP0125803A3 (en) * 1983-04-27 1987-01-21 FISONS plc Pharmaceutically active dihydropyridines
EP0132375A3 (en) * 1983-07-23 1987-07-01 Pfizer Limited Dihydropyridine anti-ischaemic and antihypertensive agents
EP0132375A2 (en) * 1983-07-23 1985-01-30 Pfizer Limited Dihydropyridine anti-ischaemic and antihypertensive agents
EP0141221A1 (en) * 1983-09-26 1985-05-15 Nissan Chemical Industries Ltd. 1,4-Dihydropyridine-5-phosphonic acid ester
EP0141222A1 (en) * 1983-09-26 1985-05-15 Nissan Chemical Industries Ltd. Dihydropyridine-5-phosphonic acid cyclic ester
US4576934A (en) * 1983-09-26 1986-03-18 Nissan Chemical Industries Ltd. Antihypertensive dihydropyridine-5-phosphonic acid cyclic esters
WO1985001940A1 (en) * 1983-11-01 1985-05-09 Sandoz Ag Derivatives of 1,4-dihydropyridine, preparation thereof and pharmaceutical compositions containing them
FR2554109A1 (en) * 1983-11-01 1985-05-03 Sandoz Sa NOVEL 1,4-DIHYDROPYRIDINE DERIVATIVES, THEIR PREPARATION AND USE IN THERAPEUTICS AS MEDICAMENTS
EP0151006A2 (en) * 1984-01-25 1985-08-07 Yamanouchi Pharmaceutical Co., Ltd. Dihydropyridine compounds, their production, pharmaceutical compositions containing them, and methods of producing these compositions
EP0151006A3 (en) * 1984-01-25 1987-07-01 Yamanouchi Pharmaceutical Co. Ltd. Dihydropyridine compounds, their production, pharmaceutical compositions containing them, and methods of producing these compositions
EP0153016A2 (en) * 1984-02-14 1985-08-28 RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY Asymmetrical diesters of 1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylic acid
EP0153016A3 (en) * 1984-02-14 1985-10-02 Recordati S.A. Chemical And Pharmaceutical Company Asymmetrical diesters of 1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylic acid
EP0164010A2 (en) * 1984-06-04 1985-12-11 Bayer Ag 3-Nitro-dihydropyridines, process for their preparation and their pharmaceutical use
EP0164010A3 (en) * 1984-06-04 1987-08-05 Bayer Ag 3-nitro-dihydropyridines, process for their preparation and their pharmaceutical use
EP0165032A2 (en) * 1984-06-15 1985-12-18 Pfizer Limited Dihydropyridine anti-ischaemic and antihypertensive agents
EP0165032A3 (en) * 1984-06-15 1987-06-16 Pfizer Limited Dihydropyridine anti-ischaemic and antihypertensive agents
EP0167371A2 (en) * 1984-06-28 1986-01-08 Yamanouchi Pharmaceutical Co. Ltd. Dihydropyridine compounds, their production, and pharmaceutical compositions containing them
EP0167371A3 (en) * 1984-06-28 1987-06-16 Yamanouchi Pharmaceutical Co. Ltd. Dihydropyridine compounds, their production, and pharmaceutical compositions containing them
EP0183091A3 (en) * 1984-11-27 1987-08-19 CASSELLA Aktiengesellschaft 1,4-dihydropyridines, process for their preparation and their use
EP0183091A2 (en) * 1984-11-27 1986-06-04 CASSELLA Aktiengesellschaft 1,4-Dihydropyridines, process for their preparation and their use
US4764516A (en) * 1984-12-22 1988-08-16 Bayer Aktiengesellschaft Mixtures of optically active nitrodihydropyridines active on the circulatory system
EP0186028A3 (en) * 1984-12-22 1988-05-25 Bayer Ag Optically active nitrodihydropyridines, process for their preparation and their use in medicines
EP0186028A2 (en) * 1984-12-22 1986-07-02 Bayer Ag Optically active nitrodihydropyridines, process for their preparation and their use in medicines
EP0189057A3 (en) * 1985-01-22 1986-10-08 Bayer Ag 5-aryl-dihydropyridines, process for their preparation as well as use in medicaments
EP0189057A2 (en) * 1985-01-22 1986-07-30 Bayer Ag 5-Aryl-dihydropyridines, process for their preparation as well as use in medicaments
EP0214437A2 (en) * 1985-08-09 1987-03-18 Bayer Ag Preparation of 1,4-Dihydropyridine derivatives using novel Intermediates
EP0214437A3 (en) * 1985-08-09 1987-10-14 Bayer Ag 1,4-dihydropyridine derivatives, their preparation and their use in medicaments
US4769375A (en) * 1985-08-09 1988-09-06 Bayer Aktiengesellschaft Circulation-active 1,4-dihydropyridine derivatives and use thereas
EP0237695A2 (en) * 1986-01-17 1987-09-23 MERCK PATENT GmbH 1,4-Dihydropyridines
EP0237695A3 (en) * 1986-01-17 1988-12-28 MERCK PATENT GmbH 1,4-dihydropyridines
EP0241281A2 (en) * 1986-04-09 1987-10-14 Ortho Pharmaceutical Corporation Substituted thiacycloalkeno [3,2-b] pyridines, methods of preparation, compositions and method of use
EP0241281A3 (en) * 1986-04-09 1989-01-25 Ortho Pharmaceutical Corporation Substituted thiacycloalkeno û3,2-b¨ pyridines, methods of preparation, compositions and method of use
EP0244713A2 (en) * 1986-05-07 1987-11-11 Bayer Ag 3-Amino-dihydropyridines, process for their preparation and their use as medicaments
EP0244713A3 (en) * 1986-05-07 1988-09-07 Bayer Ag 3-amino-dihydropyridines, process for their preparation and their use as medicaments
US4904665A (en) * 1987-02-26 1990-02-27 Bayer Aktiengesellschaft Benzylaminoaryl-dihydropyridinelactones and their use in medicaments
EP0299727A1 (en) * 1987-07-17 1989-01-18 Pfizer Limited Therapeutic agents
US4898865A (en) * 1987-07-28 1990-02-06 Bayer Aktiengesellschaft [4-(6-Oxo-1,4,5,6-tetrahydro-3-pyridazinyl) anilino hexyl 1,4-dihydro-2,6 Di methyl 5 nitro 4 aryl pyridine 3-carboxylates
EP0308608A1 (en) * 1987-07-28 1989-03-29 Bayer Ag Substituted nitro-dihydropyridines, process for their preparation and their use
EP0432751A2 (en) * 1989-12-14 1991-06-19 Marion Merrell Dow Inc. Isomers of 1-azabicyclo[2.2.2]oct-3-yl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-5-nitropyridine-3-carboxylate
EP0432751A3 (en) * 1989-12-14 1992-02-12 Marion Merrell Dow Inc. Isomers of 1-azabicyclo(2.2.2)oct-3-yl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-5-nitropyridine-3-carboxylate
US5380851A (en) * 1991-05-30 1995-01-10 Bayer Aktiengesellschaft 2-amino-5-cyano-1,4-dihydropyridines, processes for their preparation
US5225558A (en) * 1991-05-30 1993-07-06 Bayer Aktiengesellschaft 2-amino-5-cyano-1,4-dihydropyridines, and their use in medicaments
EP0515940A1 (en) * 1991-05-30 1992-12-02 Bayer Ag New 2-amino-5-cyano-1,4-dihydropyridines, process for their preparation and use in pharmaceutical compositions
US5606066A (en) * 1992-07-10 1997-02-25 Goldmann; Siegfried Light activable "caged" 1-(2-nitrobenzyl)-substituted 1,4-dihydropyridines
WO1994022829A2 (en) * 1993-04-05 1994-10-13 Synaptic Pharmaceutical Corporation Dihydropyridines and new uses thereof
US6608086B2 (en) 1993-04-05 2003-08-19 Synaptic Pharmaceutical Corporation Dihydropyridines and new uses thereof
US6310076B1 (en) 1993-04-05 2001-10-30 Synaptic Pharmaceutical Corporation Dihydropyridines and new uses thereof
US6211198B1 (en) 1993-04-05 2001-04-03 Synaptic Pharmaceutical Corporation Dihydropyridines and new uses thereof
US5767131A (en) * 1993-04-05 1998-06-16 Synaptic Pharmaceutical Corporation Dihydropyridines and new uses thereof
EP0622369A2 (en) * 1993-04-27 1994-11-02 Bayer Ag 2-Amino-4-quinoline-dihydropyridine, process for preparation and use thereof
US5550245A (en) * 1993-04-27 1996-08-27 Bayer Aktiengesellschaft 3-quinolyl-substituted dihydropyridines, processes for their preparation and their use in medicaments
US5514803A (en) * 1993-04-27 1996-05-07 Bayer Aktiengesellschaft 2,6-disubstituted 4-quinolyl-dihydropyridines
US5629320A (en) * 1993-04-27 1997-05-13 Bayer Aktiengesellschaft 3-quinolyl-substituted dihydropyridines, and their use in medicaments
US5508406A (en) * 1993-04-27 1996-04-16 Bayer Aktiengesellschaft Quinolyl-dihydropyridine esters, processes for their preparation, and their use in medicaments
US5504209A (en) * 1993-04-27 1996-04-02 Bayer Aktiengesellschaft 2-amino-5-cyano-4-quinolydihydropyridine esters, processes for their preparation and their use in medicaments
EP0622364A2 (en) * 1993-04-27 1994-11-02 Bayer Ag 2,6-Disubstituted-4-quinolyl-dihydropyridines
EP0622363A2 (en) * 1993-04-27 1994-11-02 Bayer Ag 2-amino-5-cyano-4-quinolyldihydropyridine esters, process for their preparation and their use in medicine for the treatment of heart-circulatory illnesses
AU709190B2 (en) * 1996-01-29 1999-08-26 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Dihydropyridine-, pyridine-, benzopyran- one- and triazoloquinazoline derivative, their preparation and their use as adenosine receptor antagonists

Also Published As

Publication number Publication date
DE3276112D1 (en) 1987-05-27
AU566502B2 (en) 1987-10-22
FR2511247A1 (en) 1983-02-18
IE54259B1 (en) 1989-08-02
KR890001566B1 (en) 1989-05-08
FR2511247B1 (en) 1986-03-07
US4532248A (en) 1985-07-30
IT8222620A1 (en) 1984-01-28
CH656530A5 (en) 1986-07-15
JPS5826872A (en) 1983-02-17
HK19389A (en) 1989-03-17
NL8202958A (en) 1983-02-16
DK339782A (en) 1983-01-31
NZ201395A (en) 1987-02-20
JPH066535B2 (en) 1994-01-26
IL66405A (en) 1987-12-31
JPH05271078A (en) 1993-10-19
IL66405A0 (en) 1982-11-30
FI822643L (en) 1983-02-01
CA1212672A (en) 1986-10-14
EP0071819B2 (en) 1992-06-10
ES514525A0 (en) 1983-04-16
GB2105989B (en) 1986-01-08
AU8594582A (en) 1983-02-03
IT1190929B (en) 1988-02-24
IE821827L (en) 1983-01-30
KR840000494A (en) 1984-02-22
IT8222620A0 (en) 1982-07-28
FI822643A0 (en) 1982-07-28
GB2105989A (en) 1983-04-07
SG52988G (en) 1993-02-19
ES8305716A1 (en) 1983-04-16
PH23086A (en) 1989-04-10
EP0071819A1 (en) 1983-02-16
KR890001567B1 (en) 1989-05-08

Similar Documents

Publication Publication Date Title
EP0071819B1 (en) Dihydropyridines with a positive inotropic activity, their use in pharmaceutical preparations, and processes for their preparation
EP0088276B1 (en) Compounds, process for their preparation and their use as pharmaceutical preparations
EP0002208B1 (en) Nitro 1,4-dihydropyridines, medicaments containing them and their manufacture
EP0176956B1 (en) Diaryl derivatives
EP0088274A1 (en) 1,4-Dihydropyridines, process for their preparation and their application as pharmaceutical preparations
DE2935451A1 (en) OPTICALLY ACTIVE 1,4-DIHYDROPYRIDINE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A MEDICINAL PRODUCT
EP0296316A1 (en) 1,4-Dihydropyridine enantiomers
DE2756226A1 (en) 1,4-DIHYDROPYRIDINE COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL AGENTS CONTAINING THE SAME
US4497821A (en) Medicaments having antihypoxic and ischaemia-protective activity
DE3130041A1 (en) Dihydropyridines having a positive inotropic effect, novel compounds, their use in medicaments, and processes for their preparation
EP0052300A1 (en) C-3-linked 1,4-dihydropyridines, their use in pharmaceutical preparations and processes for their preparation
EP0088940B1 (en) Pyridine-carboxylic-acid esters, process for their preparation and their use as pharmaceutical compositions
EP0039863A1 (en) 1,4-Dihydropyridines with different substituents in positions 2 and 6, processes for their preparation and their use in medicines
EP0123112A2 (en) Chromone- and thiochromone-substituted 1,4-dihydropyridines, processes for their preparation and their use in pharmaceutical preparations
EP0110259A1 (en) 1,4-Dihydropyridines, processes for their preparation and their use in medicines
EP0234196A1 (en) Substituted 1,4-dihydropyridine-3-carboxylic acid piperazides, process for their preparation and their use in medicaments
EP0157324A2 (en) Tetrahydrothienopyridines, process for their preparation and their pharmaceutical application
EP0627427A1 (en) 3-Quinolyl substituted dihydropyridines, process for their preparation and their use in drugs
EP0362632A2 (en) Basic 4-aryl-DHP amides, process for their preparation and their pharmaceutical use
EP0244595A2 (en) Dihydropyridine derivatives, process for their preparation and their use as pharmaceutical compounds
EP0225574B1 (en) Novel 1,4-dihydropyridines containing fluorine, process for their preparation and their use as medicaments
EP0242829A1 (en) Dihydropyridines, process for their preparation and their use as medicaments
DE3206671A1 (en) Dihydropyridines having positively inotropic action, novel compounds, their use in medicaments and processes for their preparation
WO1988007531A1 (en) New optically active compounds
EP0314038A1 (en) Pyrrolidines

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19820720

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

ITF It: translation for a ep patent filed

Owner name: SOCIETA' ITALIANA BREVETTI S.P.A.

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

REF Corresponds to:

Ref document number: 26706

Country of ref document: AT

Date of ref document: 19870515

Kind code of ref document: T

ET Fr: translation filed
REF Corresponds to:

Ref document number: 3276112

Country of ref document: DE

Date of ref document: 19870527

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

26 Opposition filed

Opponent name: GOEDECKE AKTIENGESELLSCHAFT,BERLIN

Effective date: 19880119

NLR1 Nl: opposition has been filed with the epo

Opponent name: GOEDECKE AKTIENGESELLSCHAFT

PUAH Patent maintained in amended form

Free format text: ORIGINAL CODE: 0009272

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT MAINTAINED AS AMENDED

27A Patent maintained in amended form

Effective date: 19920610

AK Designated contracting states

Kind code of ref document: B2

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

REG Reference to a national code

Ref country code: CH

Ref legal event code: AEN

NLR2 Nl: decision of opposition
ITF It: translation for a ep patent filed

Owner name: SOCIETA' ITALIANA BREVETTI S.P.A.

NLR3 Nl: receipt of modified translations in the netherlands language after an opposition procedure
ET3 Fr: translation filed ** decision concerning opposition
ITTA It: last paid annual fee
EPTA Lu: last paid annual fee
EAL Se: european patent in force in sweden

Ref document number: 82106537.2

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19960626

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 19960701

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 19960723

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19960725

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19960731

Year of fee payment: 15

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19970720

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19970720

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19970721

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19970731

BERE Be: lapsed

Owner name: BAYER A.G.

Effective date: 19970731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19980201

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 19980201

EUG Se: european patent has lapsed

Ref document number: 82106537.2

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19980612

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19980624

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 19980713

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19980720

Year of fee payment: 17

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990720

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990731

Ref country code: FR

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 19990731

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990731

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 19990720

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000503

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

APAH Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNO